Reported covered position: Director of Government Relations
How to read the money
Income and expense are whole-filing amounts associated with this lobbyist, not personal compensation or an allocated share.
No topic inference: each bill number appears in source LDA issue text assigned to this lobbyist.
Providing for congressional disapproval under chapter 8 of title 5, United States Code, of the rule submitted by the Environmental Protection Agency relating to "Trichloroethylene (TCE); Regulation Under the Toxic Substances Control Act (TSCA)".
Client: THE MICHAEL J. FOX FOUNDATION FOR PARKINSON'S RESEARCH · Firm: THE MICHAEL J. FOX FOUNDATION FOR PARKINSON'S RESEARCH
Lobbying to ban the use of known environmental risk factors of Parkinsons disease, including Trichloroethylene (TCE) and paraquat, in the United States. S.J.Res.19/H.J.Res.27/ H.J.Res.34 - A joint resolution providing for congressional disapproval under chapter 8 of title 5, United States Code, of the rule submitted by the Environmental Protection Agency relating to ""Trichloroethylene (TCE); Regulation Under the Toxic Substances Control Act (TSCA)"" The Harmonizing Environmental Analyses and Launching Therapeutic Hubs to Yield Bolstered Research And Innovation in Neurological Science (HEALTHY BRAINS) Act (to be reintroduced): creates a Centers of Excellence grant program within the National Institutes of Health to conduct and support of research, training, and health information dissemination with respect to environmental risk factors of neurodegenerative diseases, including Parkinsons disease.
Specific issues are shown only where the LDA source assigned them to this lobbyist. Targets apply to the associated filing.
THE MICHAEL J. FOX FOUNDATION FOR PARKINSON'S RESEARCH via THE MICHAEL J. FOX FOUNDATION FOR PARKINSON'S RESEARCH
2025 · first_quarter · Q1
General Parkinson's disease Information, including information on symptoms, health coverage, health costs, social determinants of health, data collection, research, environmental risks, and health access for underserved communities. Dr. Emmanuel Bilirakis and Honorable Jennifer Wexton National Plan to End Parkinsons Act (Public Law No: 118-66) - requires the U.S. Department of Health and Human services to produce an integrated national plan to prevent, diagnose, treat, and cure Parkinsons, ameliorate symptoms, and slow or stop progression. This plan will encompass Parkinsons disease and all other neurodegenerative Parkinsonisms, such as multiple system atrophy, corticobasal degeneration, progressive supranuclear palsy, and Parkinsons-related dementia. The Harmonizing Environmental Analyses and Launching Therapeutic Hubs to Yield Bolstered Research And Innovation in Neurological Science (HEALTHY BRAINS) Act (to be reintroduced): creates a Centers of Excellence grant program within the National Institutes of Health to conduct and support of research, training, and health information dissemination with respect to environmental risk factors of neurodegenerative diseases, including Parkinsons disease. Clinical Trials Modernization Act (to be reintroduced): seeks to improve participation in clinical research trials by removing economic barriers faced by patients. The legislation would allow HHS to issue grants or enter in contractual arrangements to support education, outreach, and recruitment for clinical trials and address financial barriers faced by patients, including excluding renumeration for participation in clinical trials from taxable income. Conrad State 30 and Physician Access Reauthorization Act (to be reintroduced): Reauthorizes the Conrad State 30 program and improves policies to address health care provider shortages, supporting neurological care for Parkinson's patients. Centralizing and prioritizing neurodegenerative disease research within the National Institutes of Health.
Source: Senate LDA
Providing for congressional disapproval under chapter 8 of title 5, United States Code, of the rule submitted by the Environmental Protection Agency relating to "Trichloroethylene (TCE); Regulation Under the Toxic Substances Control Act (TSCA)".
Client: THE MICHAEL J. FOX FOUNDATION FOR PARKINSON'S RESEARCH · Firm: THE MICHAEL J. FOX FOUNDATION FOR PARKINSON'S RESEARCH
Lobbying to ban the use of known environmental risk factors of Parkinsons disease, including Trichloroethylene (TCE) and paraquat, in the United States. S.J.Res.19/H.J.Res.27/ H.J.Res.34 - A joint resolution providing for congressional disapproval under chapter 8 of title 5, United States Code, of the rule submitted by the Environmental Protection Agency relating to ""Trichloroethylene (TCE); Regulation Under the Toxic Substances Control Act (TSCA)"" The Harmonizing Environmental Analyses and Launching Therapeutic Hubs to Yield Bolstered Research And Innovation in Neurological Science (HEALTHY BRAINS) Act (to be reintroduced): creates a Centers of Excellence grant program within the National Institutes of Health to conduct and support of research, training, and health information dissemination with respect to environmental risk factors of neurodegenerative diseases, including Parkinsons disease.
A joint resolution providing for congressional disapproval under chapter 8 of title 5, United States Code, of the rule submitted by the Environmental Protection Agency relating to "Trichloroethylene (TCE); Regulation Under the Toxic Substances Control Act (TSCA)".
Client: THE MICHAEL J. FOX FOUNDATION FOR PARKINSON'S RESEARCH · Firm: THE MICHAEL J. FOX FOUNDATION FOR PARKINSON'S RESEARCH
Lobbying to ban the use of known environmental risk factors of Parkinsons disease, including Trichloroethylene (TCE) and paraquat, in the United States. S.J.Res.19/H.J.Res.27/ H.J.Res.34 - A joint resolution providing for congressional disapproval under chapter 8 of title 5, United States Code, of the rule submitted by the Environmental Protection Agency relating to ""Trichloroethylene (TCE); Regulation Under the Toxic Substances Control Act (TSCA)"" The Harmonizing Environmental Analyses and Launching Therapeutic Hubs to Yield Bolstered Research And Innovation in Neurological Science (HEALTHY BRAINS) Act (to be reintroduced): creates a Centers of Excellence grant program within the National Institutes of Health to conduct and support of research, training, and health information dissemination with respect to environmental risk factors of neurodegenerative diseases, including Parkinsons disease.
Facilitating Innovative Nuclear Diagnostics Act of 2023
Client: THE MICHAEL J. FOX FOUNDATION FOR PARKINSON'S RESEARCH · Firm: THE MICHAEL J. FOX FOUNDATION FOR PARKINSON'S RESEARCH
H.R.2365/S.1064 - National Plan to End Parkinson's Act: a bill to create an advisory council comprising members of federal agencies that support research, care, and services for Parkinsons, plus patients, care partners, researchers, clinicians, and other non-federal experts to ensure efficient and effective coordination among all federal entities with responsibility for managing, treating, and curing Parkinsons disease. General Parkinson's disease information about symptoms, triggers, health coverage, health costs, social determinants of health related to Parkinson's disease and data collection, research, environmental risks, and health access for underserved communities. Information related to prevalence particularly at CDC's National Neurological Conditions Surveillance System (NNCSS). H.R.2630/S.652/S.1339 - Safe Step Act: a bill to require group health plans to provide an exception process for any medication step therapy protocol to help ensure that people living with Parkinson's disease can safely and efficiently access treatments. Establishing Parkinson's disease ICD-10-CM codes to assist in the continuation and coordination of care for people living with Parkinson's who experience OFF episodes and to allow researchers to gather more data to study the progression of the disease. Reauthorization of CDCs National Neurological Conditions Surveillance System (NNCSS). S.1544/H.R.1199 - Facilitating Innovative Nuclear Diagnostics Act of 2023: a bill to establish separate payment requirements for diagnostic radiopharmaceuticals, including DaTscans, which can aid in confirming a Parkinson's diagnosis, under the Medicare prospective payment system for hospital outpatient department services. H.R.3432 - Telemental Health Care Access Act of 2023: a bill to permanently remove Medicare's originating site requirements for mental health services furnished via telehealth. Parkinson's non-motor symptoms encompass mental health conditions, including anxiety, depression, dementia, and other memory problems, and the majority of people living with Parkinson's in the United States are Medicare beneficiaries, many of whom will face undue burdens meeting the unnecessary in-person requirement for telemental health services after the delay of the requirement enforcement expires December 31, 2024. H.R.830/S.1375 - Help Ensure Lower Patient Copays Act: a bill to require health insurance plans to apply certain payments made by, or on behalf of, a plan enrollee toward a plan's cost-sharing requirements. Specifically, plans must apply third-party payments, financial assistance, discounts, product vouchers, and other reductions in out-of-pocket expenses toward the requirements. Many Parkinson's patients rely on such third-party payments to afford medications to treat and manage their disease symptoms, and this legislation will ensure that all payments whether they come directly out of a pocket or with the help of copay assistance-counts toward out-of-pocket costs of patients. The Medicare Part D Six Protected Classes Policy: requires Part D plan to cover all drugs in six classes: immunosuppressants, antidepressants, antipsychotics, anticonvulsants, antiretrovirals, and antineoplastics. For people living with Parkinson's, most of whom are Medicare beneficiaries, it is essential to have access to wide range of treatment options for antidepressants and antipsychotics. Parkinson's causes non-motor symptoms, including depression and psychosis, and individuals often experience different side effects, reactions, and efficacy based on which medications they take. H.R.4752/S.2379 - the Concentrating High-value Alzheimer's Needs to Get to an End (CHANGE) Act of 2023: a bill to better utilize the existing Welcome to Medicare initial exam and Medicare annual wellness visits to screen, detect, and diagnose Alzheimers and related dementias, including Parkinson's disease dementia, in their earliest stages. Signed Leaders Engaged on Alzheimer's Disease (LEAD) Coalition letter to members of Congress in support of this legislation. H.R.4942/S.655 - the Conrad State 30 and Physician Access Reauthorization Act: a bill to reauthorize the Conrad State 30 program for three years, make several targeted policy improvements, and permit the gradual expansion of the number of waivers granted to each state to address health care provider shortages. Signed American Academy of Neurology letter to member of Congress in support of this legislation. The Medicare Part D Six Protected Classes Policy: requires Part D plan to cover all drugs in six classes: immunosuppressants, antidepressants, antipsychotics, anticonvulsants, antiretrovirals, and antineoplastics. For people living with Parkinson's, most of whom are Medicare beneficiaries, it is essential to have access to wide range of treatment options for antidepressants and antipsychotics. Parkinson's causes non-motor symptoms, including depression and psychosis, and individuals often experience different side effects, reactions, and efficacy based on which medications they take. Partnership for Part D Access coalition congressional meetings and signed coalition letter to CMS in response to Medicare Prescription Payment Plan Part One Guidance in support of continued protection for the six protected classes policy. Signed Medicare Access for Prescription Rx (MAPRx) coalition comment letter in response to Medicare Prescription Payment Plan Part One Guidance. Signed Patient and Provider Advocates for Telehealth coalition comment letter in response to CMS CY 2024 Medicare Physician Fee Schedule (PFS) in support prioritizing the needs of patients by expanding policies that improved access to safe and timely health care via telehealth. Signed Alliance for Aging Research coalition letter in response to Medicare Prescription Payment Plan Part One Guidance in support of proposed beneficiary protections and to provide feedback on implementation considerations for the Medicare Prescription Payment Plan program.
Facilitating Innovative Nuclear Diagnostics Act of 2023
Client: THE MICHAEL J. FOX FOUNDATION FOR PARKINSON'S RESEARCH · Firm: THE MICHAEL J. FOX FOUNDATION FOR PARKINSON'S RESEARCH
H.R.2365/S.1064 - National Plan to End Parkinson's Act: A bill to create an advisory council comprising members of federal agencies that support research, care, and services for Parkinson's disease, as well as patients, care partners, researchers, clinicians, and other non-federal experts, to ensure efficient and effective coordination among all federal entities responsible for managing, treating, and curing Parkinson's disease. General Parkinson's Disease Information: Covers symptoms, triggers, health coverage, health costs, social determinants of health, data collection, research, environmental risks, and health access for underserved communities, particularly through the CDC's National Neurological Conditions Surveillance System (NNCSS). H.R.2630/S.652/S.1339 - Safe Step Act: Requires group health plans to provide an exception process for any medication step therapy protocol to ensure that individuals living with Parkinson's disease can access treatments safely and efficiently. Establishing Parkinson's Disease ICD-10-CM Codes: Aims to assist in the coordination of care for Parkinson's patients who experience OFF episodes and to allow researchers to gather data to study disease progression. S.1544/H.R.1199 - Facilitating Innovative Nuclear Diagnostics Act of 2023: A bill to establish separate payment requirements for diagnostic radiopharmaceuticals, including DaTscans, which aid in confirming a Parkinson's diagnosis under the Medicare prospective payment system for hospital outpatient services. H.R.3432 - Telemental Health Care Access Act of 2023: Permanently removes Medicare's originating site requirements for mental health services furnished via telehealth. Parkinson's non-motor symptoms include mental health conditions, and many people with Parkinson's are Medicare beneficiaries who may face barriers due to in-person requirements. H.R.830/S.1375 - Help Ensure Lower Patient Copays Act: A bill requiring health insurance plans to apply certain payments, including third-party payments, financial assistance, and product vouchers, toward a plan's cost-sharing requirements. This helps Parkinson's patients afford medications for managing symptoms. The Medicare Part D Six Protected Classes Policy: Requires Part D plans to cover all drugs in six protected classes, including antidepressants and antipsychotics. For individuals with Parkinson's disease, these medications are crucial for managing non-motor symptoms such as depression and psychosis. H.R.4752/S.2379 - CHANGE Act of 2023: A bill to improve early screening, detection, and diagnosis of Alzheimer's and related dementias, including Parkinson's disease dementia, during Medicare wellness visits. H.R.4942/S.655 - Conrad State 30 and Physician Access Reauthorization Act: Reauthorizes the Conrad State 30 program and improves policies to address health care provider shortages, supporting neurological care for Parkinson's patients. H.R.8702/S.4532 - Improving Seniors Timely Access to Care Act: Establishes requirements regarding the use of prior authorization under Medicare Advantage plans. H.R.9233/S.- The HEALTHY Brains Act: Draft legislation to create a Centers of Excellence grant program within the National Institutes of Health to focus on the intersection between environmental risk factors and neurodegenerative diseases. H.R.8331/S. 4280 - Essential Caregivers Act of 2024: To amend titles XVIII and XIX of the Social Security Act to require skilled nursing facilities, nursing facilities, intermediate care facilities for the intellectually disabled, and inpatient rehabilitation facilities to permit essential caregivers access during any period in which regular visitation is restricted. General Outreach for Establishing an ""Office of Caregiver Health"": Supports the creation of an Office of Caregiver Health within the Department of Health and Human Services to address the needs of caregivers, particularly in relation to Parkinson's disease care.
Facilitating Innovative Nuclear Diagnostics Act of 2023
Client: THE MICHAEL J. FOX FOUNDATION FOR PARKINSON'S RESEARCH · Firm: THE MICHAEL J. FOX FOUNDATION FOR PARKINSON'S RESEARCH
Lobbying to Improve Prescription Drug Affordability and Accessibility: Advocacy for people living with Parkinson's via Medicare Part D redesign and benefits, including expanding the low-income subsidy (LIS) program, capping out-of-pocket costs, implementing a smoothing mechanism, and streamlining utilization management processes. Medicare Part D Six Protected Classes Policy: Requires Part D plans to cover all drugs in six classes: immunosuppressants, antidepressants, antipsychotics, anticonvulsants, antiretrovirals, and antineoplastics. Access to a wide range of treatment options for antidepressants and antipsychotics is essential for Parkinson's patients due to non-motor symptoms such as depression and psychosis. Advocacy includes coalition meetings and letters to CMS in response to Medicare Prescription Payment Plan Part One Guidance to support continued protection for the six protected classes. H.R.2360/S.652/S.1339 - Safe Step Act: A bill requiring group health plans to provide an exception process for any medication step therapy protocol to ensure that Parkinson's patients can access treatments safely and efficiently. Led a digital campaign to allow constituents to write to members of Congress in support of the legislation. H.R.830/S.1375 - Help Ensure Lower Patient Copays Act: This bill requires health insurance plans to apply third-party payments, financial assistance, discounts, and other reductions in out-of-pocket expenses toward a plan's cost-sharing requirements. Many Parkinson's patients rely on such payments to afford medications, and this legislation ensures they count toward out-of-pocket costs. S.1544/H.R.1199 - Facilitating Innovative Nuclear Diagnostics Act of 2023: A bill to establish separate payment requirements for diagnostic radiopharmaceuticals, including DaTscans, under the Medicare prospective payment system for hospital outpatient department services. This will help confirm Parkinson's diagnoses more efficiently. CMS-1809-P (2025 Medicare Outpatient Prospective Payment System Proposed Rule): Supported CMS's proposal to separate payment for certain diagnostic radiopharmaceuticals, including those used to diagnose Parkinson's disease and atypical parkinsonisms, from the procedure payment and reimburse them separately. H.R.8702/S.4532 - Improving Seniors Timely Access to Care Act: A bill to establish requirements regarding the use of prior authorization under Medicare Advantage plans. Lobbying CMS: Advocacy efforts to direct Durable Medical Equipment Medicare Administrative Contractors to provide clarification on the use of claim modifiers for DME therapies administered via an external infusion pump to expedite patient access to new Parkinson's therapies once they are approved by the FDA.
Facilitating Innovative Nuclear Diagnostics Act of 2023
Client: THE MICHAEL J. FOX FOUNDATION FOR PARKINSON'S RESEARCH · Firm: THE MICHAEL J. FOX FOUNDATION FOR PARKINSON'S RESEARCH
Lobbying to increase prescription drug affordability and accessibility for people living with Parkinson's via Medicare Part D redesign and benefits, including expanding the low-income subsidy (LIS) program, capping out-of-pocket costs, implementing a smoothing mechanism, and streamlining utilization management processes. The Medicare Part D Six Protected Classes Policy: requires Part D plan to cover all drugs in six classes: immunosuppressants, antidepressants, antipsychotics, anticonvulsants, antiretrovirals, and antineoplastics. For people living with Parkinson's, most of whom are Medicare beneficiaries, it is essential to have access to wide range of treatment options for antidepressants and antipsychotics. Parkinson's causes non-motor symptoms, including depression and psychosis, and individuals often experience different side effects, reactions, and efficacy based on which medications they take. Partnership for Part D Access coalition congressional meetings and signed coalition letter to CMS in response to Medicare Prescription Payment Plan Part One Guidance in support of continued protection for the six protected classes policy. Signed Medicare Access for Prescription Rx (MAPRx) coalition comment letter in response to Medicare Prescription Payment Plan Part One Guidance. Signed Patient and Provider Advocates for Telehealth coalition comment letter in response to CMS CY 2024 Medicare Physician Fee Schedule (PFS) in support prioritizing the needs of patients by expanding policies that improved access to safe and timely health care via telehealth. Signed Alliance for Aging Research coalition letter in response to Medicare Prescription Payment Plan Part One Guidance in support of proposed beneficiary protections and to provide feedback on implementation considerations for the Medicare Prescription Payment Plan program. H.R.4752/S.2379 - the Concentrating High-value Alzheimer's Needs to Get to an End (CHANGE) Act of 2023: a bill to better utilize the existing Welcome to Medicare initial exam and Medicare annual wellness visits to screen, detect, and diagnose Alzheimers and related dementias, including Parkinson's disease dementia, in their earliest stages. Signed Leaders Engaged on Alzheimer's Disease (LEAD) Coalition letter to members of Congress in support of this legislation. S. 3109- Alleviating Barriers for Caregivers (ABC) Act- bill to require the Administrator of the Centers for Medicare & Medicaid Services and the Commissioner of Social Security to review and simplify the processes, procedures, forms, and communications for family caregivers to assist individuals in establishing eligibility for, enrolling in, and maintaining and utilizing coverage and benefits under the Medicare, Medicaid, CHIP, and Social Security programs respectively, and for other purposes. Lobbying the Centers for Medicare and Medicaid Services to direct Durable Medical Equipment Medicare Administrative Contractors to provide additional clarification regarding the use of claim modifiers for DME therapies that require administration via an external infusion pump to expedite patient access once new Parkinson's therapies receive approvals from the Food and Drug Administration. S.1544/H.R.1199 - Facilitating Innovative Nuclear Diagnostics Act of 2023: a bill to establish separate payment requirements for diagnostic radiopharmaceuticals, including DaTscans, which can aid in confirming a Parkinson's diagnosis, under the Medicare prospective payment system for hospital outpatient department services. S. 3766/H.R. 7274- Connecting Caregivers to Medicare Act -To amend title XVIII of the Social Security Act to provide for outreach and education to Medicare beneficiaries to simplify access to information for family caregivers through 1-800-MEDICARE, and for other purposes. H.R. 8018/S. 3109- Alleviating Barriers for Caregivers (ABC) Act- bill to require the Administrator of the Centers for Medicare & Medicaid Services and the Commissioner of Social Security to review and simplify the processes, procedures, forms, and communications for family caregivers to assist individuals in establishing eligibility for, enrolling in, and maintaining and utilizing coverage and benefits under the Medicare, Medicaid, CHIP, and Social Security programs respectively, and for other purposes. H.R.8702/S.4532 - Improving Seniors Timely Access to Care Act: a bill to establish requirements with respect to the use of prior authorization under Medicare Advantage plans.
Facilitating Innovative Nuclear Diagnostics Act of 2023
Client: THE MICHAEL J. FOX FOUNDATION FOR PARKINSON'S RESEARCH · Firm: THE MICHAEL J. FOX FOUNDATION FOR PARKINSON'S RESEARCH
Lobbying to improve prescription drug affordability and accessibility for people living with Parkinson's via Medicare Part D redesign and benefits, including expanding the low-income subsidy (LIS) program, capping out-of-pocket costs, implementing a smoothing mechanism, and streamlining utilization management processes. The Medicare Part D Six Protected Classes Policy: requires Part D plan to cover all drugs in six classes: immunosuppressants, antidepressants, antipsychotics, anticonvulsants, antiretrovirals, and antineoplastics. For people living with Parkinson's, most of whom are Medicare beneficiaries, it is essential to have access to wide range of treatment options for antidepressants and antipsychotics. Parkinson's causes non-motor symptoms, including depression and psychosis, and individuals often experience different side effects, reactions, and efficacy based on which medications they take. Partnership for Part D Access coalition congressional meetings and signed coalition letter to CMS in response to Medicare Prescription Payment Plan Part One Guidance in support of continued protection for the six protected classes policy. Signed Medicare Access for Prescription Rx (MAPRx) coalition comment letter in response to Medicare Prescription Payment Plan Part One Guidance. Signed Alliance for Aging Research coalition letter in response to Medicare Prescription Payment Plan Part One Guidance in support of proposed beneficiary protections and to provide feedback on implementation considerations for the Medicare Prescription Payment Plan program. H.R.2360/S.652/S.1339 - Safe Step Act: a bill to require group health plans to provide an exception process for any medication step therapy protocol to help ensure that people living with Parkinson's disease can safely and efficiently access treatments. Led a digital campaign to allow constituents to write their members of Congress in support of this legislation. Lobbying the Centers for Medicare and Medicaid Services to direct Durable Medical Equipment Medicare Administrative Contractors to provide additional clarification regarding the use of claim modifiers for DME therapies that require administration via an external infusion pump to expedite patient access once new Parkinson's therapies receive approvals from the Food and Drug Administration. Lobbying the Centers for Medicare and Medicaid Services to direct Durable Medical Equipment Medicare Administrative Contractors to provide additional clarification regarding the use of claim modifiers for DME therapies that require administration via an external infusion pump to expedite patient access once new Parkinson's therapies receive approvals from the Food and Drug Administration. H.R.2360/S.652/S.1339 - Safe Step Act: a bill to require group health plans to provide an exception process for any medication step therapy protocol to help ensure that people living with Parkinson's disease can safely and efficiently access treatments. Led an digital campaign to allow constituents to write their members of Congress in support of this legislation. H.R.8702/S.4532 - Improving Seniors Timely Access to Care Act: a bill to establish requirements with respect to the use of prior authorization under Medicare Advantage plans. H.R.830/S.1375 - Help Ensure Lower Patient Copays Act: a bill to require health insurance plans to apply certain payments made by, or on behalf of, a plan enrollee toward a plan's cost-sharing requirements. Specifically, plans must apply third-party payments, financial assistance, discounts, product vouchers, and other reductions in out-of-pocket expenses toward the requirements. Many Parkinson's patients rely on such third-party payments to afford medications to treat and manage their disease symptoms, and this legislation will ensure that all payments whether they come directly out of a pocket or with the help of copay assistance-counts toward out-of-pocket costs of patients. S.1544/H.R.1199 - Facilitating Innovative Nuclear Diagnostics Act of 2023: a bill to establish separate payment requirements for diagnostic radiopharmaceuticals, including DaTscans, which can aid in confirming a Parkinson's diagnosis, under the Medicare prospective payment system for hospital outpatient department services.
Facilitating Innovative Nuclear Diagnostics Act of 2023
Client: THE MICHAEL J. FOX FOUNDATION FOR PARKINSON'S RESEARCH · Firm: THE MICHAEL J. FOX FOUNDATION FOR PARKINSON'S RESEARCH
Lobbying to Increase Prescription Drug Affordability and Accessibility: Advocacy for Medicare Part D redesign and benefits for people living with Parkinson's, including expanding the low-income subsidy (LIS) program, capping out-of-pocket costs, implementing a smoothing mechanism, and streamlining utilization management processes. The Medicare Part D Six Protected Classes Policy: Requires Part D plans to cover all drugs in six classes: immunosuppressants, antidepressants, antipsychotics, anticonvulsants, antiretrovirals, and antineoplastics. For people living with Parkinson's, most of whom are Medicare beneficiaries, it is essential to have access to a wide range of treatment options for antidepressants and antipsychotics, which are crucial for managing non-motor symptoms like depression and psychosis. Signed Coalition Letters: - Medicare Access for Prescription Rx (MAPRx): Comment letter in response to Medicare Prescription Payment Plan Part One Guidance. - Patient and Provider Advocates for Telehealth: Comment letter in response to CMS CY 2024 Medicare Physician Fee Schedule (PFS) supporting expanded access to telehealth. - Alliance for Aging Research: Coalition letter in response to Medicare Prescription Payment Plan Part One Guidance supporting proposed beneficiary protections. H.R.4752/S.2379 - CHANGE Act of 2023: A bill to better utilize existing Medicare wellness visits for early screening, detection, and diagnosis of Alzheimer's and related dementias, including Parkinson's disease dementia. S.1544/H.R.1199 - Facilitating Innovative Nuclear Diagnostics Act of 2023: A bill to establish separate payment requirements for diagnostic radiopharmaceuticals, including DaTscans used to confirm Parkinson's diagnoses, under the Medicare outpatient prospective payment system. CMS-1809-P (2025 Medicare OPPS Proposed Rule): Comment supporting CMS's proposal to separately reimburse certain diagnostic radiopharmaceuticals used in diagnosing Parkinson's disease and atypical parkinsonisms. H.R.8702/S.4532 - Improving Seniors' Timely Access to Care Act: Establishes requirements for the use of prior authorization under Medicare Advantage plans to ensure timely access to care for seniors, including those with Parkinson's. S.3109/H.R.8018 - Alleviating Barriers for Caregivers (ABC) Act: Requires the Centers for Medicare & Medicaid Services (CMS) and Social Security to simplify processes and communications for family caregivers to assist individuals in accessing and utilizing benefits. S.3766/H.R.7274 - Connecting Caregivers to Medicare Act: Amends the Social Security Act to provide outreach and education to Medicare beneficiaries and simplify access to information for family caregivers through 1-800-MEDICARE. Advocacy for Durable Medical Equipment (DME) Access: Lobbying CMS to direct Medicare contractors to clarify claims procedures for DME therapies requiring administration via external infusion pumps, ensuring quick access to new Parkinson's therapies after FDA approval.
Facilitating Innovative Nuclear Diagnostics Act of 2023
Client: THE MICHAEL J. FOX FOUNDATION FOR PARKINSON'S RESEARCH · Firm: THE MICHAEL J. FOX FOUNDATION FOR PARKINSON'S RESEARCH
Lobbying to Improve Prescription Drug Affordability and Accessibility: Advocacy for people living with Parkinson's via Medicare Part D redesign and benefits, including expanding the low-income subsidy (LIS) program, capping out-of-pocket costs, implementing a smoothing mechanism, and streamlining utilization management processes. Medicare Part D Six Protected Classes Policy: Requires Part D plans to cover all drugs in six classes: immunosuppressants, antidepressants, antipsychotics, anticonvulsants, antiretrovirals, and antineoplastics. Access to a wide range of treatment options for antidepressants and antipsychotics is essential for Parkinson's patients due to non-motor symptoms such as depression and psychosis. Advocacy includes coalition meetings and letters to CMS in response to Medicare Prescription Payment Plan Part One Guidance to support continued protection for the six protected classes. H.R.2360/S.652/S.1339 - Safe Step Act: A bill requiring group health plans to provide an exception process for any medication step therapy protocol to ensure that Parkinson's patients can access treatments safely and efficiently. Led a digital campaign to allow constituents to write to members of Congress in support of the legislation. H.R.830/S.1375 - Help Ensure Lower Patient Copays Act: This bill requires health insurance plans to apply third-party payments, financial assistance, discounts, and other reductions in out-of-pocket expenses toward a plan's cost-sharing requirements. Many Parkinson's patients rely on such payments to afford medications, and this legislation ensures they count toward out-of-pocket costs. S.1544/H.R.1199 - Facilitating Innovative Nuclear Diagnostics Act of 2023: A bill to establish separate payment requirements for diagnostic radiopharmaceuticals, including DaTscans, under the Medicare prospective payment system for hospital outpatient department services. This will help confirm Parkinson's diagnoses more efficiently. CMS-1809-P (2025 Medicare Outpatient Prospective Payment System Proposed Rule): Supported CMS's proposal to separate payment for certain diagnostic radiopharmaceuticals, including those used to diagnose Parkinson's disease and atypical parkinsonisms, from the procedure payment and reimburse them separately. H.R.8702/S.4532 - Improving Seniors Timely Access to Care Act: A bill to establish requirements regarding the use of prior authorization under Medicare Advantage plans. Lobbying CMS: Advocacy efforts to direct Durable Medical Equipment Medicare Administrative Contractors to provide clarification on the use of claim modifiers for DME therapies administered via an external infusion pump to expedite patient access to new Parkinson's therapies once they are approved by the FDA.
Facilitating Innovative Nuclear Diagnostics Act of 2023
Client: THE MICHAEL J. FOX FOUNDATION FOR PARKINSON'S RESEARCH · Firm: THE MICHAEL J. FOX FOUNDATION FOR PARKINSON'S RESEARCH
H.R.2365/S.1064 - National Plan to End Parkinson's Act: A bill to create an advisory council comprising members of federal agencies that support research, care, and services for Parkinson's disease, as well as patients, care partners, researchers, clinicians, and other non-federal experts, to ensure efficient and effective coordination among all federal entities responsible for managing, treating, and curing Parkinson's disease. General Parkinson's Disease Information: Covers symptoms, triggers, health coverage, health costs, social determinants of health, data collection, research, environmental risks, and health access for underserved communities, particularly through the CDC's National Neurological Conditions Surveillance System (NNCSS). H.R.2630/S.652/S.1339 - Safe Step Act: Requires group health plans to provide an exception process for any medication step therapy protocol to ensure that individuals living with Parkinson's disease can access treatments safely and efficiently. Establishing Parkinson's Disease ICD-10-CM Codes: Aims to assist in the coordination of care for Parkinson's patients who experience OFF episodes and to allow researchers to gather data to study disease progression. S.1544/H.R.1199 - Facilitating Innovative Nuclear Diagnostics Act of 2023: A bill to establish separate payment requirements for diagnostic radiopharmaceuticals, including DaTscans, which aid in confirming a Parkinson's diagnosis under the Medicare prospective payment system for hospital outpatient services. H.R.3432 - Telemental Health Care Access Act of 2023: Permanently removes Medicare's originating site requirements for mental health services furnished via telehealth. Parkinson's non-motor symptoms include mental health conditions, and many people with Parkinson's are Medicare beneficiaries who may face barriers due to in-person requirements. H.R.830/S.1375 - Help Ensure Lower Patient Copays Act: A bill requiring health insurance plans to apply certain payments, including third-party payments, financial assistance, and product vouchers, toward a plan's cost-sharing requirements. This helps Parkinson's patients afford medications for managing symptoms. The Medicare Part D Six Protected Classes Policy: Requires Part D plans to cover all drugs in six protected classes, including antidepressants and antipsychotics. For individuals with Parkinson's disease, these medications are crucial for managing non-motor symptoms such as depression and psychosis. H.R.4752/S.2379 - CHANGE Act of 2023: A bill to improve early screening, detection, and diagnosis of Alzheimer's and related dementias, including Parkinson's disease dementia, during Medicare wellness visits. H.R.4942/S.655 - Conrad State 30 and Physician Access Reauthorization Act: Reauthorizes the Conrad State 30 program and improves policies to address health care provider shortages, supporting neurological care for Parkinson's patients. H.R.8702/S.4532 - Improving Seniors Timely Access to Care Act: Establishes requirements regarding the use of prior authorization under Medicare Advantage plans. H.R.9233/S.- The HEALTHY Brains Act: Draft legislation to create a Centers of Excellence grant program within the National Institutes of Health to focus on the intersection between environmental risk factors and neurodegenerative diseases. General Outreach for Establishing an ""Office of Caregiver Health"": Supports the creation of an Office of Caregiver Health within the Department of Health and Human Services to address the needs of caregivers, particularly in relation to Parkinson's disease care.
Facilitating Innovative Nuclear Diagnostics Act of 2023
Client: THE MICHAEL J. FOX FOUNDATION FOR PARKINSON'S RESEARCH · Firm: THE MICHAEL J. FOX FOUNDATION FOR PARKINSON'S RESEARCH
Lobbying to Increase Prescription Drug Affordability and Accessibility: Advocacy for Medicare Part D redesign and benefits for people living with Parkinson's, including expanding the low-income subsidy (LIS) program, capping out-of-pocket costs, implementing a smoothing mechanism, and streamlining utilization management processes. The Medicare Part D Six Protected Classes Policy: Requires Part D plans to cover all drugs in six classes: immunosuppressants, antidepressants, antipsychotics, anticonvulsants, antiretrovirals, and antineoplastics. For people living with Parkinson's, most of whom are Medicare beneficiaries, it is essential to have access to a wide range of treatment options for antidepressants and antipsychotics, which are crucial for managing non-motor symptoms like depression and psychosis. Signed Coalition Letters: - Medicare Access for Prescription Rx (MAPRx): Comment letter in response to Medicare Prescription Payment Plan Part One Guidance. - Patient and Provider Advocates for Telehealth: Comment letter in response to CMS CY 2024 Medicare Physician Fee Schedule (PFS) supporting expanded access to telehealth. - Alliance for Aging Research: Coalition letter in response to Medicare Prescription Payment Plan Part One Guidance supporting proposed beneficiary protections. H.R.4752/S.2379 - CHANGE Act of 2023: A bill to better utilize existing Medicare wellness visits for early screening, detection, and diagnosis of Alzheimer's and related dementias, including Parkinson's disease dementia. S.1544/H.R.1199 - Facilitating Innovative Nuclear Diagnostics Act of 2023: A bill to establish separate payment requirements for diagnostic radiopharmaceuticals, including DaTscans used to confirm Parkinson's diagnoses, under the Medicare outpatient prospective payment system. CMS-1809-P (2025 Medicare OPPS Proposed Rule): Comment supporting CMS's proposal to separately reimburse certain diagnostic radiopharmaceuticals used in diagnosing Parkinson's disease and atypical parkinsonisms. H.R.8702/S.4532 - Improving Seniors' Timely Access to Care Act: Establishes requirements for the use of prior authorization under Medicare Advantage plans to ensure timely access to care for seniors, including those with Parkinson's. S.3109/H.R.8018 - Alleviating Barriers for Caregivers (ABC) Act: Requires the Centers for Medicare & Medicaid Services (CMS) and Social Security to simplify processes and communications for family caregivers to assist individuals in accessing and utilizing benefits. S.3766/H.R.7274 - Connecting Caregivers to Medicare Act: Amends the Social Security Act to provide outreach and education to Medicare beneficiaries and simplify access to information for family caregivers through 1-800-MEDICARE. Advocacy for Durable Medical Equipment (DME) Access: Lobbying CMS to direct Medicare contractors to clarify claims procedures for DME therapies requiring administration via external infusion pumps, ensuring quick access to new Parkinson's therapies after FDA approval. H.R.8331/S. 4280 - Essential Caregivers Act of 2024: To amend titles XVIII and XIX of the Social Security Act to require skilled nursing facilities, nursing facilities, intermediate care facilities for the intellectually disabled, and inpatient rehabilitation facilities to permit essential caregivers access during any period in which regular visitation is restricted.
Facilitating Innovative Nuclear Diagnostics Act of 2023
Client: THE MICHAEL J. FOX FOUNDATION FOR PARKINSON'S RESEARCH · Firm: THE MICHAEL J. FOX FOUNDATION FOR PARKINSON'S RESEARCH
H.R.2365/S.1064 - National Plan to End Parkinson's Act: a bill to create an advisory council comprising members of federal agencies that support research, care, and services for Parkinsons, plus patients, care partners, researchers, clinicians, and other non-federal experts to ensure efficient and effective coordination among all federal entities with responsibility for managing, treating, and curing Parkinsons disease. General Parkinson's disease information about symptoms, triggers, health coverage, health costs, social determinants of health related to Parkinson's disease and data collection, research, environmental risks, and health access for underserved communities. Information related to prevalence particularly at CDC's National Neurological Conditions Surveillance System (NNCSS). H.R.2630/S.652/S.1339 - Safe Step Act: a bill to require group health plans to provide an exception process for any medication step therapy protocol to help ensure that people living with Parkinson's disease can safely and efficiently access treatments. Establishing Parkinson's disease ICD-10-CM codes to assist in the continuation and coordination of care for people living with Parkinson's who experience OFF episodes and to allow researchers to gather more data to study the progression of the disease. Reauthorization of CDCs National Neurological Conditions Surveillance System (NNCSS). S.1544/H.R.1199 - Facilitating Innovative Nuclear Diagnostics Act of 2023: a bill to establish separate payment requirements for diagnostic radiopharmaceuticals, including DaTscans, which can aid in confirming a Parkinson's diagnosis, under the Medicare prospective payment system for hospital outpatient department services. H.R.3432 - Telemental Health Care Access Act of 2023: a bill to permanently remove Medicare's originating site requirements for mental health services furnished via telehealth. Parkinson's non-motor symptoms encompass mental health conditions, including anxiety, depression, dementia, and other memory problems, and the majority of people living with Parkinson's in the United States are Medicare beneficiaries, many of whom will face undue burdens meeting the unnecessary in-person requirement for telemental health services after the delay of the requirement enforcement expires December 31, 2024. H.R.830/S.1375 - Help Ensure Lower Patient Copays Act: a bill to require health insurance plans to apply certain payments made by, or on behalf of, a plan enrollee toward a plan's cost-sharing requirements. Specifically, plans must apply third-party payments, financial assistance, discounts, product vouchers, and other reductions in out-of-pocket expenses toward the requirements. Many Parkinson's patients rely on such third-party payments to afford medications to treat and manage their disease symptoms, and this legislation will ensure that all payments whether they come directly out of a pocket or with the help of copay assistance-counts toward out-of-pocket costs of patients. The Medicare Part D Six Protected Classes Policy: requires Part D plan to cover all drugs in six classes: immunosuppressants, antidepressants, antipsychotics, anticonvulsants, antiretrovirals, and antineoplastics. For people living with Parkinson's, most of whom are Medicare beneficiaries, it is essential to have access to wide range of treatment options for antidepressants and antipsychotics. Parkinson's causes non-motor symptoms, including depression and psychosis, and individuals often experience different side effects, reactions, and efficacy based on which medications they take. H.R.4752/S.2379 - the Concentrating High-value Alzheimer's Needs to Get to an End (CHANGE) Act of 2023: a bill to better utilize the existing Welcome to Medicare initial exam and Medicare annual wellness visits to screen, detect, and diagnose Alzheimers and related dementias, including Parkinson's disease dementia, in their earliest stages. Signed Leaders Engaged on Alzheimer's Disease (LEAD) Coalition letter to members of Congress in support of this legislation. H.R.4942/S.655 - the Conrad State 30 and Physician Access Reauthorization Act: a bill to reauthorize the Conrad State 30 program for three years, make several targeted policy improvements, and permit the gradual expansion of the number of waivers granted to each state to address health care provider shortages. Signed American Academy of Neurology letter to member of Congress in support of this legislation. The Medicare Part D Six Protected Classes Policy: requires Part D plan to cover all drugs in six classes: immunosuppressants, antidepressants, antipsychotics, anticonvulsants, antiretrovirals, and antineoplastics. For people living with Parkinson's, most of whom are Medicare beneficiaries, it is essential to have access to wide range of treatment options for antidepressants and antipsychotics. Parkinson's causes non-motor symptoms, including depression and psychosis, and individuals often experience different side effects, reactions, and efficacy based on which medications they take. Partnership for Part D Access coalition congressional meetings and signed coalition letter to CMS in response to Medicare Prescription Payment Plan Part One Guidance in support of continued protection for the six protected classes policy. Signed Medicare Access for Prescription Rx (MAPRx) coalition comment letter in response to Medicare Prescription Payment Plan Part One Guidance. Signed Patient and Provider Advocates for Telehealth coalition comment letter in response to CMS CY 2024 Medicare Physician Fee Schedule (PFS) in support prioritizing the needs of patients by expanding policies that improved access to safe and timely health care via telehealth. Signed Alliance for Aging Research coalition letter in response to Medicare Prescription Payment Plan Part One Guidance in support of proposed beneficiary protections and to provide feedback on implementation considerations for the Medicare Prescription Payment Plan program. H.R.8702/S.4532 - Improving Seniors Timely Access to Care Act: a bill to establish requirements with respect to the use of prior authorization under Medicare Advantage plans. H.R./S.- The HEALTHY Brains Act- draft legislation to create a Centers of Excellence grant program within the National Institute of Health to focus on the intersection between environmental risk factors and neurodegenerative disease. General outreach and support for the establishment of an "Office of Caregiver Health" within the Office of the Secretary at the Department of Health and Human Services.
To provide for a limitation on availability of funds for Contribution to the International Development Association for fiscal year 2024.
Client: THE MICHAEL J. FOX FOUNDATION FOR PARKINSON'S RESEARCH · Firm: THE MICHAEL J. FOX FOUNDATION FOR PARKINSON'S RESEARCH
Lobbying to Improve Prescription Drug Affordability and Accessibility: Advocacy for people living with Parkinson's via Medicare Part D redesign and benefits, including expanding the low-income subsidy (LIS) program, capping out-of-pocket costs, implementing a smoothing mechanism, and streamlining utilization management processes. Medicare Part D Six Protected Classes Policy: Requires Part D plans to cover all drugs in six classes: immunosuppressants, antidepressants, antipsychotics, anticonvulsants, antiretrovirals, and antineoplastics. Access to a wide range of treatment options for antidepressants and antipsychotics is essential for Parkinson's patients due to non-motor symptoms such as depression and psychosis. Advocacy includes coalition meetings and letters to CMS in response to Medicare Prescription Payment Plan Part One Guidance to support continued protection for the six protected classes. H.R.2360/S.652/S.1339 - Safe Step Act: A bill requiring group health plans to provide an exception process for any medication step therapy protocol to ensure that Parkinson's patients can access treatments safely and efficiently. Led a digital campaign to allow constituents to write to members of Congress in support of the legislation. H.R.830/S.1375 - Help Ensure Lower Patient Copays Act: This bill requires health insurance plans to apply third-party payments, financial assistance, discounts, and other reductions in out-of-pocket expenses toward a plan's cost-sharing requirements. Many Parkinson's patients rely on such payments to afford medications, and this legislation ensures they count toward out-of-pocket costs. S.1544/H.R.1199 - Facilitating Innovative Nuclear Diagnostics Act of 2023: A bill to establish separate payment requirements for diagnostic radiopharmaceuticals, including DaTscans, under the Medicare prospective payment system for hospital outpatient department services. This will help confirm Parkinson's diagnoses more efficiently. CMS-1809-P (2025 Medicare Outpatient Prospective Payment System Proposed Rule): Supported CMS's proposal to separate payment for certain diagnostic radiopharmaceuticals, including those used to diagnose Parkinson's disease and atypical parkinsonisms, from the procedure payment and reimburse them separately. H.R.8702/S.4532 - Improving Seniors Timely Access to Care Act: A bill to establish requirements regarding the use of prior authorization under Medicare Advantage plans. Lobbying CMS: Advocacy efforts to direct Durable Medical Equipment Medicare Administrative Contractors to provide clarification on the use of claim modifiers for DME therapies administered via an external infusion pump to expedite patient access to new Parkinson's therapies once they are approved by the FDA.
To provide for a limitation on availability of funds for Contribution to the International Development Association for fiscal year 2024.
Client: THE MICHAEL J. FOX FOUNDATION FOR PARKINSON'S RESEARCH · Firm: THE MICHAEL J. FOX FOUNDATION FOR PARKINSON'S RESEARCH
Lobbying to improve prescription drug affordability and accessibility for people living with Parkinson's via Medicare Part D redesign and benefits, including expanding the low-income subsidy (LIS) program, capping out-of-pocket costs, implementing a smoothing mechanism, and streamlining utilization management processes. The Medicare Part D Six Protected Classes Policy: requires Part D plan to cover all drugs in six classes: immunosuppressants, antidepressants, antipsychotics, anticonvulsants, antiretrovirals, and antineoplastics. For people living with Parkinson's, most of whom are Medicare beneficiaries, it is essential to have access to wide range of treatment options for antidepressants and antipsychotics. Parkinson's causes non-motor symptoms, including depression and psychosis, and individuals often experience different side effects, reactions, and efficacy based on which medications they take. Partnership for Part D Access coalition congressional meetings and signed coalition letter to CMS in response to Medicare Prescription Payment Plan Part One Guidance in support of continued protection for the six protected classes policy. Signed Medicare Access for Prescription Rx (MAPRx) coalition comment letter in response to Medicare Prescription Payment Plan Part One Guidance. Signed Alliance for Aging Research coalition letter in response to Medicare Prescription Payment Plan Part One Guidance in support of proposed beneficiary protections and to provide feedback on implementation considerations for the Medicare Prescription Payment Plan program. H.R.2360/S.652/S.1339 - Safe Step Act: a bill to require group health plans to provide an exception process for any medication step therapy protocol to help ensure that people living with Parkinson's disease can safely and efficiently access treatments. Led a digital campaign to allow constituents to write their members of Congress in support of this legislation. Lobbying the Centers for Medicare and Medicaid Services to direct Durable Medical Equipment Medicare Administrative Contractors to provide additional clarification regarding the use of claim modifiers for DME therapies that require administration via an external infusion pump to expedite patient access once new Parkinson's therapies receive approvals from the Food and Drug Administration. Lobbying the Centers for Medicare and Medicaid Services to direct Durable Medical Equipment Medicare Administrative Contractors to provide additional clarification regarding the use of claim modifiers for DME therapies that require administration via an external infusion pump to expedite patient access once new Parkinson's therapies receive approvals from the Food and Drug Administration. H.R.2360/S.652/S.1339 - Safe Step Act: a bill to require group health plans to provide an exception process for any medication step therapy protocol to help ensure that people living with Parkinson's disease can safely and efficiently access treatments. Led an digital campaign to allow constituents to write their members of Congress in support of this legislation. H.R.8702/S.4532 - Improving Seniors Timely Access to Care Act: a bill to establish requirements with respect to the use of prior authorization under Medicare Advantage plans. H.R.830/S.1375 - Help Ensure Lower Patient Copays Act: a bill to require health insurance plans to apply certain payments made by, or on behalf of, a plan enrollee toward a plan's cost-sharing requirements. Specifically, plans must apply third-party payments, financial assistance, discounts, product vouchers, and other reductions in out-of-pocket expenses toward the requirements. Many Parkinson's patients rely on such third-party payments to afford medications to treat and manage their disease symptoms, and this legislation will ensure that all payments whether they come directly out of a pocket or with the help of copay assistance-counts toward out-of-pocket costs of patients. S.1544/H.R.1199 - Facilitating Innovative Nuclear Diagnostics Act of 2023: a bill to establish separate payment requirements for diagnostic radiopharmaceuticals, including DaTscans, which can aid in confirming a Parkinson's diagnosis, under the Medicare prospective payment system for hospital outpatient department services.
To provide for a limitation on availability of funds for Contribution to the International Development Association for fiscal year 2024.
Client: THE MICHAEL J. FOX FOUNDATION FOR PARKINSON'S RESEARCH · Firm: THE MICHAEL J. FOX FOUNDATION FOR PARKINSON'S RESEARCH
Lobbying to Improve Prescription Drug Affordability and Accessibility: Advocacy for people living with Parkinson's via Medicare Part D redesign and benefits, including expanding the low-income subsidy (LIS) program, capping out-of-pocket costs, implementing a smoothing mechanism, and streamlining utilization management processes. Medicare Part D Six Protected Classes Policy: Requires Part D plans to cover all drugs in six classes: immunosuppressants, antidepressants, antipsychotics, anticonvulsants, antiretrovirals, and antineoplastics. Access to a wide range of treatment options for antidepressants and antipsychotics is essential for Parkinson's patients due to non-motor symptoms such as depression and psychosis. Advocacy includes coalition meetings and letters to CMS in response to Medicare Prescription Payment Plan Part One Guidance to support continued protection for the six protected classes. H.R.2360/S.652/S.1339 - Safe Step Act: A bill requiring group health plans to provide an exception process for any medication step therapy protocol to ensure that Parkinson's patients can access treatments safely and efficiently. Led a digital campaign to allow constituents to write to members of Congress in support of the legislation. H.R.830/S.1375 - Help Ensure Lower Patient Copays Act: This bill requires health insurance plans to apply third-party payments, financial assistance, discounts, and other reductions in out-of-pocket expenses toward a plan's cost-sharing requirements. Many Parkinson's patients rely on such payments to afford medications, and this legislation ensures they count toward out-of-pocket costs. S.1544/H.R.1199 - Facilitating Innovative Nuclear Diagnostics Act of 2023: A bill to establish separate payment requirements for diagnostic radiopharmaceuticals, including DaTscans, under the Medicare prospective payment system for hospital outpatient department services. This will help confirm Parkinson's diagnoses more efficiently. CMS-1809-P (2025 Medicare Outpatient Prospective Payment System Proposed Rule): Supported CMS's proposal to separate payment for certain diagnostic radiopharmaceuticals, including those used to diagnose Parkinson's disease and atypical parkinsonisms, from the procedure payment and reimburse them separately. H.R.8702/S.4532 - Improving Seniors Timely Access to Care Act: A bill to establish requirements regarding the use of prior authorization under Medicare Advantage plans. Lobbying CMS: Advocacy efforts to direct Durable Medical Equipment Medicare Administrative Contractors to provide clarification on the use of claim modifiers for DME therapies administered via an external infusion pump to expedite patient access to new Parkinson's therapies once they are approved by the FDA.
Dr. Emmanuel Bilirakis and Honorable Jennifer Wexton National Plan to End Parkinson’s Act
Client: THE MICHAEL J. FOX FOUNDATION FOR PARKINSON'S RESEARCH · Firm: THE MICHAEL J. FOX FOUNDATION FOR PARKINSON'S RESEARCH
H.R.2365/S.1064 - National Plan to End Parkinson's Act: a bill to create an advisory council comprising members of federal agencies that support research, care, and services for Parkinsons, plus patients, care partners, researchers, clinicians, and other non-federal experts to ensure efficient and effective coordination among all federal entities with responsibility for managing, treating, and curing Parkinsons disease. General Parkinson's disease information about symptoms, triggers, health coverage, health costs, social determinants of health related to Parkinson's disease and data collection, research, environmental risks, and health access for underserved communities. Information related to prevalence particularly at CDC's National Neurological Conditions Surveillance System (NNCSS). H.R.2630/S.652/S.1339 - Safe Step Act: a bill to require group health plans to provide an exception process for any medication step therapy protocol to help ensure that people living with Parkinson's disease can safely and efficiently access treatments. Establishing Parkinson's disease ICD-10-CM codes to assist in the continuation and coordination of care for people living with Parkinson's who experience OFF episodes and to allow researchers to gather more data to study the progression of the disease. Reauthorization of CDCs National Neurological Conditions Surveillance System (NNCSS). S.1544/H.R.1199 - Facilitating Innovative Nuclear Diagnostics Act of 2023: a bill to establish separate payment requirements for diagnostic radiopharmaceuticals, including DaTscans, which can aid in confirming a Parkinson's diagnosis, under the Medicare prospective payment system for hospital outpatient department services. H.R.3432 - Telemental Health Care Access Act of 2023: a bill to permanently remove Medicare's originating site requirements for mental health services furnished via telehealth. Parkinson's non-motor symptoms encompass mental health conditions, including anxiety, depression, dementia, and other memory problems, and the majority of people living with Parkinson's in the United States are Medicare beneficiaries, many of whom will face undue burdens meeting the unnecessary in-person requirement for telemental health services after the delay of the requirement enforcement expires December 31, 2024. H.R.830/S.1375 - Help Ensure Lower Patient Copays Act: a bill to require health insurance plans to apply certain payments made by, or on behalf of, a plan enrollee toward a plan's cost-sharing requirements. Specifically, plans must apply third-party payments, financial assistance, discounts, product vouchers, and other reductions in out-of-pocket expenses toward the requirements. Many Parkinson's patients rely on such third-party payments to afford medications to treat and manage their disease symptoms, and this legislation will ensure that all payments whether they come directly out of a pocket or with the help of copay assistance-counts toward out-of-pocket costs of patients. The Medicare Part D Six Protected Classes Policy: requires Part D plan to cover all drugs in six classes: immunosuppressants, antidepressants, antipsychotics, anticonvulsants, antiretrovirals, and antineoplastics. For people living with Parkinson's, most of whom are Medicare beneficiaries, it is essential to have access to wide range of treatment options for antidepressants and antipsychotics. Parkinson's causes non-motor symptoms, including depression and psychosis, and individuals often experience different side effects, reactions, and efficacy based on which medications they take. H.R.4752/S.2379 - the Concentrating High-value Alzheimer's Needs to Get to an End (CHANGE) Act of 2023: a bill to better utilize the existing Welcome to Medicare initial exam and Medicare annual wellness visits to screen, detect, and diagnose Alzheimers and related dementias, including Parkinson's disease dementia, in their earliest stages. Signed Leaders Engaged on Alzheimer's Disease (LEAD) Coalition letter to members of Congress in support of this legislation. H.R.4942/S.655 - the Conrad State 30 and Physician Access Reauthorization Act: a bill to reauthorize the Conrad State 30 program for three years, make several targeted policy improvements, and permit the gradual expansion of the number of waivers granted to each state to address health care provider shortages. Signed American Academy of Neurology letter to member of Congress in support of this legislation. The Medicare Part D Six Protected Classes Policy: requires Part D plan to cover all drugs in six classes: immunosuppressants, antidepressants, antipsychotics, anticonvulsants, antiretrovirals, and antineoplastics. For people living with Parkinson's, most of whom are Medicare beneficiaries, it is essential to have access to wide range of treatment options for antidepressants and antipsychotics. Parkinson's causes non-motor symptoms, including depression and psychosis, and individuals often experience different side effects, reactions, and efficacy based on which medications they take. Partnership for Part D Access coalition congressional meetings and signed coalition letter to CMS in response to Medicare Prescription Payment Plan Part One Guidance in support of continued protection for the six protected classes policy. Signed Medicare Access for Prescription Rx (MAPRx) coalition comment letter in response to Medicare Prescription Payment Plan Part One Guidance. Signed Patient and Provider Advocates for Telehealth coalition comment letter in response to CMS CY 2024 Medicare Physician Fee Schedule (PFS) in support prioritizing the needs of patients by expanding policies that improved access to safe and timely health care via telehealth. Signed Alliance for Aging Research coalition letter in response to Medicare Prescription Payment Plan Part One Guidance in support of proposed beneficiary protections and to provide feedback on implementation considerations for the Medicare Prescription Payment Plan program.
Dr. Emmanuel Bilirakis and Honorable Jennifer Wexton National Plan to End Parkinson’s Act
Client: THE MICHAEL J. FOX FOUNDATION FOR PARKINSON'S RESEARCH · Firm: THE MICHAEL J. FOX FOUNDATION FOR PARKINSON'S RESEARCH
H.R.2365/S.1064 - National Plan to End Parkinson's Act: a bill to create an advisory council comprising members of federal agencies that support research, care, and services for Parkinsons, plus patients, care partners, researchers, clinicians, and other non-federal experts to ensure efficient and effective coordination among all federal entities with responsibility for managing, treating, and curing Parkinsons disease. General Parkinson's disease information about symptoms, triggers, health coverage, health costs, social determinants of health related to Parkinson's disease and data collection, research, environmental risks, and health access for underserved communities. Information related to prevalence particularly at CDC's National Neurological Conditions Surveillance System (NNCSS). H.R.2630/S.652/S.1339 - Safe Step Act: a bill to require group health plans to provide an exception process for any medication step therapy protocol to help ensure that people living with Parkinson's disease can safely and efficiently access treatments. Establishing Parkinson's disease ICD-10-CM codes to assist in the continuation and coordination of care for people living with Parkinson's who experience OFF episodes and to allow researchers to gather more data to study the progression of the disease. Reauthorization of CDCs National Neurological Conditions Surveillance System (NNCSS). S.1544/H.R.1199 - Facilitating Innovative Nuclear Diagnostics Act of 2023: a bill to establish separate payment requirements for diagnostic radiopharmaceuticals, including DaTscans, which can aid in confirming a Parkinson's diagnosis, under the Medicare prospective payment system for hospital outpatient department services. H.R.3432 - Telemental Health Care Access Act of 2023: a bill to permanently remove Medicare's originating site requirements for mental health services furnished via telehealth. Parkinson's non-motor symptoms encompass mental health conditions, including anxiety, depression, dementia, and other memory problems, and the majority of people living with Parkinson's in the United States are Medicare beneficiaries, many of whom will face undue burdens meeting the unnecessary in-person requirement for telemental health services after the delay of the requirement enforcement expires December 31, 2024. H.R.830/S.1375 - Help Ensure Lower Patient Copays Act: a bill to require health insurance plans to apply certain payments made by, or on behalf of, a plan enrollee toward a plan's cost-sharing requirements. Specifically, plans must apply third-party payments, financial assistance, discounts, product vouchers, and other reductions in out-of-pocket expenses toward the requirements. Many Parkinson's patients rely on such third-party payments to afford medications to treat and manage their disease symptoms, and this legislation will ensure that all payments whether they come directly out of a pocket or with the help of copay assistance-counts toward out-of-pocket costs of patients. The Medicare Part D Six Protected Classes Policy: requires Part D plan to cover all drugs in six classes: immunosuppressants, antidepressants, antipsychotics, anticonvulsants, antiretrovirals, and antineoplastics. For people living with Parkinson's, most of whom are Medicare beneficiaries, it is essential to have access to wide range of treatment options for antidepressants and antipsychotics. Parkinson's causes non-motor symptoms, including depression and psychosis, and individuals often experience different side effects, reactions, and efficacy based on which medications they take. H.R.4752/S.2379 - the Concentrating High-value Alzheimer's Needs to Get to an End (CHANGE) Act of 2023: a bill to better utilize the existing Welcome to Medicare initial exam and Medicare annual wellness visits to screen, detect, and diagnose Alzheimers and related dementias, including Parkinson's disease dementia, in their earliest stages. Signed Leaders Engaged on Alzheimer's Disease (LEAD) Coalition letter to members of Congress in support of this legislation. H.R.4942/S.655 - the Conrad State 30 and Physician Access Reauthorization Act: a bill to reauthorize the Conrad State 30 program for three years, make several targeted policy improvements, and permit the gradual expansion of the number of waivers granted to each state to address health care provider shortages. Signed American Academy of Neurology letter to member of Congress in support of this legislation. The Medicare Part D Six Protected Classes Policy: requires Part D plan to cover all drugs in six classes: immunosuppressants, antidepressants, antipsychotics, anticonvulsants, antiretrovirals, and antineoplastics. For people living with Parkinson's, most of whom are Medicare beneficiaries, it is essential to have access to wide range of treatment options for antidepressants and antipsychotics. Parkinson's causes non-motor symptoms, including depression and psychosis, and individuals often experience different side effects, reactions, and efficacy based on which medications they take. Partnership for Part D Access coalition congressional meetings and signed coalition letter to CMS in response to Medicare Prescription Payment Plan Part One Guidance in support of continued protection for the six protected classes policy. Signed Medicare Access for Prescription Rx (MAPRx) coalition comment letter in response to Medicare Prescription Payment Plan Part One Guidance. Signed Patient and Provider Advocates for Telehealth coalition comment letter in response to CMS CY 2024 Medicare Physician Fee Schedule (PFS) in support prioritizing the needs of patients by expanding policies that improved access to safe and timely health care via telehealth. Signed Alliance for Aging Research coalition letter in response to Medicare Prescription Payment Plan Part One Guidance in support of proposed beneficiary protections and to provide feedback on implementation considerations for the Medicare Prescription Payment Plan program. H.R.8702/S.4532 - Improving Seniors Timely Access to Care Act: a bill to establish requirements with respect to the use of prior authorization under Medicare Advantage plans. H.R./S.- The HEALTHY Brains Act- draft legislation to create a Centers of Excellence grant program within the National Institute of Health to focus on the intersection between environmental risk factors and neurodegenerative disease. General outreach and support for the establishment of an "Office of Caregiver Health" within the Office of the Secretary at the Department of Health and Human Services.
Dr. Emmanuel Bilirakis and Honorable Jennifer Wexton National Plan to End Parkinson’s Act
Client: THE MICHAEL J. FOX FOUNDATION FOR PARKINSON'S RESEARCH · Firm: THE MICHAEL J. FOX FOUNDATION FOR PARKINSON'S RESEARCH
H.R.2365/S.1064 - National Plan to End Parkinson's Act: A bill to create an advisory council comprising members of federal agencies that support research, care, and services for Parkinson's disease, as well as patients, care partners, researchers, clinicians, and other non-federal experts, to ensure efficient and effective coordination among all federal entities responsible for managing, treating, and curing Parkinson's disease. General Parkinson's Disease Information: Covers symptoms, triggers, health coverage, health costs, social determinants of health, data collection, research, environmental risks, and health access for underserved communities, particularly through the CDC's National Neurological Conditions Surveillance System (NNCSS). H.R.2630/S.652/S.1339 - Safe Step Act: Requires group health plans to provide an exception process for any medication step therapy protocol to ensure that individuals living with Parkinson's disease can access treatments safely and efficiently. Establishing Parkinson's Disease ICD-10-CM Codes: Aims to assist in the coordination of care for Parkinson's patients who experience OFF episodes and to allow researchers to gather data to study disease progression. S.1544/H.R.1199 - Facilitating Innovative Nuclear Diagnostics Act of 2023: A bill to establish separate payment requirements for diagnostic radiopharmaceuticals, including DaTscans, which aid in confirming a Parkinson's diagnosis under the Medicare prospective payment system for hospital outpatient services. H.R.3432 - Telemental Health Care Access Act of 2023: Permanently removes Medicare's originating site requirements for mental health services furnished via telehealth. Parkinson's non-motor symptoms include mental health conditions, and many people with Parkinson's are Medicare beneficiaries who may face barriers due to in-person requirements. H.R.830/S.1375 - Help Ensure Lower Patient Copays Act: A bill requiring health insurance plans to apply certain payments, including third-party payments, financial assistance, and product vouchers, toward a plan's cost-sharing requirements. This helps Parkinson's patients afford medications for managing symptoms. The Medicare Part D Six Protected Classes Policy: Requires Part D plans to cover all drugs in six protected classes, including antidepressants and antipsychotics. For individuals with Parkinson's disease, these medications are crucial for managing non-motor symptoms such as depression and psychosis. H.R.4752/S.2379 - CHANGE Act of 2023: A bill to improve early screening, detection, and diagnosis of Alzheimer's and related dementias, including Parkinson's disease dementia, during Medicare wellness visits. H.R.4942/S.655 - Conrad State 30 and Physician Access Reauthorization Act: Reauthorizes the Conrad State 30 program and improves policies to address health care provider shortages, supporting neurological care for Parkinson's patients. H.R.8702/S.4532 - Improving Seniors Timely Access to Care Act: Establishes requirements regarding the use of prior authorization under Medicare Advantage plans. H.R.9233/S.- The HEALTHY Brains Act: Draft legislation to create a Centers of Excellence grant program within the National Institutes of Health to focus on the intersection between environmental risk factors and neurodegenerative diseases. General Outreach for Establishing an ""Office of Caregiver Health"": Supports the creation of an Office of Caregiver Health within the Department of Health and Human Services to address the needs of caregivers, particularly in relation to Parkinson's disease care.
Dr. Emmanuel Bilirakis and Honorable Jennifer Wexton National Plan to End Parkinson’s Act
Client: THE MICHAEL J. FOX FOUNDATION FOR PARKINSON'S RESEARCH · Firm: THE MICHAEL J. FOX FOUNDATION FOR PARKINSON'S RESEARCH
H.R.2365/S.1064 - National Plan to End Parkinson's Act: A bill to create an advisory council comprising members of federal agencies that support research, care, and services for Parkinson's disease, as well as patients, care partners, researchers, clinicians, and other non-federal experts, to ensure efficient and effective coordination among all federal entities responsible for managing, treating, and curing Parkinson's disease. General Parkinson's Disease Information: Covers symptoms, triggers, health coverage, health costs, social determinants of health, data collection, research, environmental risks, and health access for underserved communities, particularly through the CDC's National Neurological Conditions Surveillance System (NNCSS). H.R.2630/S.652/S.1339 - Safe Step Act: Requires group health plans to provide an exception process for any medication step therapy protocol to ensure that individuals living with Parkinson's disease can access treatments safely and efficiently. Establishing Parkinson's Disease ICD-10-CM Codes: Aims to assist in the coordination of care for Parkinson's patients who experience OFF episodes and to allow researchers to gather data to study disease progression. S.1544/H.R.1199 - Facilitating Innovative Nuclear Diagnostics Act of 2023: A bill to establish separate payment requirements for diagnostic radiopharmaceuticals, including DaTscans, which aid in confirming a Parkinson's diagnosis under the Medicare prospective payment system for hospital outpatient services. H.R.3432 - Telemental Health Care Access Act of 2023: Permanently removes Medicare's originating site requirements for mental health services furnished via telehealth. Parkinson's non-motor symptoms include mental health conditions, and many people with Parkinson's are Medicare beneficiaries who may face barriers due to in-person requirements. H.R.830/S.1375 - Help Ensure Lower Patient Copays Act: A bill requiring health insurance plans to apply certain payments, including third-party payments, financial assistance, and product vouchers, toward a plan's cost-sharing requirements. This helps Parkinson's patients afford medications for managing symptoms. The Medicare Part D Six Protected Classes Policy: Requires Part D plans to cover all drugs in six protected classes, including antidepressants and antipsychotics. For individuals with Parkinson's disease, these medications are crucial for managing non-motor symptoms such as depression and psychosis. H.R.4752/S.2379 - CHANGE Act of 2023: A bill to improve early screening, detection, and diagnosis of Alzheimer's and related dementias, including Parkinson's disease dementia, during Medicare wellness visits. H.R.4942/S.655 - Conrad State 30 and Physician Access Reauthorization Act: Reauthorizes the Conrad State 30 program and improves policies to address health care provider shortages, supporting neurological care for Parkinson's patients. H.R.8702/S.4532 - Improving Seniors Timely Access to Care Act: Establishes requirements regarding the use of prior authorization under Medicare Advantage plans. H.R.9233/S.- The HEALTHY Brains Act: Draft legislation to create a Centers of Excellence grant program within the National Institutes of Health to focus on the intersection between environmental risk factors and neurodegenerative diseases. H.R.8331/S. 4280 - Essential Caregivers Act of 2024: To amend titles XVIII and XIX of the Social Security Act to require skilled nursing facilities, nursing facilities, intermediate care facilities for the intellectually disabled, and inpatient rehabilitation facilities to permit essential caregivers access during any period in which regular visitation is restricted. General Outreach for Establishing an ""Office of Caregiver Health"": Supports the creation of an Office of Caregiver Health within the Department of Health and Human Services to address the needs of caregivers, particularly in relation to Parkinson's disease care.
Dr. Emmanuel Bilirakis and Honorable Jennifer Wexton National Plan to End Parkinson’s Act
Client: THE MICHAEL J. FOX FOUNDATION FOR PARKINSON'S RESEARCH · Firm: THE MICHAEL J. FOX FOUNDATION FOR PARKINSON'S RESEARCH
FY 2025 Appropriations bills including funding requests for Parkinson's research within: H.R.8774/ S.4921: The Department of Defense within the FY 2025 Defense Appropriation bill. Funding for the Parkinson's Research Program (PRP) under the Department of Defense's Congressionally Directed Medical Research Programs (CDMRP). H.R.9029/S.4942: The National Institute of Health and Centers for Disease Control and Prevention within the FY 2025 Labor, Health and Human Services, Education, and Related Agencies Appropriation bill. Possible funding to implement the National Plan to End Parkinson's Act (HR 2365/ PL 118-66) within LHHS appropriations. H.R.9027/ S.4690: The Food and Drug Administration within the FY 2025 Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriation bill. H.R.8580/ S.4677: The Department of Veterans Affairs within the FY 2025 Military Construction, Veterans Affairs, and Related Agencies Appropriation bill. Support funding for Neurology Centers of Excellence and medical care and research through Veterans Health Administration, including the Parkinson's Disease Research, Education and Clinical Centers. H.R.9029/S.4942: General advocacy in support of robust non-defense discretionary investments in Labor, Health and Human Services, Education and Related Agencies appropriations bill for FY 2025. Funding for discretionary, non-defense priorities including overall investment in the National Institute of Health, ARPA-H, and Centers for Disease Control and Prevention within the FY 2025 Labor, Health and Human Services, Education, and Related Agencies Appropriation bills. Funding for the Parkinson's Research Program (PRP) under the Department of Defense's Congressionally Directed Medical Research Programs (CDMRP). Increased funding for NIEHS (no bill introduced).
Dr. Emmanuel Bilirakis and Honorable Jennifer Wexton National Plan to End Parkinson’s Act
Client: THE MICHAEL J. FOX FOUNDATION FOR PARKINSON'S RESEARCH · Firm: THE MICHAEL J. FOX FOUNDATION FOR PARKINSON'S RESEARCH
FY 2025 Appropriations bills including funding requests for Parkinson's research within: H.R.8774/ S.4921: The Department of Defense within the FY 2025 Defense Appropriation bill. Funding for the Parkinson's Research Program (PRP) under the Department of Defense's Congressionally Directed Medical Research Programs (CDMRP). H.R.9029/S.4942: The National Institute of Health and Centers for Disease Control and Prevention within the FY 2025 Labor, Health and Human Services, Education, and Related Agencies Appropriation bill. Possible funding to implement the National Plan to End Parkinson's Act (HR 2365/ PL 118-66) within LHHS appropriations. H.R.9027/ S.4690: The Food and Drug Administration within the FY 2025 Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriation bill. H.R.8580/ S.4677: The Department of Veterans Affairs within the FY 2025 Military Construction, Veterans Affairs, and Related Agencies Appropriation bill. Support funding for Neurology Centers of Excellence and medical care and research through Veterans Health Administration, including the Parkinson's Disease Research, Education and Clinical Centers. H.R.9029/S.4942: General advocacy in support of robust non-defense discretionary investments in Labor, Health and Human Services, Education and Related Agencies appropriations bill for FY 2025. Funding for discretionary, non-defense priorities including overall investment in the National Institute of Health, ARPA-H, and Centers for Disease Control and Prevention within the FY 2025 Labor, Health and Human Services, Education, and Related Agencies Appropriation bills. Funding for the Parkinson's Research Program (PRP) under the Department of Defense's Congressionally Directed Medical Research Programs (CDMRP). Increased funding for NIEHS (no bill introduced). H.R.9233: The HEALTHY BRAINS Act - developing support for implementation funding for centers of excellence within NIH.
Safe Step Act
Client: THE MICHAEL J. FOX FOUNDATION FOR PARKINSON'S RESEARCH · Firm: THE MICHAEL J. FOX FOUNDATION FOR PARKINSON'S RESEARCH
H.R.2365/S.1064 - National Plan to End Parkinson's Act: a bill to create an advisory council comprising members of federal agencies that support research, care, and services for Parkinsons, plus patients, care partners, researchers, clinicians, and other non-federal experts to ensure efficient and effective coordination among all federal entities with responsibility for managing, treating, and curing Parkinsons disease. General Parkinson's disease information about symptoms, triggers, health coverage, health costs, social determinants of health related to Parkinson's disease and data collection, research, environmental risks, and health access for underserved communities. Information related to prevalence particularly at CDC's National Neurological Conditions Surveillance System (NNCSS). H.R.2630/S.652/S.1339 - Safe Step Act: a bill to require group health plans to provide an exception process for any medication step therapy protocol to help ensure that people living with Parkinson's disease can safely and efficiently access treatments. Establishing Parkinson's disease ICD-10-CM codes to assist in the continuation and coordination of care for people living with Parkinson's who experience OFF episodes and to allow researchers to gather more data to study the progression of the disease. Reauthorization of CDCs National Neurological Conditions Surveillance System (NNCSS). S.1544/H.R.1199 - Facilitating Innovative Nuclear Diagnostics Act of 2023: a bill to establish separate payment requirements for diagnostic radiopharmaceuticals, including DaTscans, which can aid in confirming a Parkinson's diagnosis, under the Medicare prospective payment system for hospital outpatient department services. H.R.3432 - Telemental Health Care Access Act of 2023: a bill to permanently remove Medicare's originating site requirements for mental health services furnished via telehealth. Parkinson's non-motor symptoms encompass mental health conditions, including anxiety, depression, dementia, and other memory problems, and the majority of people living with Parkinson's in the United States are Medicare beneficiaries, many of whom will face undue burdens meeting the unnecessary in-person requirement for telemental health services after the delay of the requirement enforcement expires December 31, 2024. H.R.830/S.1375 - Help Ensure Lower Patient Copays Act: a bill to require health insurance plans to apply certain payments made by, or on behalf of, a plan enrollee toward a plan's cost-sharing requirements. Specifically, plans must apply third-party payments, financial assistance, discounts, product vouchers, and other reductions in out-of-pocket expenses toward the requirements. Many Parkinson's patients rely on such third-party payments to afford medications to treat and manage their disease symptoms, and this legislation will ensure that all payments whether they come directly out of a pocket or with the help of copay assistance-counts toward out-of-pocket costs of patients. The Medicare Part D Six Protected Classes Policy: requires Part D plan to cover all drugs in six classes: immunosuppressants, antidepressants, antipsychotics, anticonvulsants, antiretrovirals, and antineoplastics. For people living with Parkinson's, most of whom are Medicare beneficiaries, it is essential to have access to wide range of treatment options for antidepressants and antipsychotics. Parkinson's causes non-motor symptoms, including depression and psychosis, and individuals often experience different side effects, reactions, and efficacy based on which medications they take. H.R.4752/S.2379 - the Concentrating High-value Alzheimer's Needs to Get to an End (CHANGE) Act of 2023: a bill to better utilize the existing Welcome to Medicare initial exam and Medicare annual wellness visits to screen, detect, and diagnose Alzheimers and related dementias, including Parkinson's disease dementia, in their earliest stages. Signed Leaders Engaged on Alzheimer's Disease (LEAD) Coalition letter to members of Congress in support of this legislation. H.R.4942/S.655 - the Conrad State 30 and Physician Access Reauthorization Act: a bill to reauthorize the Conrad State 30 program for three years, make several targeted policy improvements, and permit the gradual expansion of the number of waivers granted to each state to address health care provider shortages. Signed American Academy of Neurology letter to member of Congress in support of this legislation. The Medicare Part D Six Protected Classes Policy: requires Part D plan to cover all drugs in six classes: immunosuppressants, antidepressants, antipsychotics, anticonvulsants, antiretrovirals, and antineoplastics. For people living with Parkinson's, most of whom are Medicare beneficiaries, it is essential to have access to wide range of treatment options for antidepressants and antipsychotics. Parkinson's causes non-motor symptoms, including depression and psychosis, and individuals often experience different side effects, reactions, and efficacy based on which medications they take. Partnership for Part D Access coalition congressional meetings and signed coalition letter to CMS in response to Medicare Prescription Payment Plan Part One Guidance in support of continued protection for the six protected classes policy. Signed Medicare Access for Prescription Rx (MAPRx) coalition comment letter in response to Medicare Prescription Payment Plan Part One Guidance. Signed Patient and Provider Advocates for Telehealth coalition comment letter in response to CMS CY 2024 Medicare Physician Fee Schedule (PFS) in support prioritizing the needs of patients by expanding policies that improved access to safe and timely health care via telehealth. Signed Alliance for Aging Research coalition letter in response to Medicare Prescription Payment Plan Part One Guidance in support of proposed beneficiary protections and to provide feedback on implementation considerations for the Medicare Prescription Payment Plan program.
Safe Step Act
Client: THE MICHAEL J. FOX FOUNDATION FOR PARKINSON'S RESEARCH · Firm: THE MICHAEL J. FOX FOUNDATION FOR PARKINSON'S RESEARCH
H.R.2365/S.1064 - National Plan to End Parkinson's Act: A bill to create an advisory council comprising members of federal agencies that support research, care, and services for Parkinson's disease, as well as patients, care partners, researchers, clinicians, and other non-federal experts, to ensure efficient and effective coordination among all federal entities responsible for managing, treating, and curing Parkinson's disease. General Parkinson's Disease Information: Covers symptoms, triggers, health coverage, health costs, social determinants of health, data collection, research, environmental risks, and health access for underserved communities, particularly through the CDC's National Neurological Conditions Surveillance System (NNCSS). H.R.2630/S.652/S.1339 - Safe Step Act: Requires group health plans to provide an exception process for any medication step therapy protocol to ensure that individuals living with Parkinson's disease can access treatments safely and efficiently. Establishing Parkinson's Disease ICD-10-CM Codes: Aims to assist in the coordination of care for Parkinson's patients who experience OFF episodes and to allow researchers to gather data to study disease progression. S.1544/H.R.1199 - Facilitating Innovative Nuclear Diagnostics Act of 2023: A bill to establish separate payment requirements for diagnostic radiopharmaceuticals, including DaTscans, which aid in confirming a Parkinson's diagnosis under the Medicare prospective payment system for hospital outpatient services. H.R.3432 - Telemental Health Care Access Act of 2023: Permanently removes Medicare's originating site requirements for mental health services furnished via telehealth. Parkinson's non-motor symptoms include mental health conditions, and many people with Parkinson's are Medicare beneficiaries who may face barriers due to in-person requirements. H.R.830/S.1375 - Help Ensure Lower Patient Copays Act: A bill requiring health insurance plans to apply certain payments, including third-party payments, financial assistance, and product vouchers, toward a plan's cost-sharing requirements. This helps Parkinson's patients afford medications for managing symptoms. The Medicare Part D Six Protected Classes Policy: Requires Part D plans to cover all drugs in six protected classes, including antidepressants and antipsychotics. For individuals with Parkinson's disease, these medications are crucial for managing non-motor symptoms such as depression and psychosis. H.R.4752/S.2379 - CHANGE Act of 2023: A bill to improve early screening, detection, and diagnosis of Alzheimer's and related dementias, including Parkinson's disease dementia, during Medicare wellness visits. H.R.4942/S.655 - Conrad State 30 and Physician Access Reauthorization Act: Reauthorizes the Conrad State 30 program and improves policies to address health care provider shortages, supporting neurological care for Parkinson's patients. H.R.8702/S.4532 - Improving Seniors Timely Access to Care Act: Establishes requirements regarding the use of prior authorization under Medicare Advantage plans. H.R.9233/S.- The HEALTHY Brains Act: Draft legislation to create a Centers of Excellence grant program within the National Institutes of Health to focus on the intersection between environmental risk factors and neurodegenerative diseases. General Outreach for Establishing an ""Office of Caregiver Health"": Supports the creation of an Office of Caregiver Health within the Department of Health and Human Services to address the needs of caregivers, particularly in relation to Parkinson's disease care.
Safe Step Act
Client: THE MICHAEL J. FOX FOUNDATION FOR PARKINSON'S RESEARCH · Firm: THE MICHAEL J. FOX FOUNDATION FOR PARKINSON'S RESEARCH
H.R.2365/S.1064 - National Plan to End Parkinson's Act: a bill to create an advisory council comprising members of federal agencies that support research, care, and services for Parkinsons, plus patients, care partners, researchers, clinicians, and other non-federal experts to ensure efficient and effective coordination among all federal entities with responsibility for managing, treating, and curing Parkinsons disease. General Parkinson's disease information about symptoms, triggers, health coverage, health costs, social determinants of health related to Parkinson's disease and data collection, research, environmental risks, and health access for underserved communities. Information related to prevalence particularly at CDC's National Neurological Conditions Surveillance System (NNCSS). H.R.2630/S.652/S.1339 - Safe Step Act: a bill to require group health plans to provide an exception process for any medication step therapy protocol to help ensure that people living with Parkinson's disease can safely and efficiently access treatments. Establishing Parkinson's disease ICD-10-CM codes to assist in the continuation and coordination of care for people living with Parkinson's who experience OFF episodes and to allow researchers to gather more data to study the progression of the disease. Reauthorization of CDCs National Neurological Conditions Surveillance System (NNCSS). S.1544/H.R.1199 - Facilitating Innovative Nuclear Diagnostics Act of 2023: a bill to establish separate payment requirements for diagnostic radiopharmaceuticals, including DaTscans, which can aid in confirming a Parkinson's diagnosis, under the Medicare prospective payment system for hospital outpatient department services. H.R.3432 - Telemental Health Care Access Act of 2023: a bill to permanently remove Medicare's originating site requirements for mental health services furnished via telehealth. Parkinson's non-motor symptoms encompass mental health conditions, including anxiety, depression, dementia, and other memory problems, and the majority of people living with Parkinson's in the United States are Medicare beneficiaries, many of whom will face undue burdens meeting the unnecessary in-person requirement for telemental health services after the delay of the requirement enforcement expires December 31, 2024. H.R.830/S.1375 - Help Ensure Lower Patient Copays Act: a bill to require health insurance plans to apply certain payments made by, or on behalf of, a plan enrollee toward a plan's cost-sharing requirements. Specifically, plans must apply third-party payments, financial assistance, discounts, product vouchers, and other reductions in out-of-pocket expenses toward the requirements. Many Parkinson's patients rely on such third-party payments to afford medications to treat and manage their disease symptoms, and this legislation will ensure that all payments whether they come directly out of a pocket or with the help of copay assistance-counts toward out-of-pocket costs of patients. The Medicare Part D Six Protected Classes Policy: requires Part D plan to cover all drugs in six classes: immunosuppressants, antidepressants, antipsychotics, anticonvulsants, antiretrovirals, and antineoplastics. For people living with Parkinson's, most of whom are Medicare beneficiaries, it is essential to have access to wide range of treatment options for antidepressants and antipsychotics. Parkinson's causes non-motor symptoms, including depression and psychosis, and individuals often experience different side effects, reactions, and efficacy based on which medications they take. H.R.4752/S.2379 - the Concentrating High-value Alzheimer's Needs to Get to an End (CHANGE) Act of 2023: a bill to better utilize the existing Welcome to Medicare initial exam and Medicare annual wellness visits to screen, detect, and diagnose Alzheimers and related dementias, including Parkinson's disease dementia, in their earliest stages. Signed Leaders Engaged on Alzheimer's Disease (LEAD) Coalition letter to members of Congress in support of this legislation. H.R.4942/S.655 - the Conrad State 30 and Physician Access Reauthorization Act: a bill to reauthorize the Conrad State 30 program for three years, make several targeted policy improvements, and permit the gradual expansion of the number of waivers granted to each state to address health care provider shortages. Signed American Academy of Neurology letter to member of Congress in support of this legislation. The Medicare Part D Six Protected Classes Policy: requires Part D plan to cover all drugs in six classes: immunosuppressants, antidepressants, antipsychotics, anticonvulsants, antiretrovirals, and antineoplastics. For people living with Parkinson's, most of whom are Medicare beneficiaries, it is essential to have access to wide range of treatment options for antidepressants and antipsychotics. Parkinson's causes non-motor symptoms, including depression and psychosis, and individuals often experience different side effects, reactions, and efficacy based on which medications they take. Partnership for Part D Access coalition congressional meetings and signed coalition letter to CMS in response to Medicare Prescription Payment Plan Part One Guidance in support of continued protection for the six protected classes policy. Signed Medicare Access for Prescription Rx (MAPRx) coalition comment letter in response to Medicare Prescription Payment Plan Part One Guidance. Signed Patient and Provider Advocates for Telehealth coalition comment letter in response to CMS CY 2024 Medicare Physician Fee Schedule (PFS) in support prioritizing the needs of patients by expanding policies that improved access to safe and timely health care via telehealth. Signed Alliance for Aging Research coalition letter in response to Medicare Prescription Payment Plan Part One Guidance in support of proposed beneficiary protections and to provide feedback on implementation considerations for the Medicare Prescription Payment Plan program. H.R.8702/S.4532 - Improving Seniors Timely Access to Care Act: a bill to establish requirements with respect to the use of prior authorization under Medicare Advantage plans. H.R./S.- The HEALTHY Brains Act- draft legislation to create a Centers of Excellence grant program within the National Institute of Health to focus on the intersection between environmental risk factors and neurodegenerative disease. General outreach and support for the establishment of an "Office of Caregiver Health" within the Office of the Secretary at the Department of Health and Human Services.
Safe Step Act
Client: THE MICHAEL J. FOX FOUNDATION FOR PARKINSON'S RESEARCH · Firm: THE MICHAEL J. FOX FOUNDATION FOR PARKINSON'S RESEARCH
H.R.2365/S.1064 - National Plan to End Parkinson's Act: A bill to create an advisory council comprising members of federal agencies that support research, care, and services for Parkinson's disease, as well as patients, care partners, researchers, clinicians, and other non-federal experts, to ensure efficient and effective coordination among all federal entities responsible for managing, treating, and curing Parkinson's disease. General Parkinson's Disease Information: Covers symptoms, triggers, health coverage, health costs, social determinants of health, data collection, research, environmental risks, and health access for underserved communities, particularly through the CDC's National Neurological Conditions Surveillance System (NNCSS). H.R.2630/S.652/S.1339 - Safe Step Act: Requires group health plans to provide an exception process for any medication step therapy protocol to ensure that individuals living with Parkinson's disease can access treatments safely and efficiently. Establishing Parkinson's Disease ICD-10-CM Codes: Aims to assist in the coordination of care for Parkinson's patients who experience OFF episodes and to allow researchers to gather data to study disease progression. S.1544/H.R.1199 - Facilitating Innovative Nuclear Diagnostics Act of 2023: A bill to establish separate payment requirements for diagnostic radiopharmaceuticals, including DaTscans, which aid in confirming a Parkinson's diagnosis under the Medicare prospective payment system for hospital outpatient services. H.R.3432 - Telemental Health Care Access Act of 2023: Permanently removes Medicare's originating site requirements for mental health services furnished via telehealth. Parkinson's non-motor symptoms include mental health conditions, and many people with Parkinson's are Medicare beneficiaries who may face barriers due to in-person requirements. H.R.830/S.1375 - Help Ensure Lower Patient Copays Act: A bill requiring health insurance plans to apply certain payments, including third-party payments, financial assistance, and product vouchers, toward a plan's cost-sharing requirements. This helps Parkinson's patients afford medications for managing symptoms. The Medicare Part D Six Protected Classes Policy: Requires Part D plans to cover all drugs in six protected classes, including antidepressants and antipsychotics. For individuals with Parkinson's disease, these medications are crucial for managing non-motor symptoms such as depression and psychosis. H.R.4752/S.2379 - CHANGE Act of 2023: A bill to improve early screening, detection, and diagnosis of Alzheimer's and related dementias, including Parkinson's disease dementia, during Medicare wellness visits. H.R.4942/S.655 - Conrad State 30 and Physician Access Reauthorization Act: Reauthorizes the Conrad State 30 program and improves policies to address health care provider shortages, supporting neurological care for Parkinson's patients. H.R.8702/S.4532 - Improving Seniors Timely Access to Care Act: Establishes requirements regarding the use of prior authorization under Medicare Advantage plans. H.R.9233/S.- The HEALTHY Brains Act: Draft legislation to create a Centers of Excellence grant program within the National Institutes of Health to focus on the intersection between environmental risk factors and neurodegenerative diseases. H.R.8331/S. 4280 - Essential Caregivers Act of 2024: To amend titles XVIII and XIX of the Social Security Act to require skilled nursing facilities, nursing facilities, intermediate care facilities for the intellectually disabled, and inpatient rehabilitation facilities to permit essential caregivers access during any period in which regular visitation is restricted. General Outreach for Establishing an ""Office of Caregiver Health"": Supports the creation of an Office of Caregiver Health within the Department of Health and Human Services to address the needs of caregivers, particularly in relation to Parkinson's disease care.
Telemental Health Care Access Act of 2023
Client: THE MICHAEL J. FOX FOUNDATION FOR PARKINSON'S RESEARCH · Firm: THE MICHAEL J. FOX FOUNDATION FOR PARKINSON'S RESEARCH
H.R.2365/S.1064 - National Plan to End Parkinson's Act: A bill to create an advisory council comprising members of federal agencies that support research, care, and services for Parkinson's disease, as well as patients, care partners, researchers, clinicians, and other non-federal experts, to ensure efficient and effective coordination among all federal entities responsible for managing, treating, and curing Parkinson's disease. General Parkinson's Disease Information: Covers symptoms, triggers, health coverage, health costs, social determinants of health, data collection, research, environmental risks, and health access for underserved communities, particularly through the CDC's National Neurological Conditions Surveillance System (NNCSS). H.R.2630/S.652/S.1339 - Safe Step Act: Requires group health plans to provide an exception process for any medication step therapy protocol to ensure that individuals living with Parkinson's disease can access treatments safely and efficiently. Establishing Parkinson's Disease ICD-10-CM Codes: Aims to assist in the coordination of care for Parkinson's patients who experience OFF episodes and to allow researchers to gather data to study disease progression. S.1544/H.R.1199 - Facilitating Innovative Nuclear Diagnostics Act of 2023: A bill to establish separate payment requirements for diagnostic radiopharmaceuticals, including DaTscans, which aid in confirming a Parkinson's diagnosis under the Medicare prospective payment system for hospital outpatient services. H.R.3432 - Telemental Health Care Access Act of 2023: Permanently removes Medicare's originating site requirements for mental health services furnished via telehealth. Parkinson's non-motor symptoms include mental health conditions, and many people with Parkinson's are Medicare beneficiaries who may face barriers due to in-person requirements. H.R.830/S.1375 - Help Ensure Lower Patient Copays Act: A bill requiring health insurance plans to apply certain payments, including third-party payments, financial assistance, and product vouchers, toward a plan's cost-sharing requirements. This helps Parkinson's patients afford medications for managing symptoms. The Medicare Part D Six Protected Classes Policy: Requires Part D plans to cover all drugs in six protected classes, including antidepressants and antipsychotics. For individuals with Parkinson's disease, these medications are crucial for managing non-motor symptoms such as depression and psychosis. H.R.4752/S.2379 - CHANGE Act of 2023: A bill to improve early screening, detection, and diagnosis of Alzheimer's and related dementias, including Parkinson's disease dementia, during Medicare wellness visits. H.R.4942/S.655 - Conrad State 30 and Physician Access Reauthorization Act: Reauthorizes the Conrad State 30 program and improves policies to address health care provider shortages, supporting neurological care for Parkinson's patients. H.R.8702/S.4532 - Improving Seniors Timely Access to Care Act: Establishes requirements regarding the use of prior authorization under Medicare Advantage plans. H.R.9233/S.- The HEALTHY Brains Act: Draft legislation to create a Centers of Excellence grant program within the National Institutes of Health to focus on the intersection between environmental risk factors and neurodegenerative diseases. H.R.8331/S. 4280 - Essential Caregivers Act of 2024: To amend titles XVIII and XIX of the Social Security Act to require skilled nursing facilities, nursing facilities, intermediate care facilities for the intellectually disabled, and inpatient rehabilitation facilities to permit essential caregivers access during any period in which regular visitation is restricted. General Outreach for Establishing an ""Office of Caregiver Health"": Supports the creation of an Office of Caregiver Health within the Department of Health and Human Services to address the needs of caregivers, particularly in relation to Parkinson's disease care.
Telemental Health Care Access Act of 2023
Client: THE MICHAEL J. FOX FOUNDATION FOR PARKINSON'S RESEARCH · Firm: THE MICHAEL J. FOX FOUNDATION FOR PARKINSON'S RESEARCH
H.R.2365/S.1064 - National Plan to End Parkinson's Act: a bill to create an advisory council comprising members of federal agencies that support research, care, and services for Parkinsons, plus patients, care partners, researchers, clinicians, and other non-federal experts to ensure efficient and effective coordination among all federal entities with responsibility for managing, treating, and curing Parkinsons disease. General Parkinson's disease information about symptoms, triggers, health coverage, health costs, social determinants of health related to Parkinson's disease and data collection, research, environmental risks, and health access for underserved communities. Information related to prevalence particularly at CDC's National Neurological Conditions Surveillance System (NNCSS). H.R.2630/S.652/S.1339 - Safe Step Act: a bill to require group health plans to provide an exception process for any medication step therapy protocol to help ensure that people living with Parkinson's disease can safely and efficiently access treatments. Establishing Parkinson's disease ICD-10-CM codes to assist in the continuation and coordination of care for people living with Parkinson's who experience OFF episodes and to allow researchers to gather more data to study the progression of the disease. Reauthorization of CDCs National Neurological Conditions Surveillance System (NNCSS). S.1544/H.R.1199 - Facilitating Innovative Nuclear Diagnostics Act of 2023: a bill to establish separate payment requirements for diagnostic radiopharmaceuticals, including DaTscans, which can aid in confirming a Parkinson's diagnosis, under the Medicare prospective payment system for hospital outpatient department services. H.R.3432 - Telemental Health Care Access Act of 2023: a bill to permanently remove Medicare's originating site requirements for mental health services furnished via telehealth. Parkinson's non-motor symptoms encompass mental health conditions, including anxiety, depression, dementia, and other memory problems, and the majority of people living with Parkinson's in the United States are Medicare beneficiaries, many of whom will face undue burdens meeting the unnecessary in-person requirement for telemental health services after the delay of the requirement enforcement expires December 31, 2024. H.R.830/S.1375 - Help Ensure Lower Patient Copays Act: a bill to require health insurance plans to apply certain payments made by, or on behalf of, a plan enrollee toward a plan's cost-sharing requirements. Specifically, plans must apply third-party payments, financial assistance, discounts, product vouchers, and other reductions in out-of-pocket expenses toward the requirements. Many Parkinson's patients rely on such third-party payments to afford medications to treat and manage their disease symptoms, and this legislation will ensure that all payments whether they come directly out of a pocket or with the help of copay assistance-counts toward out-of-pocket costs of patients. The Medicare Part D Six Protected Classes Policy: requires Part D plan to cover all drugs in six classes: immunosuppressants, antidepressants, antipsychotics, anticonvulsants, antiretrovirals, and antineoplastics. For people living with Parkinson's, most of whom are Medicare beneficiaries, it is essential to have access to wide range of treatment options for antidepressants and antipsychotics. Parkinson's causes non-motor symptoms, including depression and psychosis, and individuals often experience different side effects, reactions, and efficacy based on which medications they take. H.R.4752/S.2379 - the Concentrating High-value Alzheimer's Needs to Get to an End (CHANGE) Act of 2023: a bill to better utilize the existing Welcome to Medicare initial exam and Medicare annual wellness visits to screen, detect, and diagnose Alzheimers and related dementias, including Parkinson's disease dementia, in their earliest stages. Signed Leaders Engaged on Alzheimer's Disease (LEAD) Coalition letter to members of Congress in support of this legislation. H.R.4942/S.655 - the Conrad State 30 and Physician Access Reauthorization Act: a bill to reauthorize the Conrad State 30 program for three years, make several targeted policy improvements, and permit the gradual expansion of the number of waivers granted to each state to address health care provider shortages. Signed American Academy of Neurology letter to member of Congress in support of this legislation. The Medicare Part D Six Protected Classes Policy: requires Part D plan to cover all drugs in six classes: immunosuppressants, antidepressants, antipsychotics, anticonvulsants, antiretrovirals, and antineoplastics. For people living with Parkinson's, most of whom are Medicare beneficiaries, it is essential to have access to wide range of treatment options for antidepressants and antipsychotics. Parkinson's causes non-motor symptoms, including depression and psychosis, and individuals often experience different side effects, reactions, and efficacy based on which medications they take. Partnership for Part D Access coalition congressional meetings and signed coalition letter to CMS in response to Medicare Prescription Payment Plan Part One Guidance in support of continued protection for the six protected classes policy. Signed Medicare Access for Prescription Rx (MAPRx) coalition comment letter in response to Medicare Prescription Payment Plan Part One Guidance. Signed Patient and Provider Advocates for Telehealth coalition comment letter in response to CMS CY 2024 Medicare Physician Fee Schedule (PFS) in support prioritizing the needs of patients by expanding policies that improved access to safe and timely health care via telehealth. Signed Alliance for Aging Research coalition letter in response to Medicare Prescription Payment Plan Part One Guidance in support of proposed beneficiary protections and to provide feedback on implementation considerations for the Medicare Prescription Payment Plan program.
Telemental Health Care Access Act of 2023
Client: THE MICHAEL J. FOX FOUNDATION FOR PARKINSON'S RESEARCH · Firm: THE MICHAEL J. FOX FOUNDATION FOR PARKINSON'S RESEARCH
H.R.2365/S.1064 - National Plan to End Parkinson's Act: a bill to create an advisory council comprising members of federal agencies that support research, care, and services for Parkinsons, plus patients, care partners, researchers, clinicians, and other non-federal experts to ensure efficient and effective coordination among all federal entities with responsibility for managing, treating, and curing Parkinsons disease. General Parkinson's disease information about symptoms, triggers, health coverage, health costs, social determinants of health related to Parkinson's disease and data collection, research, environmental risks, and health access for underserved communities. Information related to prevalence particularly at CDC's National Neurological Conditions Surveillance System (NNCSS). H.R.2630/S.652/S.1339 - Safe Step Act: a bill to require group health plans to provide an exception process for any medication step therapy protocol to help ensure that people living with Parkinson's disease can safely and efficiently access treatments. Establishing Parkinson's disease ICD-10-CM codes to assist in the continuation and coordination of care for people living with Parkinson's who experience OFF episodes and to allow researchers to gather more data to study the progression of the disease. Reauthorization of CDCs National Neurological Conditions Surveillance System (NNCSS). S.1544/H.R.1199 - Facilitating Innovative Nuclear Diagnostics Act of 2023: a bill to establish separate payment requirements for diagnostic radiopharmaceuticals, including DaTscans, which can aid in confirming a Parkinson's diagnosis, under the Medicare prospective payment system for hospital outpatient department services. H.R.3432 - Telemental Health Care Access Act of 2023: a bill to permanently remove Medicare's originating site requirements for mental health services furnished via telehealth. Parkinson's non-motor symptoms encompass mental health conditions, including anxiety, depression, dementia, and other memory problems, and the majority of people living with Parkinson's in the United States are Medicare beneficiaries, many of whom will face undue burdens meeting the unnecessary in-person requirement for telemental health services after the delay of the requirement enforcement expires December 31, 2024. H.R.830/S.1375 - Help Ensure Lower Patient Copays Act: a bill to require health insurance plans to apply certain payments made by, or on behalf of, a plan enrollee toward a plan's cost-sharing requirements. Specifically, plans must apply third-party payments, financial assistance, discounts, product vouchers, and other reductions in out-of-pocket expenses toward the requirements. Many Parkinson's patients rely on such third-party payments to afford medications to treat and manage their disease symptoms, and this legislation will ensure that all payments whether they come directly out of a pocket or with the help of copay assistance-counts toward out-of-pocket costs of patients. The Medicare Part D Six Protected Classes Policy: requires Part D plan to cover all drugs in six classes: immunosuppressants, antidepressants, antipsychotics, anticonvulsants, antiretrovirals, and antineoplastics. For people living with Parkinson's, most of whom are Medicare beneficiaries, it is essential to have access to wide range of treatment options for antidepressants and antipsychotics. Parkinson's causes non-motor symptoms, including depression and psychosis, and individuals often experience different side effects, reactions, and efficacy based on which medications they take. H.R.4752/S.2379 - the Concentrating High-value Alzheimer's Needs to Get to an End (CHANGE) Act of 2023: a bill to better utilize the existing Welcome to Medicare initial exam and Medicare annual wellness visits to screen, detect, and diagnose Alzheimers and related dementias, including Parkinson's disease dementia, in their earliest stages. Signed Leaders Engaged on Alzheimer's Disease (LEAD) Coalition letter to members of Congress in support of this legislation. H.R.4942/S.655 - the Conrad State 30 and Physician Access Reauthorization Act: a bill to reauthorize the Conrad State 30 program for three years, make several targeted policy improvements, and permit the gradual expansion of the number of waivers granted to each state to address health care provider shortages. Signed American Academy of Neurology letter to member of Congress in support of this legislation. The Medicare Part D Six Protected Classes Policy: requires Part D plan to cover all drugs in six classes: immunosuppressants, antidepressants, antipsychotics, anticonvulsants, antiretrovirals, and antineoplastics. For people living with Parkinson's, most of whom are Medicare beneficiaries, it is essential to have access to wide range of treatment options for antidepressants and antipsychotics. Parkinson's causes non-motor symptoms, including depression and psychosis, and individuals often experience different side effects, reactions, and efficacy based on which medications they take. Partnership for Part D Access coalition congressional meetings and signed coalition letter to CMS in response to Medicare Prescription Payment Plan Part One Guidance in support of continued protection for the six protected classes policy. Signed Medicare Access for Prescription Rx (MAPRx) coalition comment letter in response to Medicare Prescription Payment Plan Part One Guidance. Signed Patient and Provider Advocates for Telehealth coalition comment letter in response to CMS CY 2024 Medicare Physician Fee Schedule (PFS) in support prioritizing the needs of patients by expanding policies that improved access to safe and timely health care via telehealth. Signed Alliance for Aging Research coalition letter in response to Medicare Prescription Payment Plan Part One Guidance in support of proposed beneficiary protections and to provide feedback on implementation considerations for the Medicare Prescription Payment Plan program. H.R.8702/S.4532 - Improving Seniors Timely Access to Care Act: a bill to establish requirements with respect to the use of prior authorization under Medicare Advantage plans. H.R./S.- The HEALTHY Brains Act- draft legislation to create a Centers of Excellence grant program within the National Institute of Health to focus on the intersection between environmental risk factors and neurodegenerative disease. General outreach and support for the establishment of an "Office of Caregiver Health" within the Office of the Secretary at the Department of Health and Human Services.
Telemental Health Care Access Act of 2023
Client: THE MICHAEL J. FOX FOUNDATION FOR PARKINSON'S RESEARCH · Firm: THE MICHAEL J. FOX FOUNDATION FOR PARKINSON'S RESEARCH
H.R.2365/S.1064 - National Plan to End Parkinson's Act: A bill to create an advisory council comprising members of federal agencies that support research, care, and services for Parkinson's disease, as well as patients, care partners, researchers, clinicians, and other non-federal experts, to ensure efficient and effective coordination among all federal entities responsible for managing, treating, and curing Parkinson's disease. General Parkinson's Disease Information: Covers symptoms, triggers, health coverage, health costs, social determinants of health, data collection, research, environmental risks, and health access for underserved communities, particularly through the CDC's National Neurological Conditions Surveillance System (NNCSS). H.R.2630/S.652/S.1339 - Safe Step Act: Requires group health plans to provide an exception process for any medication step therapy protocol to ensure that individuals living with Parkinson's disease can access treatments safely and efficiently. Establishing Parkinson's Disease ICD-10-CM Codes: Aims to assist in the coordination of care for Parkinson's patients who experience OFF episodes and to allow researchers to gather data to study disease progression. S.1544/H.R.1199 - Facilitating Innovative Nuclear Diagnostics Act of 2023: A bill to establish separate payment requirements for diagnostic radiopharmaceuticals, including DaTscans, which aid in confirming a Parkinson's diagnosis under the Medicare prospective payment system for hospital outpatient services. H.R.3432 - Telemental Health Care Access Act of 2023: Permanently removes Medicare's originating site requirements for mental health services furnished via telehealth. Parkinson's non-motor symptoms include mental health conditions, and many people with Parkinson's are Medicare beneficiaries who may face barriers due to in-person requirements. H.R.830/S.1375 - Help Ensure Lower Patient Copays Act: A bill requiring health insurance plans to apply certain payments, including third-party payments, financial assistance, and product vouchers, toward a plan's cost-sharing requirements. This helps Parkinson's patients afford medications for managing symptoms. The Medicare Part D Six Protected Classes Policy: Requires Part D plans to cover all drugs in six protected classes, including antidepressants and antipsychotics. For individuals with Parkinson's disease, these medications are crucial for managing non-motor symptoms such as depression and psychosis. H.R.4752/S.2379 - CHANGE Act of 2023: A bill to improve early screening, detection, and diagnosis of Alzheimer's and related dementias, including Parkinson's disease dementia, during Medicare wellness visits. H.R.4942/S.655 - Conrad State 30 and Physician Access Reauthorization Act: Reauthorizes the Conrad State 30 program and improves policies to address health care provider shortages, supporting neurological care for Parkinson's patients. H.R.8702/S.4532 - Improving Seniors Timely Access to Care Act: Establishes requirements regarding the use of prior authorization under Medicare Advantage plans. H.R.9233/S.- The HEALTHY Brains Act: Draft legislation to create a Centers of Excellence grant program within the National Institutes of Health to focus on the intersection between environmental risk factors and neurodegenerative diseases. General Outreach for Establishing an ""Office of Caregiver Health"": Supports the creation of an Office of Caregiver Health within the Department of Health and Human Services to address the needs of caregivers, particularly in relation to Parkinson's disease care.
Department of Defense Appropriations Act, 2024
Client: THE MICHAEL J. FOX FOUNDATION FOR PARKINSON'S RESEARCH · Firm: THE MICHAEL J. FOX FOUNDATION FOR PARKINSON'S RESEARCH
H.R.4366/S.2127 - FY24 Military Construction, Veterans Affairs and Related Agencies Appropriations bill to support increased funding for the VA's Parkinson's Disease Research, Education and Clinical Center. FY24 (H.R.4365/S.2587) and FY25 Defense Appropriations bills to support increased funding for DOD Congressionally Directed Medical Research Programs Parkinson's Research Program. General education regarding the importance of the Department of Defense medical research programs for military service personnel and Veterans living with Parkinson's disease. Inclusion of Parkinson's disease and PD-related diseases as presumptive conditions when military Veterans are exposed to associated toxins.
Department of Defense Appropriations Act, 2024
Client: THE MICHAEL J. FOX FOUNDATION FOR PARKINSON'S RESEARCH · Firm: THE MICHAEL J. FOX FOUNDATION FOR PARKINSON'S RESEARCH
FY 2024 Appropriations bills including funding requests for Parkinson's research at: H.R.4365/S.2587 - The Department of Defense within the FY 2024 Defense Appropriation bill. H.R.5894/S.2624 - The National Institute of Health and Centers for Disease Control and Prevention within the FY 2024 Labor, Health and Human Services, Education, and Related Agencies Appropriation bill. H.R.4368/S.2131 - The Food and Drug Administration within the FY 2024 Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriation bill. H.R.4366/S.2127 - The Department of Veterans Affairs within the FY 2024 Military Construction, Veterans Affairs, and Related Agencies Appropriation bill. Increased funding for NIEHS (no bill introduced). Funding for the Parkinson's Research Program (PRP) under the Department of Defense's Congressionally Directed Medical Research Programs (CDMRP).
Consolidated Appropriations Act, 2024
Client: THE MICHAEL J. FOX FOUNDATION FOR PARKINSON'S RESEARCH · Firm: THE MICHAEL J. FOX FOUNDATION FOR PARKINSON'S RESEARCH
FY 2024 Appropriations bills including funding requests for Parkinson's research at: H.R.4365/S.2587 - The Department of Defense within the FY 2024 Defense Appropriation bill. H.R.5894/S.2624 - The National Institute of Health and Centers for Disease Control and Prevention within the FY 2024 Labor, Health and Human Services, Education, and Related Agencies Appropriation bill. H.R.4368/S.2131 - The Food and Drug Administration within the FY 2024 Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriation bill. H.R.4366/S.2127 - The Department of Veterans Affairs within the FY 2024 Military Construction, Veterans Affairs, and Related Agencies Appropriation bill. Increased funding for NIEHS (no bill introduced). Funding for the Parkinson's Research Program (PRP) under the Department of Defense's Congressionally Directed Medical Research Programs (CDMRP).
Consolidated Appropriations Act, 2024
Client: THE MICHAEL J. FOX FOUNDATION FOR PARKINSON'S RESEARCH · Firm: THE MICHAEL J. FOX FOUNDATION FOR PARKINSON'S RESEARCH
H.R.4366/S.2127 - FY24 Military Construction, Veterans Affairs and Related Agencies Appropriations bill to support increased funding for the VA's Parkinson's Disease Research, Education and Clinical Center. FY24 (H.R.4365/S.2587) and FY25 Defense Appropriations bills to support increased funding for DOD Congressionally Directed Medical Research Programs Parkinson's Research Program. General education regarding the importance of the Department of Defense medical research programs for military service personnel and Veterans living with Parkinson's disease. Inclusion of Parkinson's disease and PD-related diseases as presumptive conditions when military Veterans are exposed to associated toxins.
Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2024
Client: THE MICHAEL J. FOX FOUNDATION FOR PARKINSON'S RESEARCH · Firm: THE MICHAEL J. FOX FOUNDATION FOR PARKINSON'S RESEARCH
FY 2024 Appropriations bills including funding requests for Parkinson's research at: H.R.4365/S.2587 - The Department of Defense within the FY 2024 Defense Appropriation bill. H.R.5894/S.2624 - The National Institute of Health and Centers for Disease Control and Prevention within the FY 2024 Labor, Health and Human Services, Education, and Related Agencies Appropriation bill. H.R.4368/S.2131 - The Food and Drug Administration within the FY 2024 Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriation bill. H.R.4366/S.2127 - The Department of Veterans Affairs within the FY 2024 Military Construction, Veterans Affairs, and Related Agencies Appropriation bill. Increased funding for NIEHS (no bill introduced). Funding for the Parkinson's Research Program (PRP) under the Department of Defense's Congressionally Directed Medical Research Programs (CDMRP).
Concentrating on High-value Alzheimer's Needs to Get to an End Act of 2023
Client: THE MICHAEL J. FOX FOUNDATION FOR PARKINSON'S RESEARCH · Firm: THE MICHAEL J. FOX FOUNDATION FOR PARKINSON'S RESEARCH
Lobbying to Increase Prescription Drug Affordability and Accessibility: Advocacy for Medicare Part D redesign and benefits for people living with Parkinson's, including expanding the low-income subsidy (LIS) program, capping out-of-pocket costs, implementing a smoothing mechanism, and streamlining utilization management processes. The Medicare Part D Six Protected Classes Policy: Requires Part D plans to cover all drugs in six classes: immunosuppressants, antidepressants, antipsychotics, anticonvulsants, antiretrovirals, and antineoplastics. For people living with Parkinson's, most of whom are Medicare beneficiaries, it is essential to have access to a wide range of treatment options for antidepressants and antipsychotics, which are crucial for managing non-motor symptoms like depression and psychosis. Signed Coalition Letters: - Medicare Access for Prescription Rx (MAPRx): Comment letter in response to Medicare Prescription Payment Plan Part One Guidance. - Patient and Provider Advocates for Telehealth: Comment letter in response to CMS CY 2024 Medicare Physician Fee Schedule (PFS) supporting expanded access to telehealth. - Alliance for Aging Research: Coalition letter in response to Medicare Prescription Payment Plan Part One Guidance supporting proposed beneficiary protections. H.R.4752/S.2379 - CHANGE Act of 2023: A bill to better utilize existing Medicare wellness visits for early screening, detection, and diagnosis of Alzheimer's and related dementias, including Parkinson's disease dementia. S.1544/H.R.1199 - Facilitating Innovative Nuclear Diagnostics Act of 2023: A bill to establish separate payment requirements for diagnostic radiopharmaceuticals, including DaTscans used to confirm Parkinson's diagnoses, under the Medicare outpatient prospective payment system. CMS-1809-P (2025 Medicare OPPS Proposed Rule): Comment supporting CMS's proposal to separately reimburse certain diagnostic radiopharmaceuticals used in diagnosing Parkinson's disease and atypical parkinsonisms. H.R.8702/S.4532 - Improving Seniors' Timely Access to Care Act: Establishes requirements for the use of prior authorization under Medicare Advantage plans to ensure timely access to care for seniors, including those with Parkinson's. S.3109/H.R.8018 - Alleviating Barriers for Caregivers (ABC) Act: Requires the Centers for Medicare & Medicaid Services (CMS) and Social Security to simplify processes and communications for family caregivers to assist individuals in accessing and utilizing benefits. S.3766/H.R.7274 - Connecting Caregivers to Medicare Act: Amends the Social Security Act to provide outreach and education to Medicare beneficiaries and simplify access to information for family caregivers through 1-800-MEDICARE. Advocacy for Durable Medical Equipment (DME) Access: Lobbying CMS to direct Medicare contractors to clarify claims procedures for DME therapies requiring administration via external infusion pumps, ensuring quick access to new Parkinson's therapies after FDA approval. H.R.8331/S. 4280 - Essential Caregivers Act of 2024: To amend titles XVIII and XIX of the Social Security Act to require skilled nursing facilities, nursing facilities, intermediate care facilities for the intellectually disabled, and inpatient rehabilitation facilities to permit essential caregivers access during any period in which regular visitation is restricted.
Concentrating on High-value Alzheimer's Needs to Get to an End Act of 2023
Client: THE MICHAEL J. FOX FOUNDATION FOR PARKINSON'S RESEARCH · Firm: THE MICHAEL J. FOX FOUNDATION FOR PARKINSON'S RESEARCH
H.R.2365/S.1064 - National Plan to End Parkinson's Act: a bill to create an advisory council comprising members of federal agencies that support research, care, and services for Parkinsons, plus patients, care partners, researchers, clinicians, and other non-federal experts to ensure efficient and effective coordination among all federal entities with responsibility for managing, treating, and curing Parkinsons disease. General Parkinson's disease information about symptoms, triggers, health coverage, health costs, social determinants of health related to Parkinson's disease and data collection, research, environmental risks, and health access for underserved communities. Information related to prevalence particularly at CDC's National Neurological Conditions Surveillance System (NNCSS). H.R.2630/S.652/S.1339 - Safe Step Act: a bill to require group health plans to provide an exception process for any medication step therapy protocol to help ensure that people living with Parkinson's disease can safely and efficiently access treatments. Establishing Parkinson's disease ICD-10-CM codes to assist in the continuation and coordination of care for people living with Parkinson's who experience OFF episodes and to allow researchers to gather more data to study the progression of the disease. Reauthorization of CDCs National Neurological Conditions Surveillance System (NNCSS). S.1544/H.R.1199 - Facilitating Innovative Nuclear Diagnostics Act of 2023: a bill to establish separate payment requirements for diagnostic radiopharmaceuticals, including DaTscans, which can aid in confirming a Parkinson's diagnosis, under the Medicare prospective payment system for hospital outpatient department services. H.R.3432 - Telemental Health Care Access Act of 2023: a bill to permanently remove Medicare's originating site requirements for mental health services furnished via telehealth. Parkinson's non-motor symptoms encompass mental health conditions, including anxiety, depression, dementia, and other memory problems, and the majority of people living with Parkinson's in the United States are Medicare beneficiaries, many of whom will face undue burdens meeting the unnecessary in-person requirement for telemental health services after the delay of the requirement enforcement expires December 31, 2024. H.R.830/S.1375 - Help Ensure Lower Patient Copays Act: a bill to require health insurance plans to apply certain payments made by, or on behalf of, a plan enrollee toward a plan's cost-sharing requirements. Specifically, plans must apply third-party payments, financial assistance, discounts, product vouchers, and other reductions in out-of-pocket expenses toward the requirements. Many Parkinson's patients rely on such third-party payments to afford medications to treat and manage their disease symptoms, and this legislation will ensure that all payments whether they come directly out of a pocket or with the help of copay assistance-counts toward out-of-pocket costs of patients. The Medicare Part D Six Protected Classes Policy: requires Part D plan to cover all drugs in six classes: immunosuppressants, antidepressants, antipsychotics, anticonvulsants, antiretrovirals, and antineoplastics. For people living with Parkinson's, most of whom are Medicare beneficiaries, it is essential to have access to wide range of treatment options for antidepressants and antipsychotics. Parkinson's causes non-motor symptoms, including depression and psychosis, and individuals often experience different side effects, reactions, and efficacy based on which medications they take. H.R.4752/S.2379 - the Concentrating High-value Alzheimer's Needs to Get to an End (CHANGE) Act of 2023: a bill to better utilize the existing Welcome to Medicare initial exam and Medicare annual wellness visits to screen, detect, and diagnose Alzheimers and related dementias, including Parkinson's disease dementia, in their earliest stages. Signed Leaders Engaged on Alzheimer's Disease (LEAD) Coalition letter to members of Congress in support of this legislation. H.R.4942/S.655 - the Conrad State 30 and Physician Access Reauthorization Act: a bill to reauthorize the Conrad State 30 program for three years, make several targeted policy improvements, and permit the gradual expansion of the number of waivers granted to each state to address health care provider shortages. Signed American Academy of Neurology letter to member of Congress in support of this legislation. The Medicare Part D Six Protected Classes Policy: requires Part D plan to cover all drugs in six classes: immunosuppressants, antidepressants, antipsychotics, anticonvulsants, antiretrovirals, and antineoplastics. For people living with Parkinson's, most of whom are Medicare beneficiaries, it is essential to have access to wide range of treatment options for antidepressants and antipsychotics. Parkinson's causes non-motor symptoms, including depression and psychosis, and individuals often experience different side effects, reactions, and efficacy based on which medications they take. Partnership for Part D Access coalition congressional meetings and signed coalition letter to CMS in response to Medicare Prescription Payment Plan Part One Guidance in support of continued protection for the six protected classes policy. Signed Medicare Access for Prescription Rx (MAPRx) coalition comment letter in response to Medicare Prescription Payment Plan Part One Guidance. Signed Patient and Provider Advocates for Telehealth coalition comment letter in response to CMS CY 2024 Medicare Physician Fee Schedule (PFS) in support prioritizing the needs of patients by expanding policies that improved access to safe and timely health care via telehealth. Signed Alliance for Aging Research coalition letter in response to Medicare Prescription Payment Plan Part One Guidance in support of proposed beneficiary protections and to provide feedback on implementation considerations for the Medicare Prescription Payment Plan program.
Concentrating on High-value Alzheimer's Needs to Get to an End Act of 2023
Client: THE MICHAEL J. FOX FOUNDATION FOR PARKINSON'S RESEARCH · Firm: THE MICHAEL J. FOX FOUNDATION FOR PARKINSON'S RESEARCH
Lobbying to increase prescription drug affordability and accessibility for people living with Parkinson's via Medicare Part D redesign and benefits, including expanding the low-income subsidy (LIS) program, capping out-of-pocket costs, implementing a smoothing mechanism, and streamlining utilization management processes. The Medicare Part D Six Protected Classes Policy: requires Part D plan to cover all drugs in six classes: immunosuppressants, antidepressants, antipsychotics, anticonvulsants, antiretrovirals, and antineoplastics. For people living with Parkinson's, most of whom are Medicare beneficiaries, it is essential to have access to wide range of treatment options for antidepressants and antipsychotics. Parkinson's causes non-motor symptoms, including depression and psychosis, and individuals often experience different side effects, reactions, and efficacy based on which medications they take. Partnership for Part D Access coalition congressional meetings and signed coalition letter to CMS in response to Medicare Prescription Payment Plan Part One Guidance in support of continued protection for the six protected classes policy. Signed Medicare Access for Prescription Rx (MAPRx) coalition comment letter in response to Medicare Prescription Payment Plan Part One Guidance. Signed Patient and Provider Advocates for Telehealth coalition comment letter in response to CMS CY 2024 Medicare Physician Fee Schedule (PFS) in support prioritizing the needs of patients by expanding policies that improved access to safe and timely health care via telehealth. Signed Alliance for Aging Research coalition letter in response to Medicare Prescription Payment Plan Part One Guidance in support of proposed beneficiary protections and to provide feedback on implementation considerations for the Medicare Prescription Payment Plan program. H.R.4752/S.2379 - the Concentrating High-value Alzheimer's Needs to Get to an End (CHANGE) Act of 2023: a bill to better utilize the existing Welcome to Medicare initial exam and Medicare annual wellness visits to screen, detect, and diagnose Alzheimers and related dementias, including Parkinson's disease dementia, in their earliest stages. Signed Leaders Engaged on Alzheimer's Disease (LEAD) Coalition letter to members of Congress in support of this legislation. S. 3109- Alleviating Barriers for Caregivers (ABC) Act- bill to require the Administrator of the Centers for Medicare & Medicaid Services and the Commissioner of Social Security to review and simplify the processes, procedures, forms, and communications for family caregivers to assist individuals in establishing eligibility for, enrolling in, and maintaining and utilizing coverage and benefits under the Medicare, Medicaid, CHIP, and Social Security programs respectively, and for other purposes. Lobbying the Centers for Medicare and Medicaid Services to direct Durable Medical Equipment Medicare Administrative Contractors to provide additional clarification regarding the use of claim modifiers for DME therapies that require administration via an external infusion pump to expedite patient access once new Parkinson's therapies receive approvals from the Food and Drug Administration. S.1544/H.R.1199 - Facilitating Innovative Nuclear Diagnostics Act of 2023: a bill to establish separate payment requirements for diagnostic radiopharmaceuticals, including DaTscans, which can aid in confirming a Parkinson's diagnosis, under the Medicare prospective payment system for hospital outpatient department services. S. 3766/H.R. 7274- Connecting Caregivers to Medicare Act -To amend title XVIII of the Social Security Act to provide for outreach and education to Medicare beneficiaries to simplify access to information for family caregivers through 1-800-MEDICARE, and for other purposes. H.R. 8018/S. 3109- Alleviating Barriers for Caregivers (ABC) Act- bill to require the Administrator of the Centers for Medicare & Medicaid Services and the Commissioner of Social Security to review and simplify the processes, procedures, forms, and communications for family caregivers to assist individuals in establishing eligibility for, enrolling in, and maintaining and utilizing coverage and benefits under the Medicare, Medicaid, CHIP, and Social Security programs respectively, and for other purposes. H.R.8702/S.4532 - Improving Seniors Timely Access to Care Act: a bill to establish requirements with respect to the use of prior authorization under Medicare Advantage plans.
Concentrating on High-value Alzheimer's Needs to Get to an End Act of 2023
Client: THE MICHAEL J. FOX FOUNDATION FOR PARKINSON'S RESEARCH · Firm: THE MICHAEL J. FOX FOUNDATION FOR PARKINSON'S RESEARCH
H.R.2365/S.1064 - National Plan to End Parkinson's Act: a bill to create an advisory council comprising members of federal agencies that support research, care, and services for Parkinsons, plus patients, care partners, researchers, clinicians, and other non-federal experts to ensure efficient and effective coordination among all federal entities with responsibility for managing, treating, and curing Parkinsons disease. General Parkinson's disease information about symptoms, triggers, health coverage, health costs, social determinants of health related to Parkinson's disease and data collection, research, environmental risks, and health access for underserved communities. Information related to prevalence particularly at CDC's National Neurological Conditions Surveillance System (NNCSS). H.R.2630/S.652/S.1339 - Safe Step Act: a bill to require group health plans to provide an exception process for any medication step therapy protocol to help ensure that people living with Parkinson's disease can safely and efficiently access treatments. Establishing Parkinson's disease ICD-10-CM codes to assist in the continuation and coordination of care for people living with Parkinson's who experience OFF episodes and to allow researchers to gather more data to study the progression of the disease. Reauthorization of CDCs National Neurological Conditions Surveillance System (NNCSS). S.1544/H.R.1199 - Facilitating Innovative Nuclear Diagnostics Act of 2023: a bill to establish separate payment requirements for diagnostic radiopharmaceuticals, including DaTscans, which can aid in confirming a Parkinson's diagnosis, under the Medicare prospective payment system for hospital outpatient department services. H.R.3432 - Telemental Health Care Access Act of 2023: a bill to permanently remove Medicare's originating site requirements for mental health services furnished via telehealth. Parkinson's non-motor symptoms encompass mental health conditions, including anxiety, depression, dementia, and other memory problems, and the majority of people living with Parkinson's in the United States are Medicare beneficiaries, many of whom will face undue burdens meeting the unnecessary in-person requirement for telemental health services after the delay of the requirement enforcement expires December 31, 2024. H.R.830/S.1375 - Help Ensure Lower Patient Copays Act: a bill to require health insurance plans to apply certain payments made by, or on behalf of, a plan enrollee toward a plan's cost-sharing requirements. Specifically, plans must apply third-party payments, financial assistance, discounts, product vouchers, and other reductions in out-of-pocket expenses toward the requirements. Many Parkinson's patients rely on such third-party payments to afford medications to treat and manage their disease symptoms, and this legislation will ensure that all payments whether they come directly out of a pocket or with the help of copay assistance-counts toward out-of-pocket costs of patients. The Medicare Part D Six Protected Classes Policy: requires Part D plan to cover all drugs in six classes: immunosuppressants, antidepressants, antipsychotics, anticonvulsants, antiretrovirals, and antineoplastics. For people living with Parkinson's, most of whom are Medicare beneficiaries, it is essential to have access to wide range of treatment options for antidepressants and antipsychotics. Parkinson's causes non-motor symptoms, including depression and psychosis, and individuals often experience different side effects, reactions, and efficacy based on which medications they take. H.R.4752/S.2379 - the Concentrating High-value Alzheimer's Needs to Get to an End (CHANGE) Act of 2023: a bill to better utilize the existing Welcome to Medicare initial exam and Medicare annual wellness visits to screen, detect, and diagnose Alzheimers and related dementias, including Parkinson's disease dementia, in their earliest stages. Signed Leaders Engaged on Alzheimer's Disease (LEAD) Coalition letter to members of Congress in support of this legislation. H.R.4942/S.655 - the Conrad State 30 and Physician Access Reauthorization Act: a bill to reauthorize the Conrad State 30 program for three years, make several targeted policy improvements, and permit the gradual expansion of the number of waivers granted to each state to address health care provider shortages. Signed American Academy of Neurology letter to member of Congress in support of this legislation. The Medicare Part D Six Protected Classes Policy: requires Part D plan to cover all drugs in six classes: immunosuppressants, antidepressants, antipsychotics, anticonvulsants, antiretrovirals, and antineoplastics. For people living with Parkinson's, most of whom are Medicare beneficiaries, it is essential to have access to wide range of treatment options for antidepressants and antipsychotics. Parkinson's causes non-motor symptoms, including depression and psychosis, and individuals often experience different side effects, reactions, and efficacy based on which medications they take. Partnership for Part D Access coalition congressional meetings and signed coalition letter to CMS in response to Medicare Prescription Payment Plan Part One Guidance in support of continued protection for the six protected classes policy. Signed Medicare Access for Prescription Rx (MAPRx) coalition comment letter in response to Medicare Prescription Payment Plan Part One Guidance. Signed Patient and Provider Advocates for Telehealth coalition comment letter in response to CMS CY 2024 Medicare Physician Fee Schedule (PFS) in support prioritizing the needs of patients by expanding policies that improved access to safe and timely health care via telehealth. Signed Alliance for Aging Research coalition letter in response to Medicare Prescription Payment Plan Part One Guidance in support of proposed beneficiary protections and to provide feedback on implementation considerations for the Medicare Prescription Payment Plan program. H.R.8702/S.4532 - Improving Seniors Timely Access to Care Act: a bill to establish requirements with respect to the use of prior authorization under Medicare Advantage plans. H.R./S.- The HEALTHY Brains Act- draft legislation to create a Centers of Excellence grant program within the National Institute of Health to focus on the intersection between environmental risk factors and neurodegenerative disease. General outreach and support for the establishment of an "Office of Caregiver Health" within the Office of the Secretary at the Department of Health and Human Services.
Concentrating on High-value Alzheimer's Needs to Get to an End Act of 2023
Client: THE MICHAEL J. FOX FOUNDATION FOR PARKINSON'S RESEARCH · Firm: THE MICHAEL J. FOX FOUNDATION FOR PARKINSON'S RESEARCH
H.R.2365/S.1064 - National Plan to End Parkinson's Act: A bill to create an advisory council comprising members of federal agencies that support research, care, and services for Parkinson's disease, as well as patients, care partners, researchers, clinicians, and other non-federal experts, to ensure efficient and effective coordination among all federal entities responsible for managing, treating, and curing Parkinson's disease. General Parkinson's Disease Information: Covers symptoms, triggers, health coverage, health costs, social determinants of health, data collection, research, environmental risks, and health access for underserved communities, particularly through the CDC's National Neurological Conditions Surveillance System (NNCSS). H.R.2630/S.652/S.1339 - Safe Step Act: Requires group health plans to provide an exception process for any medication step therapy protocol to ensure that individuals living with Parkinson's disease can access treatments safely and efficiently. Establishing Parkinson's Disease ICD-10-CM Codes: Aims to assist in the coordination of care for Parkinson's patients who experience OFF episodes and to allow researchers to gather data to study disease progression. S.1544/H.R.1199 - Facilitating Innovative Nuclear Diagnostics Act of 2023: A bill to establish separate payment requirements for diagnostic radiopharmaceuticals, including DaTscans, which aid in confirming a Parkinson's diagnosis under the Medicare prospective payment system for hospital outpatient services. H.R.3432 - Telemental Health Care Access Act of 2023: Permanently removes Medicare's originating site requirements for mental health services furnished via telehealth. Parkinson's non-motor symptoms include mental health conditions, and many people with Parkinson's are Medicare beneficiaries who may face barriers due to in-person requirements. H.R.830/S.1375 - Help Ensure Lower Patient Copays Act: A bill requiring health insurance plans to apply certain payments, including third-party payments, financial assistance, and product vouchers, toward a plan's cost-sharing requirements. This helps Parkinson's patients afford medications for managing symptoms. The Medicare Part D Six Protected Classes Policy: Requires Part D plans to cover all drugs in six protected classes, including antidepressants and antipsychotics. For individuals with Parkinson's disease, these medications are crucial for managing non-motor symptoms such as depression and psychosis. H.R.4752/S.2379 - CHANGE Act of 2023: A bill to improve early screening, detection, and diagnosis of Alzheimer's and related dementias, including Parkinson's disease dementia, during Medicare wellness visits. H.R.4942/S.655 - Conrad State 30 and Physician Access Reauthorization Act: Reauthorizes the Conrad State 30 program and improves policies to address health care provider shortages, supporting neurological care for Parkinson's patients. H.R.8702/S.4532 - Improving Seniors Timely Access to Care Act: Establishes requirements regarding the use of prior authorization under Medicare Advantage plans. H.R.9233/S.- The HEALTHY Brains Act: Draft legislation to create a Centers of Excellence grant program within the National Institutes of Health to focus on the intersection between environmental risk factors and neurodegenerative diseases. H.R.8331/S. 4280 - Essential Caregivers Act of 2024: To amend titles XVIII and XIX of the Social Security Act to require skilled nursing facilities, nursing facilities, intermediate care facilities for the intellectually disabled, and inpatient rehabilitation facilities to permit essential caregivers access during any period in which regular visitation is restricted. General Outreach for Establishing an ""Office of Caregiver Health"": Supports the creation of an Office of Caregiver Health within the Department of Health and Human Services to address the needs of caregivers, particularly in relation to Parkinson's disease care.
Concentrating on High-value Alzheimer's Needs to Get to an End Act of 2023
Client: THE MICHAEL J. FOX FOUNDATION FOR PARKINSON'S RESEARCH · Firm: THE MICHAEL J. FOX FOUNDATION FOR PARKINSON'S RESEARCH
H.R.2365/S.1064 - National Plan to End Parkinson's Act: A bill to create an advisory council comprising members of federal agencies that support research, care, and services for Parkinson's disease, as well as patients, care partners, researchers, clinicians, and other non-federal experts, to ensure efficient and effective coordination among all federal entities responsible for managing, treating, and curing Parkinson's disease. General Parkinson's Disease Information: Covers symptoms, triggers, health coverage, health costs, social determinants of health, data collection, research, environmental risks, and health access for underserved communities, particularly through the CDC's National Neurological Conditions Surveillance System (NNCSS). H.R.2630/S.652/S.1339 - Safe Step Act: Requires group health plans to provide an exception process for any medication step therapy protocol to ensure that individuals living with Parkinson's disease can access treatments safely and efficiently. Establishing Parkinson's Disease ICD-10-CM Codes: Aims to assist in the coordination of care for Parkinson's patients who experience OFF episodes and to allow researchers to gather data to study disease progression. S.1544/H.R.1199 - Facilitating Innovative Nuclear Diagnostics Act of 2023: A bill to establish separate payment requirements for diagnostic radiopharmaceuticals, including DaTscans, which aid in confirming a Parkinson's diagnosis under the Medicare prospective payment system for hospital outpatient services. H.R.3432 - Telemental Health Care Access Act of 2023: Permanently removes Medicare's originating site requirements for mental health services furnished via telehealth. Parkinson's non-motor symptoms include mental health conditions, and many people with Parkinson's are Medicare beneficiaries who may face barriers due to in-person requirements. H.R.830/S.1375 - Help Ensure Lower Patient Copays Act: A bill requiring health insurance plans to apply certain payments, including third-party payments, financial assistance, and product vouchers, toward a plan's cost-sharing requirements. This helps Parkinson's patients afford medications for managing symptoms. The Medicare Part D Six Protected Classes Policy: Requires Part D plans to cover all drugs in six protected classes, including antidepressants and antipsychotics. For individuals with Parkinson's disease, these medications are crucial for managing non-motor symptoms such as depression and psychosis. H.R.4752/S.2379 - CHANGE Act of 2023: A bill to improve early screening, detection, and diagnosis of Alzheimer's and related dementias, including Parkinson's disease dementia, during Medicare wellness visits. H.R.4942/S.655 - Conrad State 30 and Physician Access Reauthorization Act: Reauthorizes the Conrad State 30 program and improves policies to address health care provider shortages, supporting neurological care for Parkinson's patients. H.R.8702/S.4532 - Improving Seniors Timely Access to Care Act: Establishes requirements regarding the use of prior authorization under Medicare Advantage plans. H.R.9233/S.- The HEALTHY Brains Act: Draft legislation to create a Centers of Excellence grant program within the National Institutes of Health to focus on the intersection between environmental risk factors and neurodegenerative diseases. General Outreach for Establishing an ""Office of Caregiver Health"": Supports the creation of an Office of Caregiver Health within the Department of Health and Human Services to address the needs of caregivers, particularly in relation to Parkinson's disease care.
Concentrating on High-value Alzheimer's Needs to Get to an End Act of 2023
Client: THE MICHAEL J. FOX FOUNDATION FOR PARKINSON'S RESEARCH · Firm: THE MICHAEL J. FOX FOUNDATION FOR PARKINSON'S RESEARCH
Lobbying to Increase Prescription Drug Affordability and Accessibility: Advocacy for Medicare Part D redesign and benefits for people living with Parkinson's, including expanding the low-income subsidy (LIS) program, capping out-of-pocket costs, implementing a smoothing mechanism, and streamlining utilization management processes. The Medicare Part D Six Protected Classes Policy: Requires Part D plans to cover all drugs in six classes: immunosuppressants, antidepressants, antipsychotics, anticonvulsants, antiretrovirals, and antineoplastics. For people living with Parkinson's, most of whom are Medicare beneficiaries, it is essential to have access to a wide range of treatment options for antidepressants and antipsychotics, which are crucial for managing non-motor symptoms like depression and psychosis. Signed Coalition Letters: - Medicare Access for Prescription Rx (MAPRx): Comment letter in response to Medicare Prescription Payment Plan Part One Guidance. - Patient and Provider Advocates for Telehealth: Comment letter in response to CMS CY 2024 Medicare Physician Fee Schedule (PFS) supporting expanded access to telehealth. - Alliance for Aging Research: Coalition letter in response to Medicare Prescription Payment Plan Part One Guidance supporting proposed beneficiary protections. H.R.4752/S.2379 - CHANGE Act of 2023: A bill to better utilize existing Medicare wellness visits for early screening, detection, and diagnosis of Alzheimer's and related dementias, including Parkinson's disease dementia. S.1544/H.R.1199 - Facilitating Innovative Nuclear Diagnostics Act of 2023: A bill to establish separate payment requirements for diagnostic radiopharmaceuticals, including DaTscans used to confirm Parkinson's diagnoses, under the Medicare outpatient prospective payment system. CMS-1809-P (2025 Medicare OPPS Proposed Rule): Comment supporting CMS's proposal to separately reimburse certain diagnostic radiopharmaceuticals used in diagnosing Parkinson's disease and atypical parkinsonisms. H.R.8702/S.4532 - Improving Seniors' Timely Access to Care Act: Establishes requirements for the use of prior authorization under Medicare Advantage plans to ensure timely access to care for seniors, including those with Parkinson's. S.3109/H.R.8018 - Alleviating Barriers for Caregivers (ABC) Act: Requires the Centers for Medicare & Medicaid Services (CMS) and Social Security to simplify processes and communications for family caregivers to assist individuals in accessing and utilizing benefits. S.3766/H.R.7274 - Connecting Caregivers to Medicare Act: Amends the Social Security Act to provide outreach and education to Medicare beneficiaries and simplify access to information for family caregivers through 1-800-MEDICARE. Advocacy for Durable Medical Equipment (DME) Access: Lobbying CMS to direct Medicare contractors to clarify claims procedures for DME therapies requiring administration via external infusion pumps, ensuring quick access to new Parkinson's therapies after FDA approval.
Conrad State 30 and Physician Access Reauthorization Act
Client: THE MICHAEL J. FOX FOUNDATION FOR PARKINSON'S RESEARCH · Firm: THE MICHAEL J. FOX FOUNDATION FOR PARKINSON'S RESEARCH
H.R.2365/S.1064 - National Plan to End Parkinson's Act: a bill to create an advisory council comprising members of federal agencies that support research, care, and services for Parkinsons, plus patients, care partners, researchers, clinicians, and other non-federal experts to ensure efficient and effective coordination among all federal entities with responsibility for managing, treating, and curing Parkinsons disease. General Parkinson's disease information about symptoms, triggers, health coverage, health costs, social determinants of health related to Parkinson's disease and data collection, research, environmental risks, and health access for underserved communities. Information related to prevalence particularly at CDC's National Neurological Conditions Surveillance System (NNCSS). H.R.2630/S.652/S.1339 - Safe Step Act: a bill to require group health plans to provide an exception process for any medication step therapy protocol to help ensure that people living with Parkinson's disease can safely and efficiently access treatments. Establishing Parkinson's disease ICD-10-CM codes to assist in the continuation and coordination of care for people living with Parkinson's who experience OFF episodes and to allow researchers to gather more data to study the progression of the disease. Reauthorization of CDCs National Neurological Conditions Surveillance System (NNCSS). S.1544/H.R.1199 - Facilitating Innovative Nuclear Diagnostics Act of 2023: a bill to establish separate payment requirements for diagnostic radiopharmaceuticals, including DaTscans, which can aid in confirming a Parkinson's diagnosis, under the Medicare prospective payment system for hospital outpatient department services. H.R.3432 - Telemental Health Care Access Act of 2023: a bill to permanently remove Medicare's originating site requirements for mental health services furnished via telehealth. Parkinson's non-motor symptoms encompass mental health conditions, including anxiety, depression, dementia, and other memory problems, and the majority of people living with Parkinson's in the United States are Medicare beneficiaries, many of whom will face undue burdens meeting the unnecessary in-person requirement for telemental health services after the delay of the requirement enforcement expires December 31, 2024. H.R.830/S.1375 - Help Ensure Lower Patient Copays Act: a bill to require health insurance plans to apply certain payments made by, or on behalf of, a plan enrollee toward a plan's cost-sharing requirements. Specifically, plans must apply third-party payments, financial assistance, discounts, product vouchers, and other reductions in out-of-pocket expenses toward the requirements. Many Parkinson's patients rely on such third-party payments to afford medications to treat and manage their disease symptoms, and this legislation will ensure that all payments whether they come directly out of a pocket or with the help of copay assistance-counts toward out-of-pocket costs of patients. The Medicare Part D Six Protected Classes Policy: requires Part D plan to cover all drugs in six classes: immunosuppressants, antidepressants, antipsychotics, anticonvulsants, antiretrovirals, and antineoplastics. For people living with Parkinson's, most of whom are Medicare beneficiaries, it is essential to have access to wide range of treatment options for antidepressants and antipsychotics. Parkinson's causes non-motor symptoms, including depression and psychosis, and individuals often experience different side effects, reactions, and efficacy based on which medications they take. H.R.4752/S.2379 - the Concentrating High-value Alzheimer's Needs to Get to an End (CHANGE) Act of 2023: a bill to better utilize the existing Welcome to Medicare initial exam and Medicare annual wellness visits to screen, detect, and diagnose Alzheimers and related dementias, including Parkinson's disease dementia, in their earliest stages. Signed Leaders Engaged on Alzheimer's Disease (LEAD) Coalition letter to members of Congress in support of this legislation. H.R.4942/S.655 - the Conrad State 30 and Physician Access Reauthorization Act: a bill to reauthorize the Conrad State 30 program for three years, make several targeted policy improvements, and permit the gradual expansion of the number of waivers granted to each state to address health care provider shortages. Signed American Academy of Neurology letter to member of Congress in support of this legislation. The Medicare Part D Six Protected Classes Policy: requires Part D plan to cover all drugs in six classes: immunosuppressants, antidepressants, antipsychotics, anticonvulsants, antiretrovirals, and antineoplastics. For people living with Parkinson's, most of whom are Medicare beneficiaries, it is essential to have access to wide range of treatment options for antidepressants and antipsychotics. Parkinson's causes non-motor symptoms, including depression and psychosis, and individuals often experience different side effects, reactions, and efficacy based on which medications they take. Partnership for Part D Access coalition congressional meetings and signed coalition letter to CMS in response to Medicare Prescription Payment Plan Part One Guidance in support of continued protection for the six protected classes policy. Signed Medicare Access for Prescription Rx (MAPRx) coalition comment letter in response to Medicare Prescription Payment Plan Part One Guidance. Signed Patient and Provider Advocates for Telehealth coalition comment letter in response to CMS CY 2024 Medicare Physician Fee Schedule (PFS) in support prioritizing the needs of patients by expanding policies that improved access to safe and timely health care via telehealth. Signed Alliance for Aging Research coalition letter in response to Medicare Prescription Payment Plan Part One Guidance in support of proposed beneficiary protections and to provide feedback on implementation considerations for the Medicare Prescription Payment Plan program. H.R.8702/S.4532 - Improving Seniors Timely Access to Care Act: a bill to establish requirements with respect to the use of prior authorization under Medicare Advantage plans. H.R./S.- The HEALTHY Brains Act- draft legislation to create a Centers of Excellence grant program within the National Institute of Health to focus on the intersection between environmental risk factors and neurodegenerative disease. General outreach and support for the establishment of an "Office of Caregiver Health" within the Office of the Secretary at the Department of Health and Human Services.
Conrad State 30 and Physician Access Reauthorization Act
Client: THE MICHAEL J. FOX FOUNDATION FOR PARKINSON'S RESEARCH · Firm: THE MICHAEL J. FOX FOUNDATION FOR PARKINSON'S RESEARCH
H.R.2365/S.1064 - National Plan to End Parkinson's Act: A bill to create an advisory council comprising members of federal agencies that support research, care, and services for Parkinson's disease, as well as patients, care partners, researchers, clinicians, and other non-federal experts, to ensure efficient and effective coordination among all federal entities responsible for managing, treating, and curing Parkinson's disease. General Parkinson's Disease Information: Covers symptoms, triggers, health coverage, health costs, social determinants of health, data collection, research, environmental risks, and health access for underserved communities, particularly through the CDC's National Neurological Conditions Surveillance System (NNCSS). H.R.2630/S.652/S.1339 - Safe Step Act: Requires group health plans to provide an exception process for any medication step therapy protocol to ensure that individuals living with Parkinson's disease can access treatments safely and efficiently. Establishing Parkinson's Disease ICD-10-CM Codes: Aims to assist in the coordination of care for Parkinson's patients who experience OFF episodes and to allow researchers to gather data to study disease progression. S.1544/H.R.1199 - Facilitating Innovative Nuclear Diagnostics Act of 2023: A bill to establish separate payment requirements for diagnostic radiopharmaceuticals, including DaTscans, which aid in confirming a Parkinson's diagnosis under the Medicare prospective payment system for hospital outpatient services. H.R.3432 - Telemental Health Care Access Act of 2023: Permanently removes Medicare's originating site requirements for mental health services furnished via telehealth. Parkinson's non-motor symptoms include mental health conditions, and many people with Parkinson's are Medicare beneficiaries who may face barriers due to in-person requirements. H.R.830/S.1375 - Help Ensure Lower Patient Copays Act: A bill requiring health insurance plans to apply certain payments, including third-party payments, financial assistance, and product vouchers, toward a plan's cost-sharing requirements. This helps Parkinson's patients afford medications for managing symptoms. The Medicare Part D Six Protected Classes Policy: Requires Part D plans to cover all drugs in six protected classes, including antidepressants and antipsychotics. For individuals with Parkinson's disease, these medications are crucial for managing non-motor symptoms such as depression and psychosis. H.R.4752/S.2379 - CHANGE Act of 2023: A bill to improve early screening, detection, and diagnosis of Alzheimer's and related dementias, including Parkinson's disease dementia, during Medicare wellness visits. H.R.4942/S.655 - Conrad State 30 and Physician Access Reauthorization Act: Reauthorizes the Conrad State 30 program and improves policies to address health care provider shortages, supporting neurological care for Parkinson's patients. H.R.8702/S.4532 - Improving Seniors Timely Access to Care Act: Establishes requirements regarding the use of prior authorization under Medicare Advantage plans. H.R.9233/S.- The HEALTHY Brains Act: Draft legislation to create a Centers of Excellence grant program within the National Institutes of Health to focus on the intersection between environmental risk factors and neurodegenerative diseases. General Outreach for Establishing an ""Office of Caregiver Health"": Supports the creation of an Office of Caregiver Health within the Department of Health and Human Services to address the needs of caregivers, particularly in relation to Parkinson's disease care.
Conrad State 30 and Physician Access Reauthorization Act
Client: THE MICHAEL J. FOX FOUNDATION FOR PARKINSON'S RESEARCH · Firm: THE MICHAEL J. FOX FOUNDATION FOR PARKINSON'S RESEARCH
H.R.2365/S.1064 - National Plan to End Parkinson's Act: A bill to create an advisory council comprising members of federal agencies that support research, care, and services for Parkinson's disease, as well as patients, care partners, researchers, clinicians, and other non-federal experts, to ensure efficient and effective coordination among all federal entities responsible for managing, treating, and curing Parkinson's disease. General Parkinson's Disease Information: Covers symptoms, triggers, health coverage, health costs, social determinants of health, data collection, research, environmental risks, and health access for underserved communities, particularly through the CDC's National Neurological Conditions Surveillance System (NNCSS). H.R.2630/S.652/S.1339 - Safe Step Act: Requires group health plans to provide an exception process for any medication step therapy protocol to ensure that individuals living with Parkinson's disease can access treatments safely and efficiently. Establishing Parkinson's Disease ICD-10-CM Codes: Aims to assist in the coordination of care for Parkinson's patients who experience OFF episodes and to allow researchers to gather data to study disease progression. S.1544/H.R.1199 - Facilitating Innovative Nuclear Diagnostics Act of 2023: A bill to establish separate payment requirements for diagnostic radiopharmaceuticals, including DaTscans, which aid in confirming a Parkinson's diagnosis under the Medicare prospective payment system for hospital outpatient services. H.R.3432 - Telemental Health Care Access Act of 2023: Permanently removes Medicare's originating site requirements for mental health services furnished via telehealth. Parkinson's non-motor symptoms include mental health conditions, and many people with Parkinson's are Medicare beneficiaries who may face barriers due to in-person requirements. H.R.830/S.1375 - Help Ensure Lower Patient Copays Act: A bill requiring health insurance plans to apply certain payments, including third-party payments, financial assistance, and product vouchers, toward a plan's cost-sharing requirements. This helps Parkinson's patients afford medications for managing symptoms. The Medicare Part D Six Protected Classes Policy: Requires Part D plans to cover all drugs in six protected classes, including antidepressants and antipsychotics. For individuals with Parkinson's disease, these medications are crucial for managing non-motor symptoms such as depression and psychosis. H.R.4752/S.2379 - CHANGE Act of 2023: A bill to improve early screening, detection, and diagnosis of Alzheimer's and related dementias, including Parkinson's disease dementia, during Medicare wellness visits. H.R.4942/S.655 - Conrad State 30 and Physician Access Reauthorization Act: Reauthorizes the Conrad State 30 program and improves policies to address health care provider shortages, supporting neurological care for Parkinson's patients. H.R.8702/S.4532 - Improving Seniors Timely Access to Care Act: Establishes requirements regarding the use of prior authorization under Medicare Advantage plans. H.R.9233/S.- The HEALTHY Brains Act: Draft legislation to create a Centers of Excellence grant program within the National Institutes of Health to focus on the intersection between environmental risk factors and neurodegenerative diseases. H.R.8331/S. 4280 - Essential Caregivers Act of 2024: To amend titles XVIII and XIX of the Social Security Act to require skilled nursing facilities, nursing facilities, intermediate care facilities for the intellectually disabled, and inpatient rehabilitation facilities to permit essential caregivers access during any period in which regular visitation is restricted. General Outreach for Establishing an ""Office of Caregiver Health"": Supports the creation of an Office of Caregiver Health within the Department of Health and Human Services to address the needs of caregivers, particularly in relation to Parkinson's disease care.
Conrad State 30 and Physician Access Reauthorization Act
Client: THE MICHAEL J. FOX FOUNDATION FOR PARKINSON'S RESEARCH · Firm: THE MICHAEL J. FOX FOUNDATION FOR PARKINSON'S RESEARCH
H.R.2365/S.1064 - National Plan to End Parkinson's Act: a bill to create an advisory council comprising members of federal agencies that support research, care, and services for Parkinsons, plus patients, care partners, researchers, clinicians, and other non-federal experts to ensure efficient and effective coordination among all federal entities with responsibility for managing, treating, and curing Parkinsons disease. General Parkinson's disease information about symptoms, triggers, health coverage, health costs, social determinants of health related to Parkinson's disease and data collection, research, environmental risks, and health access for underserved communities. Information related to prevalence particularly at CDC's National Neurological Conditions Surveillance System (NNCSS). H.R.2630/S.652/S.1339 - Safe Step Act: a bill to require group health plans to provide an exception process for any medication step therapy protocol to help ensure that people living with Parkinson's disease can safely and efficiently access treatments. Establishing Parkinson's disease ICD-10-CM codes to assist in the continuation and coordination of care for people living with Parkinson's who experience OFF episodes and to allow researchers to gather more data to study the progression of the disease. Reauthorization of CDCs National Neurological Conditions Surveillance System (NNCSS). S.1544/H.R.1199 - Facilitating Innovative Nuclear Diagnostics Act of 2023: a bill to establish separate payment requirements for diagnostic radiopharmaceuticals, including DaTscans, which can aid in confirming a Parkinson's diagnosis, under the Medicare prospective payment system for hospital outpatient department services. H.R.3432 - Telemental Health Care Access Act of 2023: a bill to permanently remove Medicare's originating site requirements for mental health services furnished via telehealth. Parkinson's non-motor symptoms encompass mental health conditions, including anxiety, depression, dementia, and other memory problems, and the majority of people living with Parkinson's in the United States are Medicare beneficiaries, many of whom will face undue burdens meeting the unnecessary in-person requirement for telemental health services after the delay of the requirement enforcement expires December 31, 2024. H.R.830/S.1375 - Help Ensure Lower Patient Copays Act: a bill to require health insurance plans to apply certain payments made by, or on behalf of, a plan enrollee toward a plan's cost-sharing requirements. Specifically, plans must apply third-party payments, financial assistance, discounts, product vouchers, and other reductions in out-of-pocket expenses toward the requirements. Many Parkinson's patients rely on such third-party payments to afford medications to treat and manage their disease symptoms, and this legislation will ensure that all payments whether they come directly out of a pocket or with the help of copay assistance-counts toward out-of-pocket costs of patients. The Medicare Part D Six Protected Classes Policy: requires Part D plan to cover all drugs in six classes: immunosuppressants, antidepressants, antipsychotics, anticonvulsants, antiretrovirals, and antineoplastics. For people living with Parkinson's, most of whom are Medicare beneficiaries, it is essential to have access to wide range of treatment options for antidepressants and antipsychotics. Parkinson's causes non-motor symptoms, including depression and psychosis, and individuals often experience different side effects, reactions, and efficacy based on which medications they take. H.R.4752/S.2379 - the Concentrating High-value Alzheimer's Needs to Get to an End (CHANGE) Act of 2023: a bill to better utilize the existing Welcome to Medicare initial exam and Medicare annual wellness visits to screen, detect, and diagnose Alzheimers and related dementias, including Parkinson's disease dementia, in their earliest stages. Signed Leaders Engaged on Alzheimer's Disease (LEAD) Coalition letter to members of Congress in support of this legislation. H.R.4942/S.655 - the Conrad State 30 and Physician Access Reauthorization Act: a bill to reauthorize the Conrad State 30 program for three years, make several targeted policy improvements, and permit the gradual expansion of the number of waivers granted to each state to address health care provider shortages. Signed American Academy of Neurology letter to member of Congress in support of this legislation. The Medicare Part D Six Protected Classes Policy: requires Part D plan to cover all drugs in six classes: immunosuppressants, antidepressants, antipsychotics, anticonvulsants, antiretrovirals, and antineoplastics. For people living with Parkinson's, most of whom are Medicare beneficiaries, it is essential to have access to wide range of treatment options for antidepressants and antipsychotics. Parkinson's causes non-motor symptoms, including depression and psychosis, and individuals often experience different side effects, reactions, and efficacy based on which medications they take. Partnership for Part D Access coalition congressional meetings and signed coalition letter to CMS in response to Medicare Prescription Payment Plan Part One Guidance in support of continued protection for the six protected classes policy. Signed Medicare Access for Prescription Rx (MAPRx) coalition comment letter in response to Medicare Prescription Payment Plan Part One Guidance. Signed Patient and Provider Advocates for Telehealth coalition comment letter in response to CMS CY 2024 Medicare Physician Fee Schedule (PFS) in support prioritizing the needs of patients by expanding policies that improved access to safe and timely health care via telehealth. Signed Alliance for Aging Research coalition letter in response to Medicare Prescription Payment Plan Part One Guidance in support of proposed beneficiary protections and to provide feedback on implementation considerations for the Medicare Prescription Payment Plan program.
Elizabeth Dole Home Care Act of 2023
Client: THE MICHAEL J. FOX FOUNDATION FOR PARKINSON'S RESEARCH · Firm: THE MICHAEL J. FOX FOUNDATION FOR PARKINSON'S RESEARCH
General education on the importance of the Department of Defense medical research programs for military service personnel and Veterans living with Parkinson's disease. H.R.8774/ S.4921: FY25 Defense Appropriations bills to support increased funding for DOD Congressionally Directed Medical Research Programs Parkinson's Research Program. H.R.542/S.141 - The Elizabeth Dole Home Care Act: Increases access to home care and caregiver programs provided by the Department of Veterans Affairs (VA) and seeks to address VA home health workforce shortages. Inclusion of Parkinson's disease and PD-related diseases as presumptive conditions when military Veterans are exposed to associated toxins. H.R.8580 / S.4677 - FY25 Military Construction, Veterans Affairs and Related Agencies Appropriations bill: Supports increased funding for the VA's Parkinson's Disease Research, Education and Clinical Center as part of Neurology Centers of Excellence. General education regarding the importance of the Department of Defense medical research programs for military service personnel and Veterans living with Parkinson's disease.
Elizabeth Dole Home Care Act of 2023
Client: THE MICHAEL J. FOX FOUNDATION FOR PARKINSON'S RESEARCH · Firm: THE MICHAEL J. FOX FOUNDATION FOR PARKINSON'S RESEARCH
General education on the importance of the Department of Defense medical research programs for military service personnel and Veterans living with Parkinson's disease. H.R.8774/ S.4921: FY25 Defense Appropriations bills to support increased funding for DOD Congressionally Directed Medical Research Programs Parkinson's Research Program. H.R.542/S.141 - The Elizabeth Dole Home Care Act: Increases access to home care and caregiver programs provided by the Department of Veterans Affairs (VA) and seeks to address VA home health workforce shortages. Inclusion of Parkinson's disease and PD-related diseases as presumptive conditions when military Veterans are exposed to associated toxins. H.R.8580 / S.4677 - FY25 Military Construction, Veterans Affairs and Related Agencies Appropriations bill: Supports increased funding for the VA's Parkinson's Disease Research, Education and Clinical Center as part of Neurology Centers of Excellence. General education regarding the importance of the Department of Defense medical research programs for military service personnel and Veterans living with Parkinson's disease.
Elizabeth Dole Home Care Act of 2023
Client: THE MICHAEL J. FOX FOUNDATION FOR PARKINSON'S RESEARCH · Firm: THE MICHAEL J. FOX FOUNDATION FOR PARKINSON'S RESEARCH
FY25 Military Construction, Veterans Affairs and Related Agencies Appropriations bill to support increased funding for the VA's Parkinson's Disease Research, Education and Clinical Center. General education regarding the importance of the Department of Defense medical research programs for military service personnel and Veterans living with Parkinson's disease. Inclusion of Parkinson's disease and PD-related diseases as presumptive conditions when military Veterans are exposed to associated toxins. FY24 and FY25 Defense Appropriations bills to support increased funding for DOD Congressionally Directed Medical Research Programs Parkinson's Research Program. H.R.542/S.141 -The Elizabeth Dole Home Care Act- increases access to home care and caregiver programs provided by the Department of Veterans Affairs (VA) and seeks to address VA home health workforce shortages. H.R. 8580 / Senate bill not filed - FY25 Military Construction, Veterans Affairs and Related Agencies Appropriations bill to support increased funding for the VA's Parkinson's Disease Research, Education and Clinical Center as part of Neurology Centers of Excellence. H.R. 8774/ Senate bill not yet filed - FY25 Defense Appropriations bills to support increased funding for DOD Congressionally Directed Medical Research Programs Parkinson's Research Program. General education regarding the importance of the Department of Defense medical research programs for military service personnel and Veterans living with Parkinson's disease. Inclusion of Parkinson's disease and PD-related diseases as presumptive conditions when military Veterans are exposed to associated toxins.
Making appropriations for the Departments of Labor, Health and Human Services, and Education, and related agencies for the fiscal year ending September 30, 2024, and for other purposes.
Client: THE MICHAEL J. FOX FOUNDATION FOR PARKINSON'S RESEARCH · Firm: THE MICHAEL J. FOX FOUNDATION FOR PARKINSON'S RESEARCH
FY 2024 Appropriations bills including funding requests for Parkinson's research at: H.R.4365/S.2587 - The Department of Defense within the FY 2024 Defense Appropriation bill. H.R.5894/S.2624 - The National Institute of Health and Centers for Disease Control and Prevention within the FY 2024 Labor, Health and Human Services, Education, and Related Agencies Appropriation bill. H.R.4368/S.2131 - The Food and Drug Administration within the FY 2024 Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriation bill. H.R.4366/S.2127 - The Department of Veterans Affairs within the FY 2024 Military Construction, Veterans Affairs, and Related Agencies Appropriation bill. Increased funding for NIEHS (no bill introduced). Funding for the Parkinson's Research Program (PRP) under the Department of Defense's Congressionally Directed Medical Research Programs (CDMRP).
Connecting Caregivers to Medicare Act of 2024
Client: THE MICHAEL J. FOX FOUNDATION FOR PARKINSON'S RESEARCH · Firm: THE MICHAEL J. FOX FOUNDATION FOR PARKINSON'S RESEARCH
Lobbying to increase prescription drug affordability and accessibility for people living with Parkinson's via Medicare Part D redesign and benefits, including expanding the low-income subsidy (LIS) program, capping out-of-pocket costs, implementing a smoothing mechanism, and streamlining utilization management processes. The Medicare Part D Six Protected Classes Policy: requires Part D plan to cover all drugs in six classes: immunosuppressants, antidepressants, antipsychotics, anticonvulsants, antiretrovirals, and antineoplastics. For people living with Parkinson's, most of whom are Medicare beneficiaries, it is essential to have access to wide range of treatment options for antidepressants and antipsychotics. Parkinson's causes non-motor symptoms, including depression and psychosis, and individuals often experience different side effects, reactions, and efficacy based on which medications they take. Partnership for Part D Access coalition congressional meetings and signed coalition letter to CMS in response to Medicare Prescription Payment Plan Part One Guidance in support of continued protection for the six protected classes policy. Signed Medicare Access for Prescription Rx (MAPRx) coalition comment letter in response to Medicare Prescription Payment Plan Part One Guidance. Signed Patient and Provider Advocates for Telehealth coalition comment letter in response to CMS CY 2024 Medicare Physician Fee Schedule (PFS) in support prioritizing the needs of patients by expanding policies that improved access to safe and timely health care via telehealth. Signed Alliance for Aging Research coalition letter in response to Medicare Prescription Payment Plan Part One Guidance in support of proposed beneficiary protections and to provide feedback on implementation considerations for the Medicare Prescription Payment Plan program. H.R.4752/S.2379 - the Concentrating High-value Alzheimer's Needs to Get to an End (CHANGE) Act of 2023: a bill to better utilize the existing Welcome to Medicare initial exam and Medicare annual wellness visits to screen, detect, and diagnose Alzheimers and related dementias, including Parkinson's disease dementia, in their earliest stages. Signed Leaders Engaged on Alzheimer's Disease (LEAD) Coalition letter to members of Congress in support of this legislation. S. 3109- Alleviating Barriers for Caregivers (ABC) Act- bill to require the Administrator of the Centers for Medicare & Medicaid Services and the Commissioner of Social Security to review and simplify the processes, procedures, forms, and communications for family caregivers to assist individuals in establishing eligibility for, enrolling in, and maintaining and utilizing coverage and benefits under the Medicare, Medicaid, CHIP, and Social Security programs respectively, and for other purposes. Lobbying the Centers for Medicare and Medicaid Services to direct Durable Medical Equipment Medicare Administrative Contractors to provide additional clarification regarding the use of claim modifiers for DME therapies that require administration via an external infusion pump to expedite patient access once new Parkinson's therapies receive approvals from the Food and Drug Administration. S.1544/H.R.1199 - Facilitating Innovative Nuclear Diagnostics Act of 2023: a bill to establish separate payment requirements for diagnostic radiopharmaceuticals, including DaTscans, which can aid in confirming a Parkinson's diagnosis, under the Medicare prospective payment system for hospital outpatient department services. S. 3766/H.R. 7274- Connecting Caregivers to Medicare Act -To amend title XVIII of the Social Security Act to provide for outreach and education to Medicare beneficiaries to simplify access to information for family caregivers through 1-800-MEDICARE, and for other purposes. H.R. 8018/S. 3109- Alleviating Barriers for Caregivers (ABC) Act- bill to require the Administrator of the Centers for Medicare & Medicaid Services and the Commissioner of Social Security to review and simplify the processes, procedures, forms, and communications for family caregivers to assist individuals in establishing eligibility for, enrolling in, and maintaining and utilizing coverage and benefits under the Medicare, Medicaid, CHIP, and Social Security programs respectively, and for other purposes. H.R.8702/S.4532 - Improving Seniors Timely Access to Care Act: a bill to establish requirements with respect to the use of prior authorization under Medicare Advantage plans.
Connecting Caregivers to Medicare Act of 2024
Client: THE MICHAEL J. FOX FOUNDATION FOR PARKINSON'S RESEARCH · Firm: THE MICHAEL J. FOX FOUNDATION FOR PARKINSON'S RESEARCH
Lobbying to Increase Prescription Drug Affordability and Accessibility: Advocacy for Medicare Part D redesign and benefits for people living with Parkinson's, including expanding the low-income subsidy (LIS) program, capping out-of-pocket costs, implementing a smoothing mechanism, and streamlining utilization management processes. The Medicare Part D Six Protected Classes Policy: Requires Part D plans to cover all drugs in six classes: immunosuppressants, antidepressants, antipsychotics, anticonvulsants, antiretrovirals, and antineoplastics. For people living with Parkinson's, most of whom are Medicare beneficiaries, it is essential to have access to a wide range of treatment options for antidepressants and antipsychotics, which are crucial for managing non-motor symptoms like depression and psychosis. Signed Coalition Letters: - Medicare Access for Prescription Rx (MAPRx): Comment letter in response to Medicare Prescription Payment Plan Part One Guidance. - Patient and Provider Advocates for Telehealth: Comment letter in response to CMS CY 2024 Medicare Physician Fee Schedule (PFS) supporting expanded access to telehealth. - Alliance for Aging Research: Coalition letter in response to Medicare Prescription Payment Plan Part One Guidance supporting proposed beneficiary protections. H.R.4752/S.2379 - CHANGE Act of 2023: A bill to better utilize existing Medicare wellness visits for early screening, detection, and diagnosis of Alzheimer's and related dementias, including Parkinson's disease dementia. S.1544/H.R.1199 - Facilitating Innovative Nuclear Diagnostics Act of 2023: A bill to establish separate payment requirements for diagnostic radiopharmaceuticals, including DaTscans used to confirm Parkinson's diagnoses, under the Medicare outpatient prospective payment system. CMS-1809-P (2025 Medicare OPPS Proposed Rule): Comment supporting CMS's proposal to separately reimburse certain diagnostic radiopharmaceuticals used in diagnosing Parkinson's disease and atypical parkinsonisms. H.R.8702/S.4532 - Improving Seniors' Timely Access to Care Act: Establishes requirements for the use of prior authorization under Medicare Advantage plans to ensure timely access to care for seniors, including those with Parkinson's. S.3109/H.R.8018 - Alleviating Barriers for Caregivers (ABC) Act: Requires the Centers for Medicare & Medicaid Services (CMS) and Social Security to simplify processes and communications for family caregivers to assist individuals in accessing and utilizing benefits. S.3766/H.R.7274 - Connecting Caregivers to Medicare Act: Amends the Social Security Act to provide outreach and education to Medicare beneficiaries and simplify access to information for family caregivers through 1-800-MEDICARE. Advocacy for Durable Medical Equipment (DME) Access: Lobbying CMS to direct Medicare contractors to clarify claims procedures for DME therapies requiring administration via external infusion pumps, ensuring quick access to new Parkinson's therapies after FDA approval.
Connecting Caregivers to Medicare Act of 2024
Client: THE MICHAEL J. FOX FOUNDATION FOR PARKINSON'S RESEARCH · Firm: THE MICHAEL J. FOX FOUNDATION FOR PARKINSON'S RESEARCH
Lobbying to Increase Prescription Drug Affordability and Accessibility: Advocacy for Medicare Part D redesign and benefits for people living with Parkinson's, including expanding the low-income subsidy (LIS) program, capping out-of-pocket costs, implementing a smoothing mechanism, and streamlining utilization management processes. The Medicare Part D Six Protected Classes Policy: Requires Part D plans to cover all drugs in six classes: immunosuppressants, antidepressants, antipsychotics, anticonvulsants, antiretrovirals, and antineoplastics. For people living with Parkinson's, most of whom are Medicare beneficiaries, it is essential to have access to a wide range of treatment options for antidepressants and antipsychotics, which are crucial for managing non-motor symptoms like depression and psychosis. Signed Coalition Letters: - Medicare Access for Prescription Rx (MAPRx): Comment letter in response to Medicare Prescription Payment Plan Part One Guidance. - Patient and Provider Advocates for Telehealth: Comment letter in response to CMS CY 2024 Medicare Physician Fee Schedule (PFS) supporting expanded access to telehealth. - Alliance for Aging Research: Coalition letter in response to Medicare Prescription Payment Plan Part One Guidance supporting proposed beneficiary protections. H.R.4752/S.2379 - CHANGE Act of 2023: A bill to better utilize existing Medicare wellness visits for early screening, detection, and diagnosis of Alzheimer's and related dementias, including Parkinson's disease dementia. S.1544/H.R.1199 - Facilitating Innovative Nuclear Diagnostics Act of 2023: A bill to establish separate payment requirements for diagnostic radiopharmaceuticals, including DaTscans used to confirm Parkinson's diagnoses, under the Medicare outpatient prospective payment system. CMS-1809-P (2025 Medicare OPPS Proposed Rule): Comment supporting CMS's proposal to separately reimburse certain diagnostic radiopharmaceuticals used in diagnosing Parkinson's disease and atypical parkinsonisms. H.R.8702/S.4532 - Improving Seniors' Timely Access to Care Act: Establishes requirements for the use of prior authorization under Medicare Advantage plans to ensure timely access to care for seniors, including those with Parkinson's. S.3109/H.R.8018 - Alleviating Barriers for Caregivers (ABC) Act: Requires the Centers for Medicare & Medicaid Services (CMS) and Social Security to simplify processes and communications for family caregivers to assist individuals in accessing and utilizing benefits. S.3766/H.R.7274 - Connecting Caregivers to Medicare Act: Amends the Social Security Act to provide outreach and education to Medicare beneficiaries and simplify access to information for family caregivers through 1-800-MEDICARE. Advocacy for Durable Medical Equipment (DME) Access: Lobbying CMS to direct Medicare contractors to clarify claims procedures for DME therapies requiring administration via external infusion pumps, ensuring quick access to new Parkinson's therapies after FDA approval. H.R.8331/S. 4280 - Essential Caregivers Act of 2024: To amend titles XVIII and XIX of the Social Security Act to require skilled nursing facilities, nursing facilities, intermediate care facilities for the intellectually disabled, and inpatient rehabilitation facilities to permit essential caregivers access during any period in which regular visitation is restricted.
ABC Act
Client: THE MICHAEL J. FOX FOUNDATION FOR PARKINSON'S RESEARCH · Firm: THE MICHAEL J. FOX FOUNDATION FOR PARKINSON'S RESEARCH
Lobbying to Increase Prescription Drug Affordability and Accessibility: Advocacy for Medicare Part D redesign and benefits for people living with Parkinson's, including expanding the low-income subsidy (LIS) program, capping out-of-pocket costs, implementing a smoothing mechanism, and streamlining utilization management processes. The Medicare Part D Six Protected Classes Policy: Requires Part D plans to cover all drugs in six classes: immunosuppressants, antidepressants, antipsychotics, anticonvulsants, antiretrovirals, and antineoplastics. For people living with Parkinson's, most of whom are Medicare beneficiaries, it is essential to have access to a wide range of treatment options for antidepressants and antipsychotics, which are crucial for managing non-motor symptoms like depression and psychosis. Signed Coalition Letters: - Medicare Access for Prescription Rx (MAPRx): Comment letter in response to Medicare Prescription Payment Plan Part One Guidance. - Patient and Provider Advocates for Telehealth: Comment letter in response to CMS CY 2024 Medicare Physician Fee Schedule (PFS) supporting expanded access to telehealth. - Alliance for Aging Research: Coalition letter in response to Medicare Prescription Payment Plan Part One Guidance supporting proposed beneficiary protections. H.R.4752/S.2379 - CHANGE Act of 2023: A bill to better utilize existing Medicare wellness visits for early screening, detection, and diagnosis of Alzheimer's and related dementias, including Parkinson's disease dementia. S.1544/H.R.1199 - Facilitating Innovative Nuclear Diagnostics Act of 2023: A bill to establish separate payment requirements for diagnostic radiopharmaceuticals, including DaTscans used to confirm Parkinson's diagnoses, under the Medicare outpatient prospective payment system. CMS-1809-P (2025 Medicare OPPS Proposed Rule): Comment supporting CMS's proposal to separately reimburse certain diagnostic radiopharmaceuticals used in diagnosing Parkinson's disease and atypical parkinsonisms. H.R.8702/S.4532 - Improving Seniors' Timely Access to Care Act: Establishes requirements for the use of prior authorization under Medicare Advantage plans to ensure timely access to care for seniors, including those with Parkinson's. S.3109/H.R.8018 - Alleviating Barriers for Caregivers (ABC) Act: Requires the Centers for Medicare & Medicaid Services (CMS) and Social Security to simplify processes and communications for family caregivers to assist individuals in accessing and utilizing benefits. S.3766/H.R.7274 - Connecting Caregivers to Medicare Act: Amends the Social Security Act to provide outreach and education to Medicare beneficiaries and simplify access to information for family caregivers through 1-800-MEDICARE. Advocacy for Durable Medical Equipment (DME) Access: Lobbying CMS to direct Medicare contractors to clarify claims procedures for DME therapies requiring administration via external infusion pumps, ensuring quick access to new Parkinson's therapies after FDA approval.
ABC Act
Client: THE MICHAEL J. FOX FOUNDATION FOR PARKINSON'S RESEARCH · Firm: THE MICHAEL J. FOX FOUNDATION FOR PARKINSON'S RESEARCH
Lobbying to increase prescription drug affordability and accessibility for people living with Parkinson's via Medicare Part D redesign and benefits, including expanding the low-income subsidy (LIS) program, capping out-of-pocket costs, implementing a smoothing mechanism, and streamlining utilization management processes. The Medicare Part D Six Protected Classes Policy: requires Part D plan to cover all drugs in six classes: immunosuppressants, antidepressants, antipsychotics, anticonvulsants, antiretrovirals, and antineoplastics. For people living with Parkinson's, most of whom are Medicare beneficiaries, it is essential to have access to wide range of treatment options for antidepressants and antipsychotics. Parkinson's causes non-motor symptoms, including depression and psychosis, and individuals often experience different side effects, reactions, and efficacy based on which medications they take. Partnership for Part D Access coalition congressional meetings and signed coalition letter to CMS in response to Medicare Prescription Payment Plan Part One Guidance in support of continued protection for the six protected classes policy. Signed Medicare Access for Prescription Rx (MAPRx) coalition comment letter in response to Medicare Prescription Payment Plan Part One Guidance. Signed Patient and Provider Advocates for Telehealth coalition comment letter in response to CMS CY 2024 Medicare Physician Fee Schedule (PFS) in support prioritizing the needs of patients by expanding policies that improved access to safe and timely health care via telehealth. Signed Alliance for Aging Research coalition letter in response to Medicare Prescription Payment Plan Part One Guidance in support of proposed beneficiary protections and to provide feedback on implementation considerations for the Medicare Prescription Payment Plan program. H.R.4752/S.2379 - the Concentrating High-value Alzheimer's Needs to Get to an End (CHANGE) Act of 2023: a bill to better utilize the existing Welcome to Medicare initial exam and Medicare annual wellness visits to screen, detect, and diagnose Alzheimers and related dementias, including Parkinson's disease dementia, in their earliest stages. Signed Leaders Engaged on Alzheimer's Disease (LEAD) Coalition letter to members of Congress in support of this legislation. S. 3109- Alleviating Barriers for Caregivers (ABC) Act- bill to require the Administrator of the Centers for Medicare & Medicaid Services and the Commissioner of Social Security to review and simplify the processes, procedures, forms, and communications for family caregivers to assist individuals in establishing eligibility for, enrolling in, and maintaining and utilizing coverage and benefits under the Medicare, Medicaid, CHIP, and Social Security programs respectively, and for other purposes. Lobbying the Centers for Medicare and Medicaid Services to direct Durable Medical Equipment Medicare Administrative Contractors to provide additional clarification regarding the use of claim modifiers for DME therapies that require administration via an external infusion pump to expedite patient access once new Parkinson's therapies receive approvals from the Food and Drug Administration. S.1544/H.R.1199 - Facilitating Innovative Nuclear Diagnostics Act of 2023: a bill to establish separate payment requirements for diagnostic radiopharmaceuticals, including DaTscans, which can aid in confirming a Parkinson's diagnosis, under the Medicare prospective payment system for hospital outpatient department services. S. 3766/H.R. 7274- Connecting Caregivers to Medicare Act -To amend title XVIII of the Social Security Act to provide for outreach and education to Medicare beneficiaries to simplify access to information for family caregivers through 1-800-MEDICARE, and for other purposes. H.R. 8018/S. 3109- Alleviating Barriers for Caregivers (ABC) Act- bill to require the Administrator of the Centers for Medicare & Medicaid Services and the Commissioner of Social Security to review and simplify the processes, procedures, forms, and communications for family caregivers to assist individuals in establishing eligibility for, enrolling in, and maintaining and utilizing coverage and benefits under the Medicare, Medicaid, CHIP, and Social Security programs respectively, and for other purposes. H.R.8702/S.4532 - Improving Seniors Timely Access to Care Act: a bill to establish requirements with respect to the use of prior authorization under Medicare Advantage plans.
ABC Act
Client: THE MICHAEL J. FOX FOUNDATION FOR PARKINSON'S RESEARCH · Firm: THE MICHAEL J. FOX FOUNDATION FOR PARKINSON'S RESEARCH
Lobbying to Increase Prescription Drug Affordability and Accessibility: Advocacy for Medicare Part D redesign and benefits for people living with Parkinson's, including expanding the low-income subsidy (LIS) program, capping out-of-pocket costs, implementing a smoothing mechanism, and streamlining utilization management processes. The Medicare Part D Six Protected Classes Policy: Requires Part D plans to cover all drugs in six classes: immunosuppressants, antidepressants, antipsychotics, anticonvulsants, antiretrovirals, and antineoplastics. For people living with Parkinson's, most of whom are Medicare beneficiaries, it is essential to have access to a wide range of treatment options for antidepressants and antipsychotics, which are crucial for managing non-motor symptoms like depression and psychosis. Signed Coalition Letters: - Medicare Access for Prescription Rx (MAPRx): Comment letter in response to Medicare Prescription Payment Plan Part One Guidance. - Patient and Provider Advocates for Telehealth: Comment letter in response to CMS CY 2024 Medicare Physician Fee Schedule (PFS) supporting expanded access to telehealth. - Alliance for Aging Research: Coalition letter in response to Medicare Prescription Payment Plan Part One Guidance supporting proposed beneficiary protections. H.R.4752/S.2379 - CHANGE Act of 2023: A bill to better utilize existing Medicare wellness visits for early screening, detection, and diagnosis of Alzheimer's and related dementias, including Parkinson's disease dementia. S.1544/H.R.1199 - Facilitating Innovative Nuclear Diagnostics Act of 2023: A bill to establish separate payment requirements for diagnostic radiopharmaceuticals, including DaTscans used to confirm Parkinson's diagnoses, under the Medicare outpatient prospective payment system. CMS-1809-P (2025 Medicare OPPS Proposed Rule): Comment supporting CMS's proposal to separately reimburse certain diagnostic radiopharmaceuticals used in diagnosing Parkinson's disease and atypical parkinsonisms. H.R.8702/S.4532 - Improving Seniors' Timely Access to Care Act: Establishes requirements for the use of prior authorization under Medicare Advantage plans to ensure timely access to care for seniors, including those with Parkinson's. S.3109/H.R.8018 - Alleviating Barriers for Caregivers (ABC) Act: Requires the Centers for Medicare & Medicaid Services (CMS) and Social Security to simplify processes and communications for family caregivers to assist individuals in accessing and utilizing benefits. S.3766/H.R.7274 - Connecting Caregivers to Medicare Act: Amends the Social Security Act to provide outreach and education to Medicare beneficiaries and simplify access to information for family caregivers through 1-800-MEDICARE. Advocacy for Durable Medical Equipment (DME) Access: Lobbying CMS to direct Medicare contractors to clarify claims procedures for DME therapies requiring administration via external infusion pumps, ensuring quick access to new Parkinson's therapies after FDA approval. H.R.8331/S. 4280 - Essential Caregivers Act of 2024: To amend titles XVIII and XIX of the Social Security Act to require skilled nursing facilities, nursing facilities, intermediate care facilities for the intellectually disabled, and inpatient rehabilitation facilities to permit essential caregivers access during any period in which regular visitation is restricted.
HELP Copays Act
Client: THE MICHAEL J. FOX FOUNDATION FOR PARKINSON'S RESEARCH · Firm: THE MICHAEL J. FOX FOUNDATION FOR PARKINSON'S RESEARCH
H.R.2365/S.1064 - National Plan to End Parkinson's Act: A bill to create an advisory council comprising members of federal agencies that support research, care, and services for Parkinson's disease, as well as patients, care partners, researchers, clinicians, and other non-federal experts, to ensure efficient and effective coordination among all federal entities responsible for managing, treating, and curing Parkinson's disease. General Parkinson's Disease Information: Covers symptoms, triggers, health coverage, health costs, social determinants of health, data collection, research, environmental risks, and health access for underserved communities, particularly through the CDC's National Neurological Conditions Surveillance System (NNCSS). H.R.2630/S.652/S.1339 - Safe Step Act: Requires group health plans to provide an exception process for any medication step therapy protocol to ensure that individuals living with Parkinson's disease can access treatments safely and efficiently. Establishing Parkinson's Disease ICD-10-CM Codes: Aims to assist in the coordination of care for Parkinson's patients who experience OFF episodes and to allow researchers to gather data to study disease progression. S.1544/H.R.1199 - Facilitating Innovative Nuclear Diagnostics Act of 2023: A bill to establish separate payment requirements for diagnostic radiopharmaceuticals, including DaTscans, which aid in confirming a Parkinson's diagnosis under the Medicare prospective payment system for hospital outpatient services. H.R.3432 - Telemental Health Care Access Act of 2023: Permanently removes Medicare's originating site requirements for mental health services furnished via telehealth. Parkinson's non-motor symptoms include mental health conditions, and many people with Parkinson's are Medicare beneficiaries who may face barriers due to in-person requirements. H.R.830/S.1375 - Help Ensure Lower Patient Copays Act: A bill requiring health insurance plans to apply certain payments, including third-party payments, financial assistance, and product vouchers, toward a plan's cost-sharing requirements. This helps Parkinson's patients afford medications for managing symptoms. The Medicare Part D Six Protected Classes Policy: Requires Part D plans to cover all drugs in six protected classes, including antidepressants and antipsychotics. For individuals with Parkinson's disease, these medications are crucial for managing non-motor symptoms such as depression and psychosis. H.R.4752/S.2379 - CHANGE Act of 2023: A bill to improve early screening, detection, and diagnosis of Alzheimer's and related dementias, including Parkinson's disease dementia, during Medicare wellness visits. H.R.4942/S.655 - Conrad State 30 and Physician Access Reauthorization Act: Reauthorizes the Conrad State 30 program and improves policies to address health care provider shortages, supporting neurological care for Parkinson's patients. H.R.8702/S.4532 - Improving Seniors Timely Access to Care Act: Establishes requirements regarding the use of prior authorization under Medicare Advantage plans. H.R.9233/S.- The HEALTHY Brains Act: Draft legislation to create a Centers of Excellence grant program within the National Institutes of Health to focus on the intersection between environmental risk factors and neurodegenerative diseases. H.R.8331/S. 4280 - Essential Caregivers Act of 2024: To amend titles XVIII and XIX of the Social Security Act to require skilled nursing facilities, nursing facilities, intermediate care facilities for the intellectually disabled, and inpatient rehabilitation facilities to permit essential caregivers access during any period in which regular visitation is restricted. General Outreach for Establishing an ""Office of Caregiver Health"": Supports the creation of an Office of Caregiver Health within the Department of Health and Human Services to address the needs of caregivers, particularly in relation to Parkinson's disease care.
HELP Copays Act
Client: THE MICHAEL J. FOX FOUNDATION FOR PARKINSON'S RESEARCH · Firm: THE MICHAEL J. FOX FOUNDATION FOR PARKINSON'S RESEARCH
Lobbying to improve prescription drug affordability and accessibility for people living with Parkinson's via Medicare Part D redesign and benefits, including expanding the low-income subsidy (LIS) program, capping out-of-pocket costs, implementing a smoothing mechanism, and streamlining utilization management processes. The Medicare Part D Six Protected Classes Policy: requires Part D plan to cover all drugs in six classes: immunosuppressants, antidepressants, antipsychotics, anticonvulsants, antiretrovirals, and antineoplastics. For people living with Parkinson's, most of whom are Medicare beneficiaries, it is essential to have access to wide range of treatment options for antidepressants and antipsychotics. Parkinson's causes non-motor symptoms, including depression and psychosis, and individuals often experience different side effects, reactions, and efficacy based on which medications they take. Partnership for Part D Access coalition congressional meetings and signed coalition letter to CMS in response to Medicare Prescription Payment Plan Part One Guidance in support of continued protection for the six protected classes policy. Signed Medicare Access for Prescription Rx (MAPRx) coalition comment letter in response to Medicare Prescription Payment Plan Part One Guidance. Signed Alliance for Aging Research coalition letter in response to Medicare Prescription Payment Plan Part One Guidance in support of proposed beneficiary protections and to provide feedback on implementation considerations for the Medicare Prescription Payment Plan program. H.R.2360/S.652/S.1339 - Safe Step Act: a bill to require group health plans to provide an exception process for any medication step therapy protocol to help ensure that people living with Parkinson's disease can safely and efficiently access treatments. Led a digital campaign to allow constituents to write their members of Congress in support of this legislation. Lobbying the Centers for Medicare and Medicaid Services to direct Durable Medical Equipment Medicare Administrative Contractors to provide additional clarification regarding the use of claim modifiers for DME therapies that require administration via an external infusion pump to expedite patient access once new Parkinson's therapies receive approvals from the Food and Drug Administration. Lobbying the Centers for Medicare and Medicaid Services to direct Durable Medical Equipment Medicare Administrative Contractors to provide additional clarification regarding the use of claim modifiers for DME therapies that require administration via an external infusion pump to expedite patient access once new Parkinson's therapies receive approvals from the Food and Drug Administration. H.R.2360/S.652/S.1339 - Safe Step Act: a bill to require group health plans to provide an exception process for any medication step therapy protocol to help ensure that people living with Parkinson's disease can safely and efficiently access treatments. Led an digital campaign to allow constituents to write their members of Congress in support of this legislation. H.R.8702/S.4532 - Improving Seniors Timely Access to Care Act: a bill to establish requirements with respect to the use of prior authorization under Medicare Advantage plans. H.R.830/S.1375 - Help Ensure Lower Patient Copays Act: a bill to require health insurance plans to apply certain payments made by, or on behalf of, a plan enrollee toward a plan's cost-sharing requirements. Specifically, plans must apply third-party payments, financial assistance, discounts, product vouchers, and other reductions in out-of-pocket expenses toward the requirements. Many Parkinson's patients rely on such third-party payments to afford medications to treat and manage their disease symptoms, and this legislation will ensure that all payments whether they come directly out of a pocket or with the help of copay assistance-counts toward out-of-pocket costs of patients. S.1544/H.R.1199 - Facilitating Innovative Nuclear Diagnostics Act of 2023: a bill to establish separate payment requirements for diagnostic radiopharmaceuticals, including DaTscans, which can aid in confirming a Parkinson's diagnosis, under the Medicare prospective payment system for hospital outpatient department services.
HELP Copays Act
Client: THE MICHAEL J. FOX FOUNDATION FOR PARKINSON'S RESEARCH · Firm: THE MICHAEL J. FOX FOUNDATION FOR PARKINSON'S RESEARCH
H.R.2365/S.1064 - National Plan to End Parkinson's Act: a bill to create an advisory council comprising members of federal agencies that support research, care, and services for Parkinsons, plus patients, care partners, researchers, clinicians, and other non-federal experts to ensure efficient and effective coordination among all federal entities with responsibility for managing, treating, and curing Parkinsons disease. General Parkinson's disease information about symptoms, triggers, health coverage, health costs, social determinants of health related to Parkinson's disease and data collection, research, environmental risks, and health access for underserved communities. Information related to prevalence particularly at CDC's National Neurological Conditions Surveillance System (NNCSS). H.R.2630/S.652/S.1339 - Safe Step Act: a bill to require group health plans to provide an exception process for any medication step therapy protocol to help ensure that people living with Parkinson's disease can safely and efficiently access treatments. Establishing Parkinson's disease ICD-10-CM codes to assist in the continuation and coordination of care for people living with Parkinson's who experience OFF episodes and to allow researchers to gather more data to study the progression of the disease. Reauthorization of CDCs National Neurological Conditions Surveillance System (NNCSS). S.1544/H.R.1199 - Facilitating Innovative Nuclear Diagnostics Act of 2023: a bill to establish separate payment requirements for diagnostic radiopharmaceuticals, including DaTscans, which can aid in confirming a Parkinson's diagnosis, under the Medicare prospective payment system for hospital outpatient department services. H.R.3432 - Telemental Health Care Access Act of 2023: a bill to permanently remove Medicare's originating site requirements for mental health services furnished via telehealth. Parkinson's non-motor symptoms encompass mental health conditions, including anxiety, depression, dementia, and other memory problems, and the majority of people living with Parkinson's in the United States are Medicare beneficiaries, many of whom will face undue burdens meeting the unnecessary in-person requirement for telemental health services after the delay of the requirement enforcement expires December 31, 2024. H.R.830/S.1375 - Help Ensure Lower Patient Copays Act: a bill to require health insurance plans to apply certain payments made by, or on behalf of, a plan enrollee toward a plan's cost-sharing requirements. Specifically, plans must apply third-party payments, financial assistance, discounts, product vouchers, and other reductions in out-of-pocket expenses toward the requirements. Many Parkinson's patients rely on such third-party payments to afford medications to treat and manage their disease symptoms, and this legislation will ensure that all payments whether they come directly out of a pocket or with the help of copay assistance-counts toward out-of-pocket costs of patients. The Medicare Part D Six Protected Classes Policy: requires Part D plan to cover all drugs in six classes: immunosuppressants, antidepressants, antipsychotics, anticonvulsants, antiretrovirals, and antineoplastics. For people living with Parkinson's, most of whom are Medicare beneficiaries, it is essential to have access to wide range of treatment options for antidepressants and antipsychotics. Parkinson's causes non-motor symptoms, including depression and psychosis, and individuals often experience different side effects, reactions, and efficacy based on which medications they take. H.R.4752/S.2379 - the Concentrating High-value Alzheimer's Needs to Get to an End (CHANGE) Act of 2023: a bill to better utilize the existing Welcome to Medicare initial exam and Medicare annual wellness visits to screen, detect, and diagnose Alzheimers and related dementias, including Parkinson's disease dementia, in their earliest stages. Signed Leaders Engaged on Alzheimer's Disease (LEAD) Coalition letter to members of Congress in support of this legislation. H.R.4942/S.655 - the Conrad State 30 and Physician Access Reauthorization Act: a bill to reauthorize the Conrad State 30 program for three years, make several targeted policy improvements, and permit the gradual expansion of the number of waivers granted to each state to address health care provider shortages. Signed American Academy of Neurology letter to member of Congress in support of this legislation. The Medicare Part D Six Protected Classes Policy: requires Part D plan to cover all drugs in six classes: immunosuppressants, antidepressants, antipsychotics, anticonvulsants, antiretrovirals, and antineoplastics. For people living with Parkinson's, most of whom are Medicare beneficiaries, it is essential to have access to wide range of treatment options for antidepressants and antipsychotics. Parkinson's causes non-motor symptoms, including depression and psychosis, and individuals often experience different side effects, reactions, and efficacy based on which medications they take. Partnership for Part D Access coalition congressional meetings and signed coalition letter to CMS in response to Medicare Prescription Payment Plan Part One Guidance in support of continued protection for the six protected classes policy. Signed Medicare Access for Prescription Rx (MAPRx) coalition comment letter in response to Medicare Prescription Payment Plan Part One Guidance. Signed Patient and Provider Advocates for Telehealth coalition comment letter in response to CMS CY 2024 Medicare Physician Fee Schedule (PFS) in support prioritizing the needs of patients by expanding policies that improved access to safe and timely health care via telehealth. Signed Alliance for Aging Research coalition letter in response to Medicare Prescription Payment Plan Part One Guidance in support of proposed beneficiary protections and to provide feedback on implementation considerations for the Medicare Prescription Payment Plan program. H.R.8702/S.4532 - Improving Seniors Timely Access to Care Act: a bill to establish requirements with respect to the use of prior authorization under Medicare Advantage plans. H.R./S.- The HEALTHY Brains Act- draft legislation to create a Centers of Excellence grant program within the National Institute of Health to focus on the intersection between environmental risk factors and neurodegenerative disease. General outreach and support for the establishment of an "Office of Caregiver Health" within the Office of the Secretary at the Department of Health and Human Services.
HELP Copays Act
Client: THE MICHAEL J. FOX FOUNDATION FOR PARKINSON'S RESEARCH · Firm: THE MICHAEL J. FOX FOUNDATION FOR PARKINSON'S RESEARCH
H.R.2365/S.1064 - National Plan to End Parkinson's Act: a bill to create an advisory council comprising members of federal agencies that support research, care, and services for Parkinsons, plus patients, care partners, researchers, clinicians, and other non-federal experts to ensure efficient and effective coordination among all federal entities with responsibility for managing, treating, and curing Parkinsons disease. General Parkinson's disease information about symptoms, triggers, health coverage, health costs, social determinants of health related to Parkinson's disease and data collection, research, environmental risks, and health access for underserved communities. Information related to prevalence particularly at CDC's National Neurological Conditions Surveillance System (NNCSS). H.R.2630/S.652/S.1339 - Safe Step Act: a bill to require group health plans to provide an exception process for any medication step therapy protocol to help ensure that people living with Parkinson's disease can safely and efficiently access treatments. Establishing Parkinson's disease ICD-10-CM codes to assist in the continuation and coordination of care for people living with Parkinson's who experience OFF episodes and to allow researchers to gather more data to study the progression of the disease. Reauthorization of CDCs National Neurological Conditions Surveillance System (NNCSS). S.1544/H.R.1199 - Facilitating Innovative Nuclear Diagnostics Act of 2023: a bill to establish separate payment requirements for diagnostic radiopharmaceuticals, including DaTscans, which can aid in confirming a Parkinson's diagnosis, under the Medicare prospective payment system for hospital outpatient department services. H.R.3432 - Telemental Health Care Access Act of 2023: a bill to permanently remove Medicare's originating site requirements for mental health services furnished via telehealth. Parkinson's non-motor symptoms encompass mental health conditions, including anxiety, depression, dementia, and other memory problems, and the majority of people living with Parkinson's in the United States are Medicare beneficiaries, many of whom will face undue burdens meeting the unnecessary in-person requirement for telemental health services after the delay of the requirement enforcement expires December 31, 2024. H.R.830/S.1375 - Help Ensure Lower Patient Copays Act: a bill to require health insurance plans to apply certain payments made by, or on behalf of, a plan enrollee toward a plan's cost-sharing requirements. Specifically, plans must apply third-party payments, financial assistance, discounts, product vouchers, and other reductions in out-of-pocket expenses toward the requirements. Many Parkinson's patients rely on such third-party payments to afford medications to treat and manage their disease symptoms, and this legislation will ensure that all payments whether they come directly out of a pocket or with the help of copay assistance-counts toward out-of-pocket costs of patients. The Medicare Part D Six Protected Classes Policy: requires Part D plan to cover all drugs in six classes: immunosuppressants, antidepressants, antipsychotics, anticonvulsants, antiretrovirals, and antineoplastics. For people living with Parkinson's, most of whom are Medicare beneficiaries, it is essential to have access to wide range of treatment options for antidepressants and antipsychotics. Parkinson's causes non-motor symptoms, including depression and psychosis, and individuals often experience different side effects, reactions, and efficacy based on which medications they take. H.R.4752/S.2379 - the Concentrating High-value Alzheimer's Needs to Get to an End (CHANGE) Act of 2023: a bill to better utilize the existing Welcome to Medicare initial exam and Medicare annual wellness visits to screen, detect, and diagnose Alzheimers and related dementias, including Parkinson's disease dementia, in their earliest stages. Signed Leaders Engaged on Alzheimer's Disease (LEAD) Coalition letter to members of Congress in support of this legislation. H.R.4942/S.655 - the Conrad State 30 and Physician Access Reauthorization Act: a bill to reauthorize the Conrad State 30 program for three years, make several targeted policy improvements, and permit the gradual expansion of the number of waivers granted to each state to address health care provider shortages. Signed American Academy of Neurology letter to member of Congress in support of this legislation. The Medicare Part D Six Protected Classes Policy: requires Part D plan to cover all drugs in six classes: immunosuppressants, antidepressants, antipsychotics, anticonvulsants, antiretrovirals, and antineoplastics. For people living with Parkinson's, most of whom are Medicare beneficiaries, it is essential to have access to wide range of treatment options for antidepressants and antipsychotics. Parkinson's causes non-motor symptoms, including depression and psychosis, and individuals often experience different side effects, reactions, and efficacy based on which medications they take. Partnership for Part D Access coalition congressional meetings and signed coalition letter to CMS in response to Medicare Prescription Payment Plan Part One Guidance in support of continued protection for the six protected classes policy. Signed Medicare Access for Prescription Rx (MAPRx) coalition comment letter in response to Medicare Prescription Payment Plan Part One Guidance. Signed Patient and Provider Advocates for Telehealth coalition comment letter in response to CMS CY 2024 Medicare Physician Fee Schedule (PFS) in support prioritizing the needs of patients by expanding policies that improved access to safe and timely health care via telehealth. Signed Alliance for Aging Research coalition letter in response to Medicare Prescription Payment Plan Part One Guidance in support of proposed beneficiary protections and to provide feedback on implementation considerations for the Medicare Prescription Payment Plan program.
HELP Copays Act
Client: THE MICHAEL J. FOX FOUNDATION FOR PARKINSON'S RESEARCH · Firm: THE MICHAEL J. FOX FOUNDATION FOR PARKINSON'S RESEARCH
Lobbying to Improve Prescription Drug Affordability and Accessibility: Advocacy for people living with Parkinson's via Medicare Part D redesign and benefits, including expanding the low-income subsidy (LIS) program, capping out-of-pocket costs, implementing a smoothing mechanism, and streamlining utilization management processes. Medicare Part D Six Protected Classes Policy: Requires Part D plans to cover all drugs in six classes: immunosuppressants, antidepressants, antipsychotics, anticonvulsants, antiretrovirals, and antineoplastics. Access to a wide range of treatment options for antidepressants and antipsychotics is essential for Parkinson's patients due to non-motor symptoms such as depression and psychosis. Advocacy includes coalition meetings and letters to CMS in response to Medicare Prescription Payment Plan Part One Guidance to support continued protection for the six protected classes. H.R.2360/S.652/S.1339 - Safe Step Act: A bill requiring group health plans to provide an exception process for any medication step therapy protocol to ensure that Parkinson's patients can access treatments safely and efficiently. Led a digital campaign to allow constituents to write to members of Congress in support of the legislation. H.R.830/S.1375 - Help Ensure Lower Patient Copays Act: This bill requires health insurance plans to apply third-party payments, financial assistance, discounts, and other reductions in out-of-pocket expenses toward a plan's cost-sharing requirements. Many Parkinson's patients rely on such payments to afford medications, and this legislation ensures they count toward out-of-pocket costs. S.1544/H.R.1199 - Facilitating Innovative Nuclear Diagnostics Act of 2023: A bill to establish separate payment requirements for diagnostic radiopharmaceuticals, including DaTscans, under the Medicare prospective payment system for hospital outpatient department services. This will help confirm Parkinson's diagnoses more efficiently. CMS-1809-P (2025 Medicare Outpatient Prospective Payment System Proposed Rule): Supported CMS's proposal to separate payment for certain diagnostic radiopharmaceuticals, including those used to diagnose Parkinson's disease and atypical parkinsonisms, from the procedure payment and reimburse them separately. H.R.8702/S.4532 - Improving Seniors Timely Access to Care Act: A bill to establish requirements regarding the use of prior authorization under Medicare Advantage plans. Lobbying CMS: Advocacy efforts to direct Durable Medical Equipment Medicare Administrative Contractors to provide clarification on the use of claim modifiers for DME therapies administered via an external infusion pump to expedite patient access to new Parkinson's therapies once they are approved by the FDA.
HELP Copays Act
Client: THE MICHAEL J. FOX FOUNDATION FOR PARKINSON'S RESEARCH · Firm: THE MICHAEL J. FOX FOUNDATION FOR PARKINSON'S RESEARCH
H.R.2365/S.1064 - National Plan to End Parkinson's Act: A bill to create an advisory council comprising members of federal agencies that support research, care, and services for Parkinson's disease, as well as patients, care partners, researchers, clinicians, and other non-federal experts, to ensure efficient and effective coordination among all federal entities responsible for managing, treating, and curing Parkinson's disease. General Parkinson's Disease Information: Covers symptoms, triggers, health coverage, health costs, social determinants of health, data collection, research, environmental risks, and health access for underserved communities, particularly through the CDC's National Neurological Conditions Surveillance System (NNCSS). H.R.2630/S.652/S.1339 - Safe Step Act: Requires group health plans to provide an exception process for any medication step therapy protocol to ensure that individuals living with Parkinson's disease can access treatments safely and efficiently. Establishing Parkinson's Disease ICD-10-CM Codes: Aims to assist in the coordination of care for Parkinson's patients who experience OFF episodes and to allow researchers to gather data to study disease progression. S.1544/H.R.1199 - Facilitating Innovative Nuclear Diagnostics Act of 2023: A bill to establish separate payment requirements for diagnostic radiopharmaceuticals, including DaTscans, which aid in confirming a Parkinson's diagnosis under the Medicare prospective payment system for hospital outpatient services. H.R.3432 - Telemental Health Care Access Act of 2023: Permanently removes Medicare's originating site requirements for mental health services furnished via telehealth. Parkinson's non-motor symptoms include mental health conditions, and many people with Parkinson's are Medicare beneficiaries who may face barriers due to in-person requirements. H.R.830/S.1375 - Help Ensure Lower Patient Copays Act: A bill requiring health insurance plans to apply certain payments, including third-party payments, financial assistance, and product vouchers, toward a plan's cost-sharing requirements. This helps Parkinson's patients afford medications for managing symptoms. The Medicare Part D Six Protected Classes Policy: Requires Part D plans to cover all drugs in six protected classes, including antidepressants and antipsychotics. For individuals with Parkinson's disease, these medications are crucial for managing non-motor symptoms such as depression and psychosis. H.R.4752/S.2379 - CHANGE Act of 2023: A bill to improve early screening, detection, and diagnosis of Alzheimer's and related dementias, including Parkinson's disease dementia, during Medicare wellness visits. H.R.4942/S.655 - Conrad State 30 and Physician Access Reauthorization Act: Reauthorizes the Conrad State 30 program and improves policies to address health care provider shortages, supporting neurological care for Parkinson's patients. H.R.8702/S.4532 - Improving Seniors Timely Access to Care Act: Establishes requirements regarding the use of prior authorization under Medicare Advantage plans. H.R.9233/S.- The HEALTHY Brains Act: Draft legislation to create a Centers of Excellence grant program within the National Institutes of Health to focus on the intersection between environmental risk factors and neurodegenerative diseases. General Outreach for Establishing an ""Office of Caregiver Health"": Supports the creation of an Office of Caregiver Health within the Department of Health and Human Services to address the needs of caregivers, particularly in relation to Parkinson's disease care.
HELP Copays Act
Client: THE MICHAEL J. FOX FOUNDATION FOR PARKINSON'S RESEARCH · Firm: THE MICHAEL J. FOX FOUNDATION FOR PARKINSON'S RESEARCH
Lobbying to Improve Prescription Drug Affordability and Accessibility: Advocacy for people living with Parkinson's via Medicare Part D redesign and benefits, including expanding the low-income subsidy (LIS) program, capping out-of-pocket costs, implementing a smoothing mechanism, and streamlining utilization management processes. Medicare Part D Six Protected Classes Policy: Requires Part D plans to cover all drugs in six classes: immunosuppressants, antidepressants, antipsychotics, anticonvulsants, antiretrovirals, and antineoplastics. Access to a wide range of treatment options for antidepressants and antipsychotics is essential for Parkinson's patients due to non-motor symptoms such as depression and psychosis. Advocacy includes coalition meetings and letters to CMS in response to Medicare Prescription Payment Plan Part One Guidance to support continued protection for the six protected classes. H.R.2360/S.652/S.1339 - Safe Step Act: A bill requiring group health plans to provide an exception process for any medication step therapy protocol to ensure that Parkinson's patients can access treatments safely and efficiently. Led a digital campaign to allow constituents to write to members of Congress in support of the legislation. H.R.830/S.1375 - Help Ensure Lower Patient Copays Act: This bill requires health insurance plans to apply third-party payments, financial assistance, discounts, and other reductions in out-of-pocket expenses toward a plan's cost-sharing requirements. Many Parkinson's patients rely on such payments to afford medications, and this legislation ensures they count toward out-of-pocket costs. S.1544/H.R.1199 - Facilitating Innovative Nuclear Diagnostics Act of 2023: A bill to establish separate payment requirements for diagnostic radiopharmaceuticals, including DaTscans, under the Medicare prospective payment system for hospital outpatient department services. This will help confirm Parkinson's diagnoses more efficiently. CMS-1809-P (2025 Medicare Outpatient Prospective Payment System Proposed Rule): Supported CMS's proposal to separate payment for certain diagnostic radiopharmaceuticals, including those used to diagnose Parkinson's disease and atypical parkinsonisms, from the procedure payment and reimburse them separately. H.R.8702/S.4532 - Improving Seniors Timely Access to Care Act: A bill to establish requirements regarding the use of prior authorization under Medicare Advantage plans. Lobbying CMS: Advocacy efforts to direct Durable Medical Equipment Medicare Administrative Contractors to provide clarification on the use of claim modifiers for DME therapies administered via an external infusion pump to expedite patient access to new Parkinson's therapies once they are approved by the FDA.
Essential Caregivers Act of 2024
Client: THE MICHAEL J. FOX FOUNDATION FOR PARKINSON'S RESEARCH · Firm: THE MICHAEL J. FOX FOUNDATION FOR PARKINSON'S RESEARCH
H.R.2365/S.1064 - National Plan to End Parkinson's Act: A bill to create an advisory council comprising members of federal agencies that support research, care, and services for Parkinson's disease, as well as patients, care partners, researchers, clinicians, and other non-federal experts, to ensure efficient and effective coordination among all federal entities responsible for managing, treating, and curing Parkinson's disease. General Parkinson's Disease Information: Covers symptoms, triggers, health coverage, health costs, social determinants of health, data collection, research, environmental risks, and health access for underserved communities, particularly through the CDC's National Neurological Conditions Surveillance System (NNCSS). H.R.2630/S.652/S.1339 - Safe Step Act: Requires group health plans to provide an exception process for any medication step therapy protocol to ensure that individuals living with Parkinson's disease can access treatments safely and efficiently. Establishing Parkinson's Disease ICD-10-CM Codes: Aims to assist in the coordination of care for Parkinson's patients who experience OFF episodes and to allow researchers to gather data to study disease progression. S.1544/H.R.1199 - Facilitating Innovative Nuclear Diagnostics Act of 2023: A bill to establish separate payment requirements for diagnostic radiopharmaceuticals, including DaTscans, which aid in confirming a Parkinson's diagnosis under the Medicare prospective payment system for hospital outpatient services. H.R.3432 - Telemental Health Care Access Act of 2023: Permanently removes Medicare's originating site requirements for mental health services furnished via telehealth. Parkinson's non-motor symptoms include mental health conditions, and many people with Parkinson's are Medicare beneficiaries who may face barriers due to in-person requirements. H.R.830/S.1375 - Help Ensure Lower Patient Copays Act: A bill requiring health insurance plans to apply certain payments, including third-party payments, financial assistance, and product vouchers, toward a plan's cost-sharing requirements. This helps Parkinson's patients afford medications for managing symptoms. The Medicare Part D Six Protected Classes Policy: Requires Part D plans to cover all drugs in six protected classes, including antidepressants and antipsychotics. For individuals with Parkinson's disease, these medications are crucial for managing non-motor symptoms such as depression and psychosis. H.R.4752/S.2379 - CHANGE Act of 2023: A bill to improve early screening, detection, and diagnosis of Alzheimer's and related dementias, including Parkinson's disease dementia, during Medicare wellness visits. H.R.4942/S.655 - Conrad State 30 and Physician Access Reauthorization Act: Reauthorizes the Conrad State 30 program and improves policies to address health care provider shortages, supporting neurological care for Parkinson's patients. H.R.8702/S.4532 - Improving Seniors Timely Access to Care Act: Establishes requirements regarding the use of prior authorization under Medicare Advantage plans. H.R.9233/S.- The HEALTHY Brains Act: Draft legislation to create a Centers of Excellence grant program within the National Institutes of Health to focus on the intersection between environmental risk factors and neurodegenerative diseases. H.R.8331/S. 4280 - Essential Caregivers Act of 2024: To amend titles XVIII and XIX of the Social Security Act to require skilled nursing facilities, nursing facilities, intermediate care facilities for the intellectually disabled, and inpatient rehabilitation facilities to permit essential caregivers access during any period in which regular visitation is restricted. General Outreach for Establishing an ""Office of Caregiver Health"": Supports the creation of an Office of Caregiver Health within the Department of Health and Human Services to address the needs of caregivers, particularly in relation to Parkinson's disease care.
Essential Caregivers Act of 2024
Client: THE MICHAEL J. FOX FOUNDATION FOR PARKINSON'S RESEARCH · Firm: THE MICHAEL J. FOX FOUNDATION FOR PARKINSON'S RESEARCH
Lobbying to Increase Prescription Drug Affordability and Accessibility: Advocacy for Medicare Part D redesign and benefits for people living with Parkinson's, including expanding the low-income subsidy (LIS) program, capping out-of-pocket costs, implementing a smoothing mechanism, and streamlining utilization management processes. The Medicare Part D Six Protected Classes Policy: Requires Part D plans to cover all drugs in six classes: immunosuppressants, antidepressants, antipsychotics, anticonvulsants, antiretrovirals, and antineoplastics. For people living with Parkinson's, most of whom are Medicare beneficiaries, it is essential to have access to a wide range of treatment options for antidepressants and antipsychotics, which are crucial for managing non-motor symptoms like depression and psychosis. Signed Coalition Letters: - Medicare Access for Prescription Rx (MAPRx): Comment letter in response to Medicare Prescription Payment Plan Part One Guidance. - Patient and Provider Advocates for Telehealth: Comment letter in response to CMS CY 2024 Medicare Physician Fee Schedule (PFS) supporting expanded access to telehealth. - Alliance for Aging Research: Coalition letter in response to Medicare Prescription Payment Plan Part One Guidance supporting proposed beneficiary protections. H.R.4752/S.2379 - CHANGE Act of 2023: A bill to better utilize existing Medicare wellness visits for early screening, detection, and diagnosis of Alzheimer's and related dementias, including Parkinson's disease dementia. S.1544/H.R.1199 - Facilitating Innovative Nuclear Diagnostics Act of 2023: A bill to establish separate payment requirements for diagnostic radiopharmaceuticals, including DaTscans used to confirm Parkinson's diagnoses, under the Medicare outpatient prospective payment system. CMS-1809-P (2025 Medicare OPPS Proposed Rule): Comment supporting CMS's proposal to separately reimburse certain diagnostic radiopharmaceuticals used in diagnosing Parkinson's disease and atypical parkinsonisms. H.R.8702/S.4532 - Improving Seniors' Timely Access to Care Act: Establishes requirements for the use of prior authorization under Medicare Advantage plans to ensure timely access to care for seniors, including those with Parkinson's. S.3109/H.R.8018 - Alleviating Barriers for Caregivers (ABC) Act: Requires the Centers for Medicare & Medicaid Services (CMS) and Social Security to simplify processes and communications for family caregivers to assist individuals in accessing and utilizing benefits. S.3766/H.R.7274 - Connecting Caregivers to Medicare Act: Amends the Social Security Act to provide outreach and education to Medicare beneficiaries and simplify access to information for family caregivers through 1-800-MEDICARE. Advocacy for Durable Medical Equipment (DME) Access: Lobbying CMS to direct Medicare contractors to clarify claims procedures for DME therapies requiring administration via external infusion pumps, ensuring quick access to new Parkinson's therapies after FDA approval. H.R.8331/S. 4280 - Essential Caregivers Act of 2024: To amend titles XVIII and XIX of the Social Security Act to require skilled nursing facilities, nursing facilities, intermediate care facilities for the intellectually disabled, and inpatient rehabilitation facilities to permit essential caregivers access during any period in which regular visitation is restricted.
Military Construction, Veterans Affairs, and Related Agencies Appropriations Act, 2025
Client: THE MICHAEL J. FOX FOUNDATION FOR PARKINSON'S RESEARCH · Firm: THE MICHAEL J. FOX FOUNDATION FOR PARKINSON'S RESEARCH
FY 2025 Appropriations bills including funding requests for Parkinson's research within: H.R.8774/ S.4921: The Department of Defense within the FY 2025 Defense Appropriation bill. Funding for the Parkinson's Research Program (PRP) under the Department of Defense's Congressionally Directed Medical Research Programs (CDMRP). H.R.9029/S.4942: The National Institute of Health and Centers for Disease Control and Prevention within the FY 2025 Labor, Health and Human Services, Education, and Related Agencies Appropriation bill. Possible funding to implement the National Plan to End Parkinson's Act (HR 2365/ PL 118-66) within LHHS appropriations. H.R.9027/ S.4690: The Food and Drug Administration within the FY 2025 Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriation bill. H.R.8580/ S.4677: The Department of Veterans Affairs within the FY 2025 Military Construction, Veterans Affairs, and Related Agencies Appropriation bill. Support funding for Neurology Centers of Excellence and medical care and research through Veterans Health Administration, including the Parkinson's Disease Research, Education and Clinical Centers. H.R.9029/S.4942: General advocacy in support of robust non-defense discretionary investments in Labor, Health and Human Services, Education and Related Agencies appropriations bill for FY 2025. Funding for discretionary, non-defense priorities including overall investment in the National Institute of Health, ARPA-H, and Centers for Disease Control and Prevention within the FY 2025 Labor, Health and Human Services, Education, and Related Agencies Appropriation bills. Funding for the Parkinson's Research Program (PRP) under the Department of Defense's Congressionally Directed Medical Research Programs (CDMRP). Increased funding for NIEHS (no bill introduced). H.R.9233: The HEALTHY BRAINS Act - developing support for implementation funding for centers of excellence within NIH.
Military Construction, Veterans Affairs, and Related Agencies Appropriations Act, 2025
Client: THE MICHAEL J. FOX FOUNDATION FOR PARKINSON'S RESEARCH · Firm: THE MICHAEL J. FOX FOUNDATION FOR PARKINSON'S RESEARCH
FY 2025 Appropriations bills including funding requests for Parkinson's research within: H.R.8774/ S.4921: The Department of Defense within the FY 2025 Defense Appropriation bill. Funding for the Parkinson's Research Program (PRP) under the Department of Defense's Congressionally Directed Medical Research Programs (CDMRP). H.R.9029/S.4942: The National Institute of Health and Centers for Disease Control and Prevention within the FY 2025 Labor, Health and Human Services, Education, and Related Agencies Appropriation bill. Possible funding to implement the National Plan to End Parkinson's Act (HR 2365/ PL 118-66) within LHHS appropriations. H.R.9027/ S.4690: The Food and Drug Administration within the FY 2025 Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriation bill. H.R.8580/ S.4677: The Department of Veterans Affairs within the FY 2025 Military Construction, Veterans Affairs, and Related Agencies Appropriation bill. Support funding for Neurology Centers of Excellence and medical care and research through Veterans Health Administration, including the Parkinson's Disease Research, Education and Clinical Centers. H.R.9029/S.4942: General advocacy in support of robust non-defense discretionary investments in Labor, Health and Human Services, Education and Related Agencies appropriations bill for FY 2025. Funding for discretionary, non-defense priorities including overall investment in the National Institute of Health, ARPA-H, and Centers for Disease Control and Prevention within the FY 2025 Labor, Health and Human Services, Education, and Related Agencies Appropriation bills. Funding for the Parkinson's Research Program (PRP) under the Department of Defense's Congressionally Directed Medical Research Programs (CDMRP). Increased funding for NIEHS (no bill introduced).
Military Construction, Veterans Affairs, and Related Agencies Appropriations Act, 2025
Client: THE MICHAEL J. FOX FOUNDATION FOR PARKINSON'S RESEARCH · Firm: THE MICHAEL J. FOX FOUNDATION FOR PARKINSON'S RESEARCH
FY25 Military Construction, Veterans Affairs and Related Agencies Appropriations bill to support increased funding for the VA's Parkinson's Disease Research, Education and Clinical Center. General education regarding the importance of the Department of Defense medical research programs for military service personnel and Veterans living with Parkinson's disease. Inclusion of Parkinson's disease and PD-related diseases as presumptive conditions when military Veterans are exposed to associated toxins. FY24 and FY25 Defense Appropriations bills to support increased funding for DOD Congressionally Directed Medical Research Programs Parkinson's Research Program. H.R.542/S.141 -The Elizabeth Dole Home Care Act- increases access to home care and caregiver programs provided by the Department of Veterans Affairs (VA) and seeks to address VA home health workforce shortages. H.R. 8580 / Senate bill not filed - FY25 Military Construction, Veterans Affairs and Related Agencies Appropriations bill to support increased funding for the VA's Parkinson's Disease Research, Education and Clinical Center as part of Neurology Centers of Excellence. H.R. 8774/ Senate bill not yet filed - FY25 Defense Appropriations bills to support increased funding for DOD Congressionally Directed Medical Research Programs Parkinson's Research Program. General education regarding the importance of the Department of Defense medical research programs for military service personnel and Veterans living with Parkinson's disease. Inclusion of Parkinson's disease and PD-related diseases as presumptive conditions when military Veterans are exposed to associated toxins.
Military Construction, Veterans Affairs, and Related Agencies Appropriations Act, 2025
Client: THE MICHAEL J. FOX FOUNDATION FOR PARKINSON'S RESEARCH · Firm: THE MICHAEL J. FOX FOUNDATION FOR PARKINSON'S RESEARCH
General education on the importance of the Department of Defense medical research programs for military service personnel and Veterans living with Parkinson's disease. H.R.8774/ S.4921: FY25 Defense Appropriations bills to support increased funding for DOD Congressionally Directed Medical Research Programs Parkinson's Research Program. H.R.542/S.141 - The Elizabeth Dole Home Care Act: Increases access to home care and caregiver programs provided by the Department of Veterans Affairs (VA) and seeks to address VA home health workforce shortages. Inclusion of Parkinson's disease and PD-related diseases as presumptive conditions when military Veterans are exposed to associated toxins. H.R.8580 / S.4677 - FY25 Military Construction, Veterans Affairs and Related Agencies Appropriations bill: Supports increased funding for the VA's Parkinson's Disease Research, Education and Clinical Center as part of Neurology Centers of Excellence. General education regarding the importance of the Department of Defense medical research programs for military service personnel and Veterans living with Parkinson's disease.
Military Construction, Veterans Affairs, and Related Agencies Appropriations Act, 2025
Client: THE MICHAEL J. FOX FOUNDATION FOR PARKINSON'S RESEARCH · Firm: THE MICHAEL J. FOX FOUNDATION FOR PARKINSON'S RESEARCH
General education on the importance of the Department of Defense medical research programs for military service personnel and Veterans living with Parkinson's disease. H.R.8774/ S.4921: FY25 Defense Appropriations bills to support increased funding for DOD Congressionally Directed Medical Research Programs Parkinson's Research Program. H.R.542/S.141 - The Elizabeth Dole Home Care Act: Increases access to home care and caregiver programs provided by the Department of Veterans Affairs (VA) and seeks to address VA home health workforce shortages. Inclusion of Parkinson's disease and PD-related diseases as presumptive conditions when military Veterans are exposed to associated toxins. H.R.8580 / S.4677 - FY25 Military Construction, Veterans Affairs and Related Agencies Appropriations bill: Supports increased funding for the VA's Parkinson's Disease Research, Education and Clinical Center as part of Neurology Centers of Excellence. General education regarding the importance of the Department of Defense medical research programs for military service personnel and Veterans living with Parkinson's disease.
Improving Seniors’ Timely Access to Care Act of 2024
Client: THE MICHAEL J. FOX FOUNDATION FOR PARKINSON'S RESEARCH · Firm: THE MICHAEL J. FOX FOUNDATION FOR PARKINSON'S RESEARCH
Lobbying to Improve Prescription Drug Affordability and Accessibility: Advocacy for people living with Parkinson's via Medicare Part D redesign and benefits, including expanding the low-income subsidy (LIS) program, capping out-of-pocket costs, implementing a smoothing mechanism, and streamlining utilization management processes. Medicare Part D Six Protected Classes Policy: Requires Part D plans to cover all drugs in six classes: immunosuppressants, antidepressants, antipsychotics, anticonvulsants, antiretrovirals, and antineoplastics. Access to a wide range of treatment options for antidepressants and antipsychotics is essential for Parkinson's patients due to non-motor symptoms such as depression and psychosis. Advocacy includes coalition meetings and letters to CMS in response to Medicare Prescription Payment Plan Part One Guidance to support continued protection for the six protected classes. H.R.2360/S.652/S.1339 - Safe Step Act: A bill requiring group health plans to provide an exception process for any medication step therapy protocol to ensure that Parkinson's patients can access treatments safely and efficiently. Led a digital campaign to allow constituents to write to members of Congress in support of the legislation. H.R.830/S.1375 - Help Ensure Lower Patient Copays Act: This bill requires health insurance plans to apply third-party payments, financial assistance, discounts, and other reductions in out-of-pocket expenses toward a plan's cost-sharing requirements. Many Parkinson's patients rely on such payments to afford medications, and this legislation ensures they count toward out-of-pocket costs. S.1544/H.R.1199 - Facilitating Innovative Nuclear Diagnostics Act of 2023: A bill to establish separate payment requirements for diagnostic radiopharmaceuticals, including DaTscans, under the Medicare prospective payment system for hospital outpatient department services. This will help confirm Parkinson's diagnoses more efficiently. CMS-1809-P (2025 Medicare Outpatient Prospective Payment System Proposed Rule): Supported CMS's proposal to separate payment for certain diagnostic radiopharmaceuticals, including those used to diagnose Parkinson's disease and atypical parkinsonisms, from the procedure payment and reimburse them separately. H.R.8702/S.4532 - Improving Seniors Timely Access to Care Act: A bill to establish requirements regarding the use of prior authorization under Medicare Advantage plans. Lobbying CMS: Advocacy efforts to direct Durable Medical Equipment Medicare Administrative Contractors to provide clarification on the use of claim modifiers for DME therapies administered via an external infusion pump to expedite patient access to new Parkinson's therapies once they are approved by the FDA.
Improving Seniors’ Timely Access to Care Act of 2024
Client: THE MICHAEL J. FOX FOUNDATION FOR PARKINSON'S RESEARCH · Firm: THE MICHAEL J. FOX FOUNDATION FOR PARKINSON'S RESEARCH
H.R.2365/S.1064 - National Plan to End Parkinson's Act: A bill to create an advisory council comprising members of federal agencies that support research, care, and services for Parkinson's disease, as well as patients, care partners, researchers, clinicians, and other non-federal experts, to ensure efficient and effective coordination among all federal entities responsible for managing, treating, and curing Parkinson's disease. General Parkinson's Disease Information: Covers symptoms, triggers, health coverage, health costs, social determinants of health, data collection, research, environmental risks, and health access for underserved communities, particularly through the CDC's National Neurological Conditions Surveillance System (NNCSS). H.R.2630/S.652/S.1339 - Safe Step Act: Requires group health plans to provide an exception process for any medication step therapy protocol to ensure that individuals living with Parkinson's disease can access treatments safely and efficiently. Establishing Parkinson's Disease ICD-10-CM Codes: Aims to assist in the coordination of care for Parkinson's patients who experience OFF episodes and to allow researchers to gather data to study disease progression. S.1544/H.R.1199 - Facilitating Innovative Nuclear Diagnostics Act of 2023: A bill to establish separate payment requirements for diagnostic radiopharmaceuticals, including DaTscans, which aid in confirming a Parkinson's diagnosis under the Medicare prospective payment system for hospital outpatient services. H.R.3432 - Telemental Health Care Access Act of 2023: Permanently removes Medicare's originating site requirements for mental health services furnished via telehealth. Parkinson's non-motor symptoms include mental health conditions, and many people with Parkinson's are Medicare beneficiaries who may face barriers due to in-person requirements. H.R.830/S.1375 - Help Ensure Lower Patient Copays Act: A bill requiring health insurance plans to apply certain payments, including third-party payments, financial assistance, and product vouchers, toward a plan's cost-sharing requirements. This helps Parkinson's patients afford medications for managing symptoms. The Medicare Part D Six Protected Classes Policy: Requires Part D plans to cover all drugs in six protected classes, including antidepressants and antipsychotics. For individuals with Parkinson's disease, these medications are crucial for managing non-motor symptoms such as depression and psychosis. H.R.4752/S.2379 - CHANGE Act of 2023: A bill to improve early screening, detection, and diagnosis of Alzheimer's and related dementias, including Parkinson's disease dementia, during Medicare wellness visits. H.R.4942/S.655 - Conrad State 30 and Physician Access Reauthorization Act: Reauthorizes the Conrad State 30 program and improves policies to address health care provider shortages, supporting neurological care for Parkinson's patients. H.R.8702/S.4532 - Improving Seniors Timely Access to Care Act: Establishes requirements regarding the use of prior authorization under Medicare Advantage plans. H.R.9233/S.- The HEALTHY Brains Act: Draft legislation to create a Centers of Excellence grant program within the National Institutes of Health to focus on the intersection between environmental risk factors and neurodegenerative diseases. General Outreach for Establishing an ""Office of Caregiver Health"": Supports the creation of an Office of Caregiver Health within the Department of Health and Human Services to address the needs of caregivers, particularly in relation to Parkinson's disease care.
Improving Seniors’ Timely Access to Care Act of 2024
Client: THE MICHAEL J. FOX FOUNDATION FOR PARKINSON'S RESEARCH · Firm: THE MICHAEL J. FOX FOUNDATION FOR PARKINSON'S RESEARCH
H.R.2365/S.1064 - National Plan to End Parkinson's Act: a bill to create an advisory council comprising members of federal agencies that support research, care, and services for Parkinsons, plus patients, care partners, researchers, clinicians, and other non-federal experts to ensure efficient and effective coordination among all federal entities with responsibility for managing, treating, and curing Parkinsons disease. General Parkinson's disease information about symptoms, triggers, health coverage, health costs, social determinants of health related to Parkinson's disease and data collection, research, environmental risks, and health access for underserved communities. Information related to prevalence particularly at CDC's National Neurological Conditions Surveillance System (NNCSS). H.R.2630/S.652/S.1339 - Safe Step Act: a bill to require group health plans to provide an exception process for any medication step therapy protocol to help ensure that people living with Parkinson's disease can safely and efficiently access treatments. Establishing Parkinson's disease ICD-10-CM codes to assist in the continuation and coordination of care for people living with Parkinson's who experience OFF episodes and to allow researchers to gather more data to study the progression of the disease. Reauthorization of CDCs National Neurological Conditions Surveillance System (NNCSS). S.1544/H.R.1199 - Facilitating Innovative Nuclear Diagnostics Act of 2023: a bill to establish separate payment requirements for diagnostic radiopharmaceuticals, including DaTscans, which can aid in confirming a Parkinson's diagnosis, under the Medicare prospective payment system for hospital outpatient department services. H.R.3432 - Telemental Health Care Access Act of 2023: a bill to permanently remove Medicare's originating site requirements for mental health services furnished via telehealth. Parkinson's non-motor symptoms encompass mental health conditions, including anxiety, depression, dementia, and other memory problems, and the majority of people living with Parkinson's in the United States are Medicare beneficiaries, many of whom will face undue burdens meeting the unnecessary in-person requirement for telemental health services after the delay of the requirement enforcement expires December 31, 2024. H.R.830/S.1375 - Help Ensure Lower Patient Copays Act: a bill to require health insurance plans to apply certain payments made by, or on behalf of, a plan enrollee toward a plan's cost-sharing requirements. Specifically, plans must apply third-party payments, financial assistance, discounts, product vouchers, and other reductions in out-of-pocket expenses toward the requirements. Many Parkinson's patients rely on such third-party payments to afford medications to treat and manage their disease symptoms, and this legislation will ensure that all payments whether they come directly out of a pocket or with the help of copay assistance-counts toward out-of-pocket costs of patients. The Medicare Part D Six Protected Classes Policy: requires Part D plan to cover all drugs in six classes: immunosuppressants, antidepressants, antipsychotics, anticonvulsants, antiretrovirals, and antineoplastics. For people living with Parkinson's, most of whom are Medicare beneficiaries, it is essential to have access to wide range of treatment options for antidepressants and antipsychotics. Parkinson's causes non-motor symptoms, including depression and psychosis, and individuals often experience different side effects, reactions, and efficacy based on which medications they take. H.R.4752/S.2379 - the Concentrating High-value Alzheimer's Needs to Get to an End (CHANGE) Act of 2023: a bill to better utilize the existing Welcome to Medicare initial exam and Medicare annual wellness visits to screen, detect, and diagnose Alzheimers and related dementias, including Parkinson's disease dementia, in their earliest stages. Signed Leaders Engaged on Alzheimer's Disease (LEAD) Coalition letter to members of Congress in support of this legislation. H.R.4942/S.655 - the Conrad State 30 and Physician Access Reauthorization Act: a bill to reauthorize the Conrad State 30 program for three years, make several targeted policy improvements, and permit the gradual expansion of the number of waivers granted to each state to address health care provider shortages. Signed American Academy of Neurology letter to member of Congress in support of this legislation. The Medicare Part D Six Protected Classes Policy: requires Part D plan to cover all drugs in six classes: immunosuppressants, antidepressants, antipsychotics, anticonvulsants, antiretrovirals, and antineoplastics. For people living with Parkinson's, most of whom are Medicare beneficiaries, it is essential to have access to wide range of treatment options for antidepressants and antipsychotics. Parkinson's causes non-motor symptoms, including depression and psychosis, and individuals often experience different side effects, reactions, and efficacy based on which medications they take. Partnership for Part D Access coalition congressional meetings and signed coalition letter to CMS in response to Medicare Prescription Payment Plan Part One Guidance in support of continued protection for the six protected classes policy. Signed Medicare Access for Prescription Rx (MAPRx) coalition comment letter in response to Medicare Prescription Payment Plan Part One Guidance. Signed Patient and Provider Advocates for Telehealth coalition comment letter in response to CMS CY 2024 Medicare Physician Fee Schedule (PFS) in support prioritizing the needs of patients by expanding policies that improved access to safe and timely health care via telehealth. Signed Alliance for Aging Research coalition letter in response to Medicare Prescription Payment Plan Part One Guidance in support of proposed beneficiary protections and to provide feedback on implementation considerations for the Medicare Prescription Payment Plan program. H.R.8702/S.4532 - Improving Seniors Timely Access to Care Act: a bill to establish requirements with respect to the use of prior authorization under Medicare Advantage plans. H.R./S.- The HEALTHY Brains Act- draft legislation to create a Centers of Excellence grant program within the National Institute of Health to focus on the intersection between environmental risk factors and neurodegenerative disease. General outreach and support for the establishment of an "Office of Caregiver Health" within the Office of the Secretary at the Department of Health and Human Services.
Improving Seniors’ Timely Access to Care Act of 2024
Client: THE MICHAEL J. FOX FOUNDATION FOR PARKINSON'S RESEARCH · Firm: THE MICHAEL J. FOX FOUNDATION FOR PARKINSON'S RESEARCH
Lobbying to Increase Prescription Drug Affordability and Accessibility: Advocacy for Medicare Part D redesign and benefits for people living with Parkinson's, including expanding the low-income subsidy (LIS) program, capping out-of-pocket costs, implementing a smoothing mechanism, and streamlining utilization management processes. The Medicare Part D Six Protected Classes Policy: Requires Part D plans to cover all drugs in six classes: immunosuppressants, antidepressants, antipsychotics, anticonvulsants, antiretrovirals, and antineoplastics. For people living with Parkinson's, most of whom are Medicare beneficiaries, it is essential to have access to a wide range of treatment options for antidepressants and antipsychotics, which are crucial for managing non-motor symptoms like depression and psychosis. Signed Coalition Letters: - Medicare Access for Prescription Rx (MAPRx): Comment letter in response to Medicare Prescription Payment Plan Part One Guidance. - Patient and Provider Advocates for Telehealth: Comment letter in response to CMS CY 2024 Medicare Physician Fee Schedule (PFS) supporting expanded access to telehealth. - Alliance for Aging Research: Coalition letter in response to Medicare Prescription Payment Plan Part One Guidance supporting proposed beneficiary protections. H.R.4752/S.2379 - CHANGE Act of 2023: A bill to better utilize existing Medicare wellness visits for early screening, detection, and diagnosis of Alzheimer's and related dementias, including Parkinson's disease dementia. S.1544/H.R.1199 - Facilitating Innovative Nuclear Diagnostics Act of 2023: A bill to establish separate payment requirements for diagnostic radiopharmaceuticals, including DaTscans used to confirm Parkinson's diagnoses, under the Medicare outpatient prospective payment system. CMS-1809-P (2025 Medicare OPPS Proposed Rule): Comment supporting CMS's proposal to separately reimburse certain diagnostic radiopharmaceuticals used in diagnosing Parkinson's disease and atypical parkinsonisms. H.R.8702/S.4532 - Improving Seniors' Timely Access to Care Act: Establishes requirements for the use of prior authorization under Medicare Advantage plans to ensure timely access to care for seniors, including those with Parkinson's. S.3109/H.R.8018 - Alleviating Barriers for Caregivers (ABC) Act: Requires the Centers for Medicare & Medicaid Services (CMS) and Social Security to simplify processes and communications for family caregivers to assist individuals in accessing and utilizing benefits. S.3766/H.R.7274 - Connecting Caregivers to Medicare Act: Amends the Social Security Act to provide outreach and education to Medicare beneficiaries and simplify access to information for family caregivers through 1-800-MEDICARE. Advocacy for Durable Medical Equipment (DME) Access: Lobbying CMS to direct Medicare contractors to clarify claims procedures for DME therapies requiring administration via external infusion pumps, ensuring quick access to new Parkinson's therapies after FDA approval. H.R.8331/S. 4280 - Essential Caregivers Act of 2024: To amend titles XVIII and XIX of the Social Security Act to require skilled nursing facilities, nursing facilities, intermediate care facilities for the intellectually disabled, and inpatient rehabilitation facilities to permit essential caregivers access during any period in which regular visitation is restricted.
Improving Seniors’ Timely Access to Care Act of 2024
Client: THE MICHAEL J. FOX FOUNDATION FOR PARKINSON'S RESEARCH · Firm: THE MICHAEL J. FOX FOUNDATION FOR PARKINSON'S RESEARCH
Lobbying to Increase Prescription Drug Affordability and Accessibility: Advocacy for Medicare Part D redesign and benefits for people living with Parkinson's, including expanding the low-income subsidy (LIS) program, capping out-of-pocket costs, implementing a smoothing mechanism, and streamlining utilization management processes. The Medicare Part D Six Protected Classes Policy: Requires Part D plans to cover all drugs in six classes: immunosuppressants, antidepressants, antipsychotics, anticonvulsants, antiretrovirals, and antineoplastics. For people living with Parkinson's, most of whom are Medicare beneficiaries, it is essential to have access to a wide range of treatment options for antidepressants and antipsychotics, which are crucial for managing non-motor symptoms like depression and psychosis. Signed Coalition Letters: - Medicare Access for Prescription Rx (MAPRx): Comment letter in response to Medicare Prescription Payment Plan Part One Guidance. - Patient and Provider Advocates for Telehealth: Comment letter in response to CMS CY 2024 Medicare Physician Fee Schedule (PFS) supporting expanded access to telehealth. - Alliance for Aging Research: Coalition letter in response to Medicare Prescription Payment Plan Part One Guidance supporting proposed beneficiary protections. H.R.4752/S.2379 - CHANGE Act of 2023: A bill to better utilize existing Medicare wellness visits for early screening, detection, and diagnosis of Alzheimer's and related dementias, including Parkinson's disease dementia. S.1544/H.R.1199 - Facilitating Innovative Nuclear Diagnostics Act of 2023: A bill to establish separate payment requirements for diagnostic radiopharmaceuticals, including DaTscans used to confirm Parkinson's diagnoses, under the Medicare outpatient prospective payment system. CMS-1809-P (2025 Medicare OPPS Proposed Rule): Comment supporting CMS's proposal to separately reimburse certain diagnostic radiopharmaceuticals used in diagnosing Parkinson's disease and atypical parkinsonisms. H.R.8702/S.4532 - Improving Seniors' Timely Access to Care Act: Establishes requirements for the use of prior authorization under Medicare Advantage plans to ensure timely access to care for seniors, including those with Parkinson's. S.3109/H.R.8018 - Alleviating Barriers for Caregivers (ABC) Act: Requires the Centers for Medicare & Medicaid Services (CMS) and Social Security to simplify processes and communications for family caregivers to assist individuals in accessing and utilizing benefits. S.3766/H.R.7274 - Connecting Caregivers to Medicare Act: Amends the Social Security Act to provide outreach and education to Medicare beneficiaries and simplify access to information for family caregivers through 1-800-MEDICARE. Advocacy for Durable Medical Equipment (DME) Access: Lobbying CMS to direct Medicare contractors to clarify claims procedures for DME therapies requiring administration via external infusion pumps, ensuring quick access to new Parkinson's therapies after FDA approval.
Improving Seniors’ Timely Access to Care Act of 2024
Client: THE MICHAEL J. FOX FOUNDATION FOR PARKINSON'S RESEARCH · Firm: THE MICHAEL J. FOX FOUNDATION FOR PARKINSON'S RESEARCH
H.R.2365/S.1064 - National Plan to End Parkinson's Act: A bill to create an advisory council comprising members of federal agencies that support research, care, and services for Parkinson's disease, as well as patients, care partners, researchers, clinicians, and other non-federal experts, to ensure efficient and effective coordination among all federal entities responsible for managing, treating, and curing Parkinson's disease. General Parkinson's Disease Information: Covers symptoms, triggers, health coverage, health costs, social determinants of health, data collection, research, environmental risks, and health access for underserved communities, particularly through the CDC's National Neurological Conditions Surveillance System (NNCSS). H.R.2630/S.652/S.1339 - Safe Step Act: Requires group health plans to provide an exception process for any medication step therapy protocol to ensure that individuals living with Parkinson's disease can access treatments safely and efficiently. Establishing Parkinson's Disease ICD-10-CM Codes: Aims to assist in the coordination of care for Parkinson's patients who experience OFF episodes and to allow researchers to gather data to study disease progression. S.1544/H.R.1199 - Facilitating Innovative Nuclear Diagnostics Act of 2023: A bill to establish separate payment requirements for diagnostic radiopharmaceuticals, including DaTscans, which aid in confirming a Parkinson's diagnosis under the Medicare prospective payment system for hospital outpatient services. H.R.3432 - Telemental Health Care Access Act of 2023: Permanently removes Medicare's originating site requirements for mental health services furnished via telehealth. Parkinson's non-motor symptoms include mental health conditions, and many people with Parkinson's are Medicare beneficiaries who may face barriers due to in-person requirements. H.R.830/S.1375 - Help Ensure Lower Patient Copays Act: A bill requiring health insurance plans to apply certain payments, including third-party payments, financial assistance, and product vouchers, toward a plan's cost-sharing requirements. This helps Parkinson's patients afford medications for managing symptoms. The Medicare Part D Six Protected Classes Policy: Requires Part D plans to cover all drugs in six protected classes, including antidepressants and antipsychotics. For individuals with Parkinson's disease, these medications are crucial for managing non-motor symptoms such as depression and psychosis. H.R.4752/S.2379 - CHANGE Act of 2023: A bill to improve early screening, detection, and diagnosis of Alzheimer's and related dementias, including Parkinson's disease dementia, during Medicare wellness visits. H.R.4942/S.655 - Conrad State 30 and Physician Access Reauthorization Act: Reauthorizes the Conrad State 30 program and improves policies to address health care provider shortages, supporting neurological care for Parkinson's patients. H.R.8702/S.4532 - Improving Seniors Timely Access to Care Act: Establishes requirements regarding the use of prior authorization under Medicare Advantage plans. H.R.9233/S.- The HEALTHY Brains Act: Draft legislation to create a Centers of Excellence grant program within the National Institutes of Health to focus on the intersection between environmental risk factors and neurodegenerative diseases. H.R.8331/S. 4280 - Essential Caregivers Act of 2024: To amend titles XVIII and XIX of the Social Security Act to require skilled nursing facilities, nursing facilities, intermediate care facilities for the intellectually disabled, and inpatient rehabilitation facilities to permit essential caregivers access during any period in which regular visitation is restricted. General Outreach for Establishing an ""Office of Caregiver Health"": Supports the creation of an Office of Caregiver Health within the Department of Health and Human Services to address the needs of caregivers, particularly in relation to Parkinson's disease care.
Improving Seniors’ Timely Access to Care Act of 2024
Client: THE MICHAEL J. FOX FOUNDATION FOR PARKINSON'S RESEARCH · Firm: THE MICHAEL J. FOX FOUNDATION FOR PARKINSON'S RESEARCH
Lobbying to increase prescription drug affordability and accessibility for people living with Parkinson's via Medicare Part D redesign and benefits, including expanding the low-income subsidy (LIS) program, capping out-of-pocket costs, implementing a smoothing mechanism, and streamlining utilization management processes. The Medicare Part D Six Protected Classes Policy: requires Part D plan to cover all drugs in six classes: immunosuppressants, antidepressants, antipsychotics, anticonvulsants, antiretrovirals, and antineoplastics. For people living with Parkinson's, most of whom are Medicare beneficiaries, it is essential to have access to wide range of treatment options for antidepressants and antipsychotics. Parkinson's causes non-motor symptoms, including depression and psychosis, and individuals often experience different side effects, reactions, and efficacy based on which medications they take. Partnership for Part D Access coalition congressional meetings and signed coalition letter to CMS in response to Medicare Prescription Payment Plan Part One Guidance in support of continued protection for the six protected classes policy. Signed Medicare Access for Prescription Rx (MAPRx) coalition comment letter in response to Medicare Prescription Payment Plan Part One Guidance. Signed Patient and Provider Advocates for Telehealth coalition comment letter in response to CMS CY 2024 Medicare Physician Fee Schedule (PFS) in support prioritizing the needs of patients by expanding policies that improved access to safe and timely health care via telehealth. Signed Alliance for Aging Research coalition letter in response to Medicare Prescription Payment Plan Part One Guidance in support of proposed beneficiary protections and to provide feedback on implementation considerations for the Medicare Prescription Payment Plan program. H.R.4752/S.2379 - the Concentrating High-value Alzheimer's Needs to Get to an End (CHANGE) Act of 2023: a bill to better utilize the existing Welcome to Medicare initial exam and Medicare annual wellness visits to screen, detect, and diagnose Alzheimers and related dementias, including Parkinson's disease dementia, in their earliest stages. Signed Leaders Engaged on Alzheimer's Disease (LEAD) Coalition letter to members of Congress in support of this legislation. S. 3109- Alleviating Barriers for Caregivers (ABC) Act- bill to require the Administrator of the Centers for Medicare & Medicaid Services and the Commissioner of Social Security to review and simplify the processes, procedures, forms, and communications for family caregivers to assist individuals in establishing eligibility for, enrolling in, and maintaining and utilizing coverage and benefits under the Medicare, Medicaid, CHIP, and Social Security programs respectively, and for other purposes. Lobbying the Centers for Medicare and Medicaid Services to direct Durable Medical Equipment Medicare Administrative Contractors to provide additional clarification regarding the use of claim modifiers for DME therapies that require administration via an external infusion pump to expedite patient access once new Parkinson's therapies receive approvals from the Food and Drug Administration. S.1544/H.R.1199 - Facilitating Innovative Nuclear Diagnostics Act of 2023: a bill to establish separate payment requirements for diagnostic radiopharmaceuticals, including DaTscans, which can aid in confirming a Parkinson's diagnosis, under the Medicare prospective payment system for hospital outpatient department services. S. 3766/H.R. 7274- Connecting Caregivers to Medicare Act -To amend title XVIII of the Social Security Act to provide for outreach and education to Medicare beneficiaries to simplify access to information for family caregivers through 1-800-MEDICARE, and for other purposes. H.R. 8018/S. 3109- Alleviating Barriers for Caregivers (ABC) Act- bill to require the Administrator of the Centers for Medicare & Medicaid Services and the Commissioner of Social Security to review and simplify the processes, procedures, forms, and communications for family caregivers to assist individuals in establishing eligibility for, enrolling in, and maintaining and utilizing coverage and benefits under the Medicare, Medicaid, CHIP, and Social Security programs respectively, and for other purposes. H.R.8702/S.4532 - Improving Seniors Timely Access to Care Act: a bill to establish requirements with respect to the use of prior authorization under Medicare Advantage plans.
Improving Seniors’ Timely Access to Care Act of 2024
Client: THE MICHAEL J. FOX FOUNDATION FOR PARKINSON'S RESEARCH · Firm: THE MICHAEL J. FOX FOUNDATION FOR PARKINSON'S RESEARCH
Lobbying to Improve Prescription Drug Affordability and Accessibility: Advocacy for people living with Parkinson's via Medicare Part D redesign and benefits, including expanding the low-income subsidy (LIS) program, capping out-of-pocket costs, implementing a smoothing mechanism, and streamlining utilization management processes. Medicare Part D Six Protected Classes Policy: Requires Part D plans to cover all drugs in six classes: immunosuppressants, antidepressants, antipsychotics, anticonvulsants, antiretrovirals, and antineoplastics. Access to a wide range of treatment options for antidepressants and antipsychotics is essential for Parkinson's patients due to non-motor symptoms such as depression and psychosis. Advocacy includes coalition meetings and letters to CMS in response to Medicare Prescription Payment Plan Part One Guidance to support continued protection for the six protected classes. H.R.2360/S.652/S.1339 - Safe Step Act: A bill requiring group health plans to provide an exception process for any medication step therapy protocol to ensure that Parkinson's patients can access treatments safely and efficiently. Led a digital campaign to allow constituents to write to members of Congress in support of the legislation. H.R.830/S.1375 - Help Ensure Lower Patient Copays Act: This bill requires health insurance plans to apply third-party payments, financial assistance, discounts, and other reductions in out-of-pocket expenses toward a plan's cost-sharing requirements. Many Parkinson's patients rely on such payments to afford medications, and this legislation ensures they count toward out-of-pocket costs. S.1544/H.R.1199 - Facilitating Innovative Nuclear Diagnostics Act of 2023: A bill to establish separate payment requirements for diagnostic radiopharmaceuticals, including DaTscans, under the Medicare prospective payment system for hospital outpatient department services. This will help confirm Parkinson's diagnoses more efficiently. CMS-1809-P (2025 Medicare Outpatient Prospective Payment System Proposed Rule): Supported CMS's proposal to separate payment for certain diagnostic radiopharmaceuticals, including those used to diagnose Parkinson's disease and atypical parkinsonisms, from the procedure payment and reimburse them separately. H.R.8702/S.4532 - Improving Seniors Timely Access to Care Act: A bill to establish requirements regarding the use of prior authorization under Medicare Advantage plans. Lobbying CMS: Advocacy efforts to direct Durable Medical Equipment Medicare Administrative Contractors to provide clarification on the use of claim modifiers for DME therapies administered via an external infusion pump to expedite patient access to new Parkinson's therapies once they are approved by the FDA.
Improving Seniors’ Timely Access to Care Act of 2024
Client: THE MICHAEL J. FOX FOUNDATION FOR PARKINSON'S RESEARCH · Firm: THE MICHAEL J. FOX FOUNDATION FOR PARKINSON'S RESEARCH
Lobbying to improve prescription drug affordability and accessibility for people living with Parkinson's via Medicare Part D redesign and benefits, including expanding the low-income subsidy (LIS) program, capping out-of-pocket costs, implementing a smoothing mechanism, and streamlining utilization management processes. The Medicare Part D Six Protected Classes Policy: requires Part D plan to cover all drugs in six classes: immunosuppressants, antidepressants, antipsychotics, anticonvulsants, antiretrovirals, and antineoplastics. For people living with Parkinson's, most of whom are Medicare beneficiaries, it is essential to have access to wide range of treatment options for antidepressants and antipsychotics. Parkinson's causes non-motor symptoms, including depression and psychosis, and individuals often experience different side effects, reactions, and efficacy based on which medications they take. Partnership for Part D Access coalition congressional meetings and signed coalition letter to CMS in response to Medicare Prescription Payment Plan Part One Guidance in support of continued protection for the six protected classes policy. Signed Medicare Access for Prescription Rx (MAPRx) coalition comment letter in response to Medicare Prescription Payment Plan Part One Guidance. Signed Alliance for Aging Research coalition letter in response to Medicare Prescription Payment Plan Part One Guidance in support of proposed beneficiary protections and to provide feedback on implementation considerations for the Medicare Prescription Payment Plan program. H.R.2360/S.652/S.1339 - Safe Step Act: a bill to require group health plans to provide an exception process for any medication step therapy protocol to help ensure that people living with Parkinson's disease can safely and efficiently access treatments. Led a digital campaign to allow constituents to write their members of Congress in support of this legislation. Lobbying the Centers for Medicare and Medicaid Services to direct Durable Medical Equipment Medicare Administrative Contractors to provide additional clarification regarding the use of claim modifiers for DME therapies that require administration via an external infusion pump to expedite patient access once new Parkinson's therapies receive approvals from the Food and Drug Administration. Lobbying the Centers for Medicare and Medicaid Services to direct Durable Medical Equipment Medicare Administrative Contractors to provide additional clarification regarding the use of claim modifiers for DME therapies that require administration via an external infusion pump to expedite patient access once new Parkinson's therapies receive approvals from the Food and Drug Administration. H.R.2360/S.652/S.1339 - Safe Step Act: a bill to require group health plans to provide an exception process for any medication step therapy protocol to help ensure that people living with Parkinson's disease can safely and efficiently access treatments. Led an digital campaign to allow constituents to write their members of Congress in support of this legislation. H.R.8702/S.4532 - Improving Seniors Timely Access to Care Act: a bill to establish requirements with respect to the use of prior authorization under Medicare Advantage plans. H.R.830/S.1375 - Help Ensure Lower Patient Copays Act: a bill to require health insurance plans to apply certain payments made by, or on behalf of, a plan enrollee toward a plan's cost-sharing requirements. Specifically, plans must apply third-party payments, financial assistance, discounts, product vouchers, and other reductions in out-of-pocket expenses toward the requirements. Many Parkinson's patients rely on such third-party payments to afford medications to treat and manage their disease symptoms, and this legislation will ensure that all payments whether they come directly out of a pocket or with the help of copay assistance-counts toward out-of-pocket costs of patients. S.1544/H.R.1199 - Facilitating Innovative Nuclear Diagnostics Act of 2023: a bill to establish separate payment requirements for diagnostic radiopharmaceuticals, including DaTscans, which can aid in confirming a Parkinson's diagnosis, under the Medicare prospective payment system for hospital outpatient department services.
Department of Defense Appropriations Act, 2025
Client: THE MICHAEL J. FOX FOUNDATION FOR PARKINSON'S RESEARCH · Firm: THE MICHAEL J. FOX FOUNDATION FOR PARKINSON'S RESEARCH
FY 2025 Appropriations bills including funding requests for Parkinson's research within: H.R.8774/ S.4921: The Department of Defense within the FY 2025 Defense Appropriation bill. Funding for the Parkinson's Research Program (PRP) under the Department of Defense's Congressionally Directed Medical Research Programs (CDMRP). H.R.9029/S.4942: The National Institute of Health and Centers for Disease Control and Prevention within the FY 2025 Labor, Health and Human Services, Education, and Related Agencies Appropriation bill. Possible funding to implement the National Plan to End Parkinson's Act (HR 2365/ PL 118-66) within LHHS appropriations. H.R.9027/ S.4690: The Food and Drug Administration within the FY 2025 Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriation bill. H.R.8580/ S.4677: The Department of Veterans Affairs within the FY 2025 Military Construction, Veterans Affairs, and Related Agencies Appropriation bill. Support funding for Neurology Centers of Excellence and medical care and research through Veterans Health Administration, including the Parkinson's Disease Research, Education and Clinical Centers. H.R.9029/S.4942: General advocacy in support of robust non-defense discretionary investments in Labor, Health and Human Services, Education and Related Agencies appropriations bill for FY 2025. Funding for discretionary, non-defense priorities including overall investment in the National Institute of Health, ARPA-H, and Centers for Disease Control and Prevention within the FY 2025 Labor, Health and Human Services, Education, and Related Agencies Appropriation bills. Funding for the Parkinson's Research Program (PRP) under the Department of Defense's Congressionally Directed Medical Research Programs (CDMRP). Increased funding for NIEHS (no bill introduced). H.R.9233: The HEALTHY BRAINS Act - developing support for implementation funding for centers of excellence within NIH.
Department of Defense Appropriations Act, 2025
Client: THE MICHAEL J. FOX FOUNDATION FOR PARKINSON'S RESEARCH · Firm: THE MICHAEL J. FOX FOUNDATION FOR PARKINSON'S RESEARCH
General education on the importance of the Department of Defense medical research programs for military service personnel and Veterans living with Parkinson's disease. H.R.8774/ S.4921: FY25 Defense Appropriations bills to support increased funding for DOD Congressionally Directed Medical Research Programs Parkinson's Research Program. H.R.542/S.141 - The Elizabeth Dole Home Care Act: Increases access to home care and caregiver programs provided by the Department of Veterans Affairs (VA) and seeks to address VA home health workforce shortages. Inclusion of Parkinson's disease and PD-related diseases as presumptive conditions when military Veterans are exposed to associated toxins. H.R.8580 / S.4677 - FY25 Military Construction, Veterans Affairs and Related Agencies Appropriations bill: Supports increased funding for the VA's Parkinson's Disease Research, Education and Clinical Center as part of Neurology Centers of Excellence. General education regarding the importance of the Department of Defense medical research programs for military service personnel and Veterans living with Parkinson's disease.
Department of Defense Appropriations Act, 2025
Client: THE MICHAEL J. FOX FOUNDATION FOR PARKINSON'S RESEARCH · Firm: THE MICHAEL J. FOX FOUNDATION FOR PARKINSON'S RESEARCH
FY25 Military Construction, Veterans Affairs and Related Agencies Appropriations bill to support increased funding for the VA's Parkinson's Disease Research, Education and Clinical Center. General education regarding the importance of the Department of Defense medical research programs for military service personnel and Veterans living with Parkinson's disease. Inclusion of Parkinson's disease and PD-related diseases as presumptive conditions when military Veterans are exposed to associated toxins. FY24 and FY25 Defense Appropriations bills to support increased funding for DOD Congressionally Directed Medical Research Programs Parkinson's Research Program. H.R.542/S.141 -The Elizabeth Dole Home Care Act- increases access to home care and caregiver programs provided by the Department of Veterans Affairs (VA) and seeks to address VA home health workforce shortages. H.R. 8580 / Senate bill not filed - FY25 Military Construction, Veterans Affairs and Related Agencies Appropriations bill to support increased funding for the VA's Parkinson's Disease Research, Education and Clinical Center as part of Neurology Centers of Excellence. H.R. 8774/ Senate bill not yet filed - FY25 Defense Appropriations bills to support increased funding for DOD Congressionally Directed Medical Research Programs Parkinson's Research Program. General education regarding the importance of the Department of Defense medical research programs for military service personnel and Veterans living with Parkinson's disease. Inclusion of Parkinson's disease and PD-related diseases as presumptive conditions when military Veterans are exposed to associated toxins.
Department of Defense Appropriations Act, 2025
Client: THE MICHAEL J. FOX FOUNDATION FOR PARKINSON'S RESEARCH · Firm: THE MICHAEL J. FOX FOUNDATION FOR PARKINSON'S RESEARCH
General education on the importance of the Department of Defense medical research programs for military service personnel and Veterans living with Parkinson's disease. H.R.8774/ S.4921: FY25 Defense Appropriations bills to support increased funding for DOD Congressionally Directed Medical Research Programs Parkinson's Research Program. H.R.542/S.141 - The Elizabeth Dole Home Care Act: Increases access to home care and caregiver programs provided by the Department of Veterans Affairs (VA) and seeks to address VA home health workforce shortages. Inclusion of Parkinson's disease and PD-related diseases as presumptive conditions when military Veterans are exposed to associated toxins. H.R.8580 / S.4677 - FY25 Military Construction, Veterans Affairs and Related Agencies Appropriations bill: Supports increased funding for the VA's Parkinson's Disease Research, Education and Clinical Center as part of Neurology Centers of Excellence. General education regarding the importance of the Department of Defense medical research programs for military service personnel and Veterans living with Parkinson's disease.
Department of Defense Appropriations Act, 2025
Client: THE MICHAEL J. FOX FOUNDATION FOR PARKINSON'S RESEARCH · Firm: THE MICHAEL J. FOX FOUNDATION FOR PARKINSON'S RESEARCH
FY 2025 Appropriations bills including funding requests for Parkinson's research within: H.R.8774/ S.4921: The Department of Defense within the FY 2025 Defense Appropriation bill. Funding for the Parkinson's Research Program (PRP) under the Department of Defense's Congressionally Directed Medical Research Programs (CDMRP). H.R.9029/S.4942: The National Institute of Health and Centers for Disease Control and Prevention within the FY 2025 Labor, Health and Human Services, Education, and Related Agencies Appropriation bill. Possible funding to implement the National Plan to End Parkinson's Act (HR 2365/ PL 118-66) within LHHS appropriations. H.R.9027/ S.4690: The Food and Drug Administration within the FY 2025 Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriation bill. H.R.8580/ S.4677: The Department of Veterans Affairs within the FY 2025 Military Construction, Veterans Affairs, and Related Agencies Appropriation bill. Support funding for Neurology Centers of Excellence and medical care and research through Veterans Health Administration, including the Parkinson's Disease Research, Education and Clinical Centers. H.R.9029/S.4942: General advocacy in support of robust non-defense discretionary investments in Labor, Health and Human Services, Education and Related Agencies appropriations bill for FY 2025. Funding for discretionary, non-defense priorities including overall investment in the National Institute of Health, ARPA-H, and Centers for Disease Control and Prevention within the FY 2025 Labor, Health and Human Services, Education, and Related Agencies Appropriation bills. Funding for the Parkinson's Research Program (PRP) under the Department of Defense's Congressionally Directed Medical Research Programs (CDMRP). Increased funding for NIEHS (no bill introduced).
Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2025
Client: THE MICHAEL J. FOX FOUNDATION FOR PARKINSON'S RESEARCH · Firm: THE MICHAEL J. FOX FOUNDATION FOR PARKINSON'S RESEARCH
FY 2025 Appropriations bills including funding requests for Parkinson's research within: H.R.8774/ S.4921: The Department of Defense within the FY 2025 Defense Appropriation bill. Funding for the Parkinson's Research Program (PRP) under the Department of Defense's Congressionally Directed Medical Research Programs (CDMRP). H.R.9029/S.4942: The National Institute of Health and Centers for Disease Control and Prevention within the FY 2025 Labor, Health and Human Services, Education, and Related Agencies Appropriation bill. Possible funding to implement the National Plan to End Parkinson's Act (HR 2365/ PL 118-66) within LHHS appropriations. H.R.9027/ S.4690: The Food and Drug Administration within the FY 2025 Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriation bill. H.R.8580/ S.4677: The Department of Veterans Affairs within the FY 2025 Military Construction, Veterans Affairs, and Related Agencies Appropriation bill. Support funding for Neurology Centers of Excellence and medical care and research through Veterans Health Administration, including the Parkinson's Disease Research, Education and Clinical Centers. H.R.9029/S.4942: General advocacy in support of robust non-defense discretionary investments in Labor, Health and Human Services, Education and Related Agencies appropriations bill for FY 2025. Funding for discretionary, non-defense priorities including overall investment in the National Institute of Health, ARPA-H, and Centers for Disease Control and Prevention within the FY 2025 Labor, Health and Human Services, Education, and Related Agencies Appropriation bills. Funding for the Parkinson's Research Program (PRP) under the Department of Defense's Congressionally Directed Medical Research Programs (CDMRP). Increased funding for NIEHS (no bill introduced).
Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2025
Client: THE MICHAEL J. FOX FOUNDATION FOR PARKINSON'S RESEARCH · Firm: THE MICHAEL J. FOX FOUNDATION FOR PARKINSON'S RESEARCH
FY 2025 Appropriations bills including funding requests for Parkinson's research within: H.R.8774/ S.4921: The Department of Defense within the FY 2025 Defense Appropriation bill. Funding for the Parkinson's Research Program (PRP) under the Department of Defense's Congressionally Directed Medical Research Programs (CDMRP). H.R.9029/S.4942: The National Institute of Health and Centers for Disease Control and Prevention within the FY 2025 Labor, Health and Human Services, Education, and Related Agencies Appropriation bill. Possible funding to implement the National Plan to End Parkinson's Act (HR 2365/ PL 118-66) within LHHS appropriations. H.R.9027/ S.4690: The Food and Drug Administration within the FY 2025 Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriation bill. H.R.8580/ S.4677: The Department of Veterans Affairs within the FY 2025 Military Construction, Veterans Affairs, and Related Agencies Appropriation bill. Support funding for Neurology Centers of Excellence and medical care and research through Veterans Health Administration, including the Parkinson's Disease Research, Education and Clinical Centers. H.R.9029/S.4942: General advocacy in support of robust non-defense discretionary investments in Labor, Health and Human Services, Education and Related Agencies appropriations bill for FY 2025. Funding for discretionary, non-defense priorities including overall investment in the National Institute of Health, ARPA-H, and Centers for Disease Control and Prevention within the FY 2025 Labor, Health and Human Services, Education, and Related Agencies Appropriation bills. Funding for the Parkinson's Research Program (PRP) under the Department of Defense's Congressionally Directed Medical Research Programs (CDMRP). Increased funding for NIEHS (no bill introduced). H.R.9233: The HEALTHY BRAINS Act - developing support for implementation funding for centers of excellence within NIH.
Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2025
Client: THE MICHAEL J. FOX FOUNDATION FOR PARKINSON'S RESEARCH · Firm: THE MICHAEL J. FOX FOUNDATION FOR PARKINSON'S RESEARCH
General Education on Parkinson's Risk Factors: Focused on raising awareness about triggers and risks of Parkinson's disease, including exposure to TCE, paraquat, air pollution, and other environmental chemicals. H.R.9233/S. - The HEALTHY BRAINS Act: Draft legislation to create a Centers of Excellence grant program within the National Institutes of Health to focus on the intersection between environmental risk factors and neurodegenerative diseases. Supporting FDA Neurology Drug Program Funding: Advocacy for funding through the FY 2025 Agriculture Appropriations bills (H.R. 9027, S. 4690) and the Labor, Health and Human Services FY 2025 Appropriations bill (not yet filed). S.269 - Protect America's Children from Toxic Pesticides Act (PACTPA): Legislation focused on protecting children from harmful pesticides, including those linked to Parkinson's. S.806 - The Healthy H2O Act: A bill that addresses concerns about water quality and its effects on health, relevant to Parkinsons disease prevention. Neurodegenerative Disease Center of Excellence: Ongoing development of a legislative proposal to create a center at the National Institute of Environmental Health Sciences (NIEHS) to focus on neurodegenerative diseases like Parkinsons. Efforts to ban paraquat.
Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2025
Client: THE MICHAEL J. FOX FOUNDATION FOR PARKINSON'S RESEARCH · Firm: THE MICHAEL J. FOX FOUNDATION FOR PARKINSON'S RESEARCH
FY 2025 Appropriations bills including funding requests for Parkinson's research within: H.R.8774/ S.4921: The Department of Defense within the FY 2025 Defense Appropriation bill. Funding for the Parkinson's Research Program (PRP) under the Department of Defense's Congressionally Directed Medical Research Programs (CDMRP). H.R.9029/S.4942: The National Institute of Health and Centers for Disease Control and Prevention within the FY 2025 Labor, Health and Human Services, Education, and Related Agencies Appropriation bill. Possible funding to implement the National Plan to End Parkinson's Act (HR 2365/ PL 118-66) within LHHS appropriations. H.R.9027/ S.4690: The Food and Drug Administration within the FY 2025 Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriation bill. H.R.8580/ S.4677: The Department of Veterans Affairs within the FY 2025 Military Construction, Veterans Affairs, and Related Agencies Appropriation bill. Support funding for Neurology Centers of Excellence and medical care and research through Veterans Health Administration, including the Parkinson's Disease Research, Education and Clinical Centers. H.R.9029/S.4942: General advocacy in support of robust non-defense discretionary investments in Labor, Health and Human Services, Education and Related Agencies appropriations bill for FY 2025. Funding for discretionary, non-defense priorities including overall investment in the National Institute of Health, ARPA-H, and Centers for Disease Control and Prevention within the FY 2025 Labor, Health and Human Services, Education, and Related Agencies Appropriation bills. Funding for the Parkinson's Research Program (PRP) under the Department of Defense's Congressionally Directed Medical Research Programs (CDMRP). Increased funding for NIEHS (no bill introduced). H.R.9233: The HEALTHY BRAINS Act - developing support for implementation funding for centers of excellence within NIH.
Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2025
Client: THE MICHAEL J. FOX FOUNDATION FOR PARKINSON'S RESEARCH · Firm: THE MICHAEL J. FOX FOUNDATION FOR PARKINSON'S RESEARCH
FY 2025 Appropriations bills including funding requests for Parkinson's research within: H.R.8774/ S.4921: The Department of Defense within the FY 2025 Defense Appropriation bill. Funding for the Parkinson's Research Program (PRP) under the Department of Defense's Congressionally Directed Medical Research Programs (CDMRP). H.R.9029/S.4942: The National Institute of Health and Centers for Disease Control and Prevention within the FY 2025 Labor, Health and Human Services, Education, and Related Agencies Appropriation bill. Possible funding to implement the National Plan to End Parkinson's Act (HR 2365/ PL 118-66) within LHHS appropriations. H.R.9027/ S.4690: The Food and Drug Administration within the FY 2025 Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriation bill. H.R.8580/ S.4677: The Department of Veterans Affairs within the FY 2025 Military Construction, Veterans Affairs, and Related Agencies Appropriation bill. Support funding for Neurology Centers of Excellence and medical care and research through Veterans Health Administration, including the Parkinson's Disease Research, Education and Clinical Centers. H.R.9029/S.4942: General advocacy in support of robust non-defense discretionary investments in Labor, Health and Human Services, Education and Related Agencies appropriations bill for FY 2025. Funding for discretionary, non-defense priorities including overall investment in the National Institute of Health, ARPA-H, and Centers for Disease Control and Prevention within the FY 2025 Labor, Health and Human Services, Education, and Related Agencies Appropriation bills. Funding for the Parkinson's Research Program (PRP) under the Department of Defense's Congressionally Directed Medical Research Programs (CDMRP). Increased funding for NIEHS (no bill introduced).
HEALTHY BRAINS Act of 2024
Client: THE MICHAEL J. FOX FOUNDATION FOR PARKINSON'S RESEARCH · Firm: THE MICHAEL J. FOX FOUNDATION FOR PARKINSON'S RESEARCH
H.R.2365/S.1064 - National Plan to End Parkinson's Act: A bill to create an advisory council comprising members of federal agencies that support research, care, and services for Parkinson's disease, as well as patients, care partners, researchers, clinicians, and other non-federal experts, to ensure efficient and effective coordination among all federal entities responsible for managing, treating, and curing Parkinson's disease. General Parkinson's Disease Information: Covers symptoms, triggers, health coverage, health costs, social determinants of health, data collection, research, environmental risks, and health access for underserved communities, particularly through the CDC's National Neurological Conditions Surveillance System (NNCSS). H.R.2630/S.652/S.1339 - Safe Step Act: Requires group health plans to provide an exception process for any medication step therapy protocol to ensure that individuals living with Parkinson's disease can access treatments safely and efficiently. Establishing Parkinson's Disease ICD-10-CM Codes: Aims to assist in the coordination of care for Parkinson's patients who experience OFF episodes and to allow researchers to gather data to study disease progression. S.1544/H.R.1199 - Facilitating Innovative Nuclear Diagnostics Act of 2023: A bill to establish separate payment requirements for diagnostic radiopharmaceuticals, including DaTscans, which aid in confirming a Parkinson's diagnosis under the Medicare prospective payment system for hospital outpatient services. H.R.3432 - Telemental Health Care Access Act of 2023: Permanently removes Medicare's originating site requirements for mental health services furnished via telehealth. Parkinson's non-motor symptoms include mental health conditions, and many people with Parkinson's are Medicare beneficiaries who may face barriers due to in-person requirements. H.R.830/S.1375 - Help Ensure Lower Patient Copays Act: A bill requiring health insurance plans to apply certain payments, including third-party payments, financial assistance, and product vouchers, toward a plan's cost-sharing requirements. This helps Parkinson's patients afford medications for managing symptoms. The Medicare Part D Six Protected Classes Policy: Requires Part D plans to cover all drugs in six protected classes, including antidepressants and antipsychotics. For individuals with Parkinson's disease, these medications are crucial for managing non-motor symptoms such as depression and psychosis. H.R.4752/S.2379 - CHANGE Act of 2023: A bill to improve early screening, detection, and diagnosis of Alzheimer's and related dementias, including Parkinson's disease dementia, during Medicare wellness visits. H.R.4942/S.655 - Conrad State 30 and Physician Access Reauthorization Act: Reauthorizes the Conrad State 30 program and improves policies to address health care provider shortages, supporting neurological care for Parkinson's patients. H.R.8702/S.4532 - Improving Seniors Timely Access to Care Act: Establishes requirements regarding the use of prior authorization under Medicare Advantage plans. H.R.9233/S.- The HEALTHY Brains Act: Draft legislation to create a Centers of Excellence grant program within the National Institutes of Health to focus on the intersection between environmental risk factors and neurodegenerative diseases. H.R.8331/S. 4280 - Essential Caregivers Act of 2024: To amend titles XVIII and XIX of the Social Security Act to require skilled nursing facilities, nursing facilities, intermediate care facilities for the intellectually disabled, and inpatient rehabilitation facilities to permit essential caregivers access during any period in which regular visitation is restricted. General Outreach for Establishing an ""Office of Caregiver Health"": Supports the creation of an Office of Caregiver Health within the Department of Health and Human Services to address the needs of caregivers, particularly in relation to Parkinson's disease care.
HEALTHY BRAINS Act of 2024
Client: THE MICHAEL J. FOX FOUNDATION FOR PARKINSON'S RESEARCH · Firm: THE MICHAEL J. FOX FOUNDATION FOR PARKINSON'S RESEARCH
FY 2025 Appropriations bills including funding requests for Parkinson's research within: H.R.8774/ S.4921: The Department of Defense within the FY 2025 Defense Appropriation bill. Funding for the Parkinson's Research Program (PRP) under the Department of Defense's Congressionally Directed Medical Research Programs (CDMRP). H.R.9029/S.4942: The National Institute of Health and Centers for Disease Control and Prevention within the FY 2025 Labor, Health and Human Services, Education, and Related Agencies Appropriation bill. Possible funding to implement the National Plan to End Parkinson's Act (HR 2365/ PL 118-66) within LHHS appropriations. H.R.9027/ S.4690: The Food and Drug Administration within the FY 2025 Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriation bill. H.R.8580/ S.4677: The Department of Veterans Affairs within the FY 2025 Military Construction, Veterans Affairs, and Related Agencies Appropriation bill. Support funding for Neurology Centers of Excellence and medical care and research through Veterans Health Administration, including the Parkinson's Disease Research, Education and Clinical Centers. H.R.9029/S.4942: General advocacy in support of robust non-defense discretionary investments in Labor, Health and Human Services, Education and Related Agencies appropriations bill for FY 2025. Funding for discretionary, non-defense priorities including overall investment in the National Institute of Health, ARPA-H, and Centers for Disease Control and Prevention within the FY 2025 Labor, Health and Human Services, Education, and Related Agencies Appropriation bills. Funding for the Parkinson's Research Program (PRP) under the Department of Defense's Congressionally Directed Medical Research Programs (CDMRP). Increased funding for NIEHS (no bill introduced). H.R.9233: The HEALTHY BRAINS Act - developing support for implementation funding for centers of excellence within NIH.
HEALTHY BRAINS Act of 2024
Client: THE MICHAEL J. FOX FOUNDATION FOR PARKINSON'S RESEARCH · Firm: THE MICHAEL J. FOX FOUNDATION FOR PARKINSON'S RESEARCH
H.R.2365/S.1064 - National Plan to End Parkinson's Act: A bill to create an advisory council comprising members of federal agencies that support research, care, and services for Parkinson's disease, as well as patients, care partners, researchers, clinicians, and other non-federal experts, to ensure efficient and effective coordination among all federal entities responsible for managing, treating, and curing Parkinson's disease. General Parkinson's Disease Information: Covers symptoms, triggers, health coverage, health costs, social determinants of health, data collection, research, environmental risks, and health access for underserved communities, particularly through the CDC's National Neurological Conditions Surveillance System (NNCSS). H.R.2630/S.652/S.1339 - Safe Step Act: Requires group health plans to provide an exception process for any medication step therapy protocol to ensure that individuals living with Parkinson's disease can access treatments safely and efficiently. Establishing Parkinson's Disease ICD-10-CM Codes: Aims to assist in the coordination of care for Parkinson's patients who experience OFF episodes and to allow researchers to gather data to study disease progression. S.1544/H.R.1199 - Facilitating Innovative Nuclear Diagnostics Act of 2023: A bill to establish separate payment requirements for diagnostic radiopharmaceuticals, including DaTscans, which aid in confirming a Parkinson's diagnosis under the Medicare prospective payment system for hospital outpatient services. H.R.3432 - Telemental Health Care Access Act of 2023: Permanently removes Medicare's originating site requirements for mental health services furnished via telehealth. Parkinson's non-motor symptoms include mental health conditions, and many people with Parkinson's are Medicare beneficiaries who may face barriers due to in-person requirements. H.R.830/S.1375 - Help Ensure Lower Patient Copays Act: A bill requiring health insurance plans to apply certain payments, including third-party payments, financial assistance, and product vouchers, toward a plan's cost-sharing requirements. This helps Parkinson's patients afford medications for managing symptoms. The Medicare Part D Six Protected Classes Policy: Requires Part D plans to cover all drugs in six protected classes, including antidepressants and antipsychotics. For individuals with Parkinson's disease, these medications are crucial for managing non-motor symptoms such as depression and psychosis. H.R.4752/S.2379 - CHANGE Act of 2023: A bill to improve early screening, detection, and diagnosis of Alzheimer's and related dementias, including Parkinson's disease dementia, during Medicare wellness visits. H.R.4942/S.655 - Conrad State 30 and Physician Access Reauthorization Act: Reauthorizes the Conrad State 30 program and improves policies to address health care provider shortages, supporting neurological care for Parkinson's patients. H.R.8702/S.4532 - Improving Seniors Timely Access to Care Act: Establishes requirements regarding the use of prior authorization under Medicare Advantage plans. H.R.9233/S.- The HEALTHY Brains Act: Draft legislation to create a Centers of Excellence grant program within the National Institutes of Health to focus on the intersection between environmental risk factors and neurodegenerative diseases. General Outreach for Establishing an ""Office of Caregiver Health"": Supports the creation of an Office of Caregiver Health within the Department of Health and Human Services to address the needs of caregivers, particularly in relation to Parkinson's disease care.
HEALTHY BRAINS Act of 2024
Client: THE MICHAEL J. FOX FOUNDATION FOR PARKINSON'S RESEARCH · Firm: THE MICHAEL J. FOX FOUNDATION FOR PARKINSON'S RESEARCH
Advocating for a ban on Trichloroethylene (TCE) and paraquat. H.R.9233 - The Harmonizing Environmental Analyses and Launching Therapeutic Hubs to Yield Bolstered Research And Innovation in Neurological Science (HEALTHY BRAINS) Act of 2024 - a bill to create a Centers of Excellence grant program within the National Institute of Health to focus on the intersection between environmental risk factors and neurodegenerative disease.
HEALTHY BRAINS Act of 2024
Client: THE MICHAEL J. FOX FOUNDATION FOR PARKINSON'S RESEARCH · Firm: THE MICHAEL J. FOX FOUNDATION FOR PARKINSON'S RESEARCH
Advocating for a ban on Trichloroethylene (TCE) and paraquat. H.R.9233 - The Harmonizing Environmental Analyses and Launching Therapeutic Hubs to Yield Bolstered Research And Innovation in Neurological Science (HEALTHY BRAINS) Act of 2024 - a bill to create a Centers of Excellence grant program within the National Institute of Health to focus on the intersection between environmental risk factors and neurodegenerative disease. Efforts to ban paraquat.
HEALTHY BRAINS Act of 2024
Client: THE MICHAEL J. FOX FOUNDATION FOR PARKINSON'S RESEARCH · Firm: THE MICHAEL J. FOX FOUNDATION FOR PARKINSON'S RESEARCH
General Education on Parkinson's Risk Factors: Focused on raising awareness about triggers and risks of Parkinson's disease, including exposure to TCE, paraquat, air pollution, and other environmental chemicals. H.R.9233/S. - The HEALTHY BRAINS Act: Draft legislation to create a Centers of Excellence grant program within the National Institutes of Health to focus on the intersection between environmental risk factors and neurodegenerative diseases. Supporting FDA Neurology Drug Program Funding: Advocacy for funding through the FY 2025 Agriculture Appropriations bills (H.R. 9027, S. 4690) and the Labor, Health and Human Services FY 2025 Appropriations bill (not yet filed). S.269 - Protect America's Children from Toxic Pesticides Act (PACTPA): Legislation focused on protecting children from harmful pesticides, including those linked to Parkinson's. S.806 - The Healthy H2O Act: A bill that addresses concerns about water quality and its effects on health, relevant to Parkinsons disease prevention. Neurodegenerative Disease Center of Excellence: Ongoing development of a legislative proposal to create a center at the National Institute of Environmental Health Sciences (NIEHS) to focus on neurodegenerative diseases like Parkinsons. Efforts to ban paraquat.
National Plan to End Parkinson’s Act
Client: THE MICHAEL J. FOX FOUNDATION FOR PARKINSON'S RESEARCH · Firm: THE MICHAEL J. FOX FOUNDATION FOR PARKINSON'S RESEARCH
H.R.2365/S.1064 - National Plan to End Parkinson's Act: A bill to create an advisory council comprising members of federal agencies that support research, care, and services for Parkinson's disease, as well as patients, care partners, researchers, clinicians, and other non-federal experts, to ensure efficient and effective coordination among all federal entities responsible for managing, treating, and curing Parkinson's disease. General Parkinson's Disease Information: Covers symptoms, triggers, health coverage, health costs, social determinants of health, data collection, research, environmental risks, and health access for underserved communities, particularly through the CDC's National Neurological Conditions Surveillance System (NNCSS). H.R.2630/S.652/S.1339 - Safe Step Act: Requires group health plans to provide an exception process for any medication step therapy protocol to ensure that individuals living with Parkinson's disease can access treatments safely and efficiently. Establishing Parkinson's Disease ICD-10-CM Codes: Aims to assist in the coordination of care for Parkinson's patients who experience OFF episodes and to allow researchers to gather data to study disease progression. S.1544/H.R.1199 - Facilitating Innovative Nuclear Diagnostics Act of 2023: A bill to establish separate payment requirements for diagnostic radiopharmaceuticals, including DaTscans, which aid in confirming a Parkinson's diagnosis under the Medicare prospective payment system for hospital outpatient services. H.R.3432 - Telemental Health Care Access Act of 2023: Permanently removes Medicare's originating site requirements for mental health services furnished via telehealth. Parkinson's non-motor symptoms include mental health conditions, and many people with Parkinson's are Medicare beneficiaries who may face barriers due to in-person requirements. H.R.830/S.1375 - Help Ensure Lower Patient Copays Act: A bill requiring health insurance plans to apply certain payments, including third-party payments, financial assistance, and product vouchers, toward a plan's cost-sharing requirements. This helps Parkinson's patients afford medications for managing symptoms. The Medicare Part D Six Protected Classes Policy: Requires Part D plans to cover all drugs in six protected classes, including antidepressants and antipsychotics. For individuals with Parkinson's disease, these medications are crucial for managing non-motor symptoms such as depression and psychosis. H.R.4752/S.2379 - CHANGE Act of 2023: A bill to improve early screening, detection, and diagnosis of Alzheimer's and related dementias, including Parkinson's disease dementia, during Medicare wellness visits. H.R.4942/S.655 - Conrad State 30 and Physician Access Reauthorization Act: Reauthorizes the Conrad State 30 program and improves policies to address health care provider shortages, supporting neurological care for Parkinson's patients. H.R.8702/S.4532 - Improving Seniors Timely Access to Care Act: Establishes requirements regarding the use of prior authorization under Medicare Advantage plans. H.R.9233/S.- The HEALTHY Brains Act: Draft legislation to create a Centers of Excellence grant program within the National Institutes of Health to focus on the intersection between environmental risk factors and neurodegenerative diseases. H.R.8331/S. 4280 - Essential Caregivers Act of 2024: To amend titles XVIII and XIX of the Social Security Act to require skilled nursing facilities, nursing facilities, intermediate care facilities for the intellectually disabled, and inpatient rehabilitation facilities to permit essential caregivers access during any period in which regular visitation is restricted. General Outreach for Establishing an ""Office of Caregiver Health"": Supports the creation of an Office of Caregiver Health within the Department of Health and Human Services to address the needs of caregivers, particularly in relation to Parkinson's disease care.
National Plan to End Parkinson’s Act
Client: THE MICHAEL J. FOX FOUNDATION FOR PARKINSON'S RESEARCH · Firm: THE MICHAEL J. FOX FOUNDATION FOR PARKINSON'S RESEARCH
H.R.2365/S.1064 - National Plan to End Parkinson's Act: A bill to create an advisory council comprising members of federal agencies that support research, care, and services for Parkinson's disease, as well as patients, care partners, researchers, clinicians, and other non-federal experts, to ensure efficient and effective coordination among all federal entities responsible for managing, treating, and curing Parkinson's disease. General Parkinson's Disease Information: Covers symptoms, triggers, health coverage, health costs, social determinants of health, data collection, research, environmental risks, and health access for underserved communities, particularly through the CDC's National Neurological Conditions Surveillance System (NNCSS). H.R.2630/S.652/S.1339 - Safe Step Act: Requires group health plans to provide an exception process for any medication step therapy protocol to ensure that individuals living with Parkinson's disease can access treatments safely and efficiently. Establishing Parkinson's Disease ICD-10-CM Codes: Aims to assist in the coordination of care for Parkinson's patients who experience OFF episodes and to allow researchers to gather data to study disease progression. S.1544/H.R.1199 - Facilitating Innovative Nuclear Diagnostics Act of 2023: A bill to establish separate payment requirements for diagnostic radiopharmaceuticals, including DaTscans, which aid in confirming a Parkinson's diagnosis under the Medicare prospective payment system for hospital outpatient services. H.R.3432 - Telemental Health Care Access Act of 2023: Permanently removes Medicare's originating site requirements for mental health services furnished via telehealth. Parkinson's non-motor symptoms include mental health conditions, and many people with Parkinson's are Medicare beneficiaries who may face barriers due to in-person requirements. H.R.830/S.1375 - Help Ensure Lower Patient Copays Act: A bill requiring health insurance plans to apply certain payments, including third-party payments, financial assistance, and product vouchers, toward a plan's cost-sharing requirements. This helps Parkinson's patients afford medications for managing symptoms. The Medicare Part D Six Protected Classes Policy: Requires Part D plans to cover all drugs in six protected classes, including antidepressants and antipsychotics. For individuals with Parkinson's disease, these medications are crucial for managing non-motor symptoms such as depression and psychosis. H.R.4752/S.2379 - CHANGE Act of 2023: A bill to improve early screening, detection, and diagnosis of Alzheimer's and related dementias, including Parkinson's disease dementia, during Medicare wellness visits. H.R.4942/S.655 - Conrad State 30 and Physician Access Reauthorization Act: Reauthorizes the Conrad State 30 program and improves policies to address health care provider shortages, supporting neurological care for Parkinson's patients. H.R.8702/S.4532 - Improving Seniors Timely Access to Care Act: Establishes requirements regarding the use of prior authorization under Medicare Advantage plans. H.R.9233/S.- The HEALTHY Brains Act: Draft legislation to create a Centers of Excellence grant program within the National Institutes of Health to focus on the intersection between environmental risk factors and neurodegenerative diseases. General Outreach for Establishing an ""Office of Caregiver Health"": Supports the creation of an Office of Caregiver Health within the Department of Health and Human Services to address the needs of caregivers, particularly in relation to Parkinson's disease care.
National Plan to End Parkinson’s Act
Client: THE MICHAEL J. FOX FOUNDATION FOR PARKINSON'S RESEARCH · Firm: THE MICHAEL J. FOX FOUNDATION FOR PARKINSON'S RESEARCH
H.R.2365/S.1064 - National Plan to End Parkinson's Act: a bill to create an advisory council comprising members of federal agencies that support research, care, and services for Parkinsons, plus patients, care partners, researchers, clinicians, and other non-federal experts to ensure efficient and effective coordination among all federal entities with responsibility for managing, treating, and curing Parkinsons disease. General Parkinson's disease information about symptoms, triggers, health coverage, health costs, social determinants of health related to Parkinson's disease and data collection, research, environmental risks, and health access for underserved communities. Information related to prevalence particularly at CDC's National Neurological Conditions Surveillance System (NNCSS). H.R.2630/S.652/S.1339 - Safe Step Act: a bill to require group health plans to provide an exception process for any medication step therapy protocol to help ensure that people living with Parkinson's disease can safely and efficiently access treatments. Establishing Parkinson's disease ICD-10-CM codes to assist in the continuation and coordination of care for people living with Parkinson's who experience OFF episodes and to allow researchers to gather more data to study the progression of the disease. Reauthorization of CDCs National Neurological Conditions Surveillance System (NNCSS). S.1544/H.R.1199 - Facilitating Innovative Nuclear Diagnostics Act of 2023: a bill to establish separate payment requirements for diagnostic radiopharmaceuticals, including DaTscans, which can aid in confirming a Parkinson's diagnosis, under the Medicare prospective payment system for hospital outpatient department services. H.R.3432 - Telemental Health Care Access Act of 2023: a bill to permanently remove Medicare's originating site requirements for mental health services furnished via telehealth. Parkinson's non-motor symptoms encompass mental health conditions, including anxiety, depression, dementia, and other memory problems, and the majority of people living with Parkinson's in the United States are Medicare beneficiaries, many of whom will face undue burdens meeting the unnecessary in-person requirement for telemental health services after the delay of the requirement enforcement expires December 31, 2024. H.R.830/S.1375 - Help Ensure Lower Patient Copays Act: a bill to require health insurance plans to apply certain payments made by, or on behalf of, a plan enrollee toward a plan's cost-sharing requirements. Specifically, plans must apply third-party payments, financial assistance, discounts, product vouchers, and other reductions in out-of-pocket expenses toward the requirements. Many Parkinson's patients rely on such third-party payments to afford medications to treat and manage their disease symptoms, and this legislation will ensure that all payments whether they come directly out of a pocket or with the help of copay assistance-counts toward out-of-pocket costs of patients. The Medicare Part D Six Protected Classes Policy: requires Part D plan to cover all drugs in six classes: immunosuppressants, antidepressants, antipsychotics, anticonvulsants, antiretrovirals, and antineoplastics. For people living with Parkinson's, most of whom are Medicare beneficiaries, it is essential to have access to wide range of treatment options for antidepressants and antipsychotics. Parkinson's causes non-motor symptoms, including depression and psychosis, and individuals often experience different side effects, reactions, and efficacy based on which medications they take. H.R.4752/S.2379 - the Concentrating High-value Alzheimer's Needs to Get to an End (CHANGE) Act of 2023: a bill to better utilize the existing Welcome to Medicare initial exam and Medicare annual wellness visits to screen, detect, and diagnose Alzheimers and related dementias, including Parkinson's disease dementia, in their earliest stages. Signed Leaders Engaged on Alzheimer's Disease (LEAD) Coalition letter to members of Congress in support of this legislation. H.R.4942/S.655 - the Conrad State 30 and Physician Access Reauthorization Act: a bill to reauthorize the Conrad State 30 program for three years, make several targeted policy improvements, and permit the gradual expansion of the number of waivers granted to each state to address health care provider shortages. Signed American Academy of Neurology letter to member of Congress in support of this legislation. The Medicare Part D Six Protected Classes Policy: requires Part D plan to cover all drugs in six classes: immunosuppressants, antidepressants, antipsychotics, anticonvulsants, antiretrovirals, and antineoplastics. For people living with Parkinson's, most of whom are Medicare beneficiaries, it is essential to have access to wide range of treatment options for antidepressants and antipsychotics. Parkinson's causes non-motor symptoms, including depression and psychosis, and individuals often experience different side effects, reactions, and efficacy based on which medications they take. Partnership for Part D Access coalition congressional meetings and signed coalition letter to CMS in response to Medicare Prescription Payment Plan Part One Guidance in support of continued protection for the six protected classes policy. Signed Medicare Access for Prescription Rx (MAPRx) coalition comment letter in response to Medicare Prescription Payment Plan Part One Guidance. Signed Patient and Provider Advocates for Telehealth coalition comment letter in response to CMS CY 2024 Medicare Physician Fee Schedule (PFS) in support prioritizing the needs of patients by expanding policies that improved access to safe and timely health care via telehealth. Signed Alliance for Aging Research coalition letter in response to Medicare Prescription Payment Plan Part One Guidance in support of proposed beneficiary protections and to provide feedback on implementation considerations for the Medicare Prescription Payment Plan program.
National Plan to End Parkinson’s Act
Client: THE MICHAEL J. FOX FOUNDATION FOR PARKINSON'S RESEARCH · Firm: THE MICHAEL J. FOX FOUNDATION FOR PARKINSON'S RESEARCH
H.R.2365/S.1064 - National Plan to End Parkinson's Act: a bill to create an advisory council comprising members of federal agencies that support research, care, and services for Parkinsons, plus patients, care partners, researchers, clinicians, and other non-federal experts to ensure efficient and effective coordination among all federal entities with responsibility for managing, treating, and curing Parkinsons disease. General Parkinson's disease information about symptoms, triggers, health coverage, health costs, social determinants of health related to Parkinson's disease and data collection, research, environmental risks, and health access for underserved communities. Information related to prevalence particularly at CDC's National Neurological Conditions Surveillance System (NNCSS). H.R.2630/S.652/S.1339 - Safe Step Act: a bill to require group health plans to provide an exception process for any medication step therapy protocol to help ensure that people living with Parkinson's disease can safely and efficiently access treatments. Establishing Parkinson's disease ICD-10-CM codes to assist in the continuation and coordination of care for people living with Parkinson's who experience OFF episodes and to allow researchers to gather more data to study the progression of the disease. Reauthorization of CDCs National Neurological Conditions Surveillance System (NNCSS). S.1544/H.R.1199 - Facilitating Innovative Nuclear Diagnostics Act of 2023: a bill to establish separate payment requirements for diagnostic radiopharmaceuticals, including DaTscans, which can aid in confirming a Parkinson's diagnosis, under the Medicare prospective payment system for hospital outpatient department services. H.R.3432 - Telemental Health Care Access Act of 2023: a bill to permanently remove Medicare's originating site requirements for mental health services furnished via telehealth. Parkinson's non-motor symptoms encompass mental health conditions, including anxiety, depression, dementia, and other memory problems, and the majority of people living with Parkinson's in the United States are Medicare beneficiaries, many of whom will face undue burdens meeting the unnecessary in-person requirement for telemental health services after the delay of the requirement enforcement expires December 31, 2024. H.R.830/S.1375 - Help Ensure Lower Patient Copays Act: a bill to require health insurance plans to apply certain payments made by, or on behalf of, a plan enrollee toward a plan's cost-sharing requirements. Specifically, plans must apply third-party payments, financial assistance, discounts, product vouchers, and other reductions in out-of-pocket expenses toward the requirements. Many Parkinson's patients rely on such third-party payments to afford medications to treat and manage their disease symptoms, and this legislation will ensure that all payments whether they come directly out of a pocket or with the help of copay assistance-counts toward out-of-pocket costs of patients. The Medicare Part D Six Protected Classes Policy: requires Part D plan to cover all drugs in six classes: immunosuppressants, antidepressants, antipsychotics, anticonvulsants, antiretrovirals, and antineoplastics. For people living with Parkinson's, most of whom are Medicare beneficiaries, it is essential to have access to wide range of treatment options for antidepressants and antipsychotics. Parkinson's causes non-motor symptoms, including depression and psychosis, and individuals often experience different side effects, reactions, and efficacy based on which medications they take. H.R.4752/S.2379 - the Concentrating High-value Alzheimer's Needs to Get to an End (CHANGE) Act of 2023: a bill to better utilize the existing Welcome to Medicare initial exam and Medicare annual wellness visits to screen, detect, and diagnose Alzheimers and related dementias, including Parkinson's disease dementia, in their earliest stages. Signed Leaders Engaged on Alzheimer's Disease (LEAD) Coalition letter to members of Congress in support of this legislation. H.R.4942/S.655 - the Conrad State 30 and Physician Access Reauthorization Act: a bill to reauthorize the Conrad State 30 program for three years, make several targeted policy improvements, and permit the gradual expansion of the number of waivers granted to each state to address health care provider shortages. Signed American Academy of Neurology letter to member of Congress in support of this legislation. The Medicare Part D Six Protected Classes Policy: requires Part D plan to cover all drugs in six classes: immunosuppressants, antidepressants, antipsychotics, anticonvulsants, antiretrovirals, and antineoplastics. For people living with Parkinson's, most of whom are Medicare beneficiaries, it is essential to have access to wide range of treatment options for antidepressants and antipsychotics. Parkinson's causes non-motor symptoms, including depression and psychosis, and individuals often experience different side effects, reactions, and efficacy based on which medications they take. Partnership for Part D Access coalition congressional meetings and signed coalition letter to CMS in response to Medicare Prescription Payment Plan Part One Guidance in support of continued protection for the six protected classes policy. Signed Medicare Access for Prescription Rx (MAPRx) coalition comment letter in response to Medicare Prescription Payment Plan Part One Guidance. Signed Patient and Provider Advocates for Telehealth coalition comment letter in response to CMS CY 2024 Medicare Physician Fee Schedule (PFS) in support prioritizing the needs of patients by expanding policies that improved access to safe and timely health care via telehealth. Signed Alliance for Aging Research coalition letter in response to Medicare Prescription Payment Plan Part One Guidance in support of proposed beneficiary protections and to provide feedback on implementation considerations for the Medicare Prescription Payment Plan program. H.R.8702/S.4532 - Improving Seniors Timely Access to Care Act: a bill to establish requirements with respect to the use of prior authorization under Medicare Advantage plans. H.R./S.- The HEALTHY Brains Act- draft legislation to create a Centers of Excellence grant program within the National Institute of Health to focus on the intersection between environmental risk factors and neurodegenerative disease. General outreach and support for the establishment of an "Office of Caregiver Health" within the Office of the Secretary at the Department of Health and Human Services.
Pharmacy Benefit Manager Reform Act
Client: THE MICHAEL J. FOX FOUNDATION FOR PARKINSON'S RESEARCH · Firm: THE MICHAEL J. FOX FOUNDATION FOR PARKINSON'S RESEARCH
Lobbying to Improve Prescription Drug Affordability and Accessibility: Advocacy for people living with Parkinson's via Medicare Part D redesign and benefits, including expanding the low-income subsidy (LIS) program, capping out-of-pocket costs, implementing a smoothing mechanism, and streamlining utilization management processes. Medicare Part D Six Protected Classes Policy: Requires Part D plans to cover all drugs in six classes: immunosuppressants, antidepressants, antipsychotics, anticonvulsants, antiretrovirals, and antineoplastics. Access to a wide range of treatment options for antidepressants and antipsychotics is essential for Parkinson's patients due to non-motor symptoms such as depression and psychosis. Advocacy includes coalition meetings and letters to CMS in response to Medicare Prescription Payment Plan Part One Guidance to support continued protection for the six protected classes. H.R.2360/S.652/S.1339 - Safe Step Act: A bill requiring group health plans to provide an exception process for any medication step therapy protocol to ensure that Parkinson's patients can access treatments safely and efficiently. Led a digital campaign to allow constituents to write to members of Congress in support of the legislation. H.R.830/S.1375 - Help Ensure Lower Patient Copays Act: This bill requires health insurance plans to apply third-party payments, financial assistance, discounts, and other reductions in out-of-pocket expenses toward a plan's cost-sharing requirements. Many Parkinson's patients rely on such payments to afford medications, and this legislation ensures they count toward out-of-pocket costs. S.1544/H.R.1199 - Facilitating Innovative Nuclear Diagnostics Act of 2023: A bill to establish separate payment requirements for diagnostic radiopharmaceuticals, including DaTscans, under the Medicare prospective payment system for hospital outpatient department services. This will help confirm Parkinson's diagnoses more efficiently. CMS-1809-P (2025 Medicare Outpatient Prospective Payment System Proposed Rule): Supported CMS's proposal to separate payment for certain diagnostic radiopharmaceuticals, including those used to diagnose Parkinson's disease and atypical parkinsonisms, from the procedure payment and reimburse them separately. H.R.8702/S.4532 - Improving Seniors Timely Access to Care Act: A bill to establish requirements regarding the use of prior authorization under Medicare Advantage plans. Lobbying CMS: Advocacy efforts to direct Durable Medical Equipment Medicare Administrative Contractors to provide clarification on the use of claim modifiers for DME therapies administered via an external infusion pump to expedite patient access to new Parkinson's therapies once they are approved by the FDA.
Lobbying to increase the affordability and accessibility of treatments for Parkinsons disease. Alleviating Barriers for Caregivers (ABC) Act (to be reintroduced): requires the Centers for Medicare & Medicaid Services (CMS) and Social Security to simplify processes and communications for family caregivers to assist individuals in accessing and utilizing benefits.
General Education on Parkinson's Risk Factors: Focused on raising awareness about triggers and risks of Parkinson's disease, including exposure to TCE, paraquat, air pollution, and other environmental chemicals. Banning environmental risk factors of Parkinsons disease, including paraquat.
Funding for implementation of Dr. Emmanuel Bilirakis and Honorable Jennifer Wexton National Plan to End Parkinsons Act (Public Law No: 118-66). Funding for discretionary, non-defense priorities including overall investment in the National Institute of Health, ARPA-H, and Centers for Disease Control and Prevention within the FY 2025 Labor, Health and Human Services, Education, and Related Agencies Appropriation bills. Funding for the Parkinson's Research Program (PRP) under the Department of Defense's Congressionally Directed Medical Research Programs (CDMRP) within the FY 2025 and FY 2026 Defense Appropriation bills. Funding for the Parkinsons Disease Research, Education and Clinical Centers under the Department of Veterans Affairs within the FY 2025 and FY 2026 Military Construction, Veterans Affairs and Related Agencies Appropriation bills. Funding for the National Neurological Conditions Surveillance System under the Centers for Disease Control and Prevention within the FY 2025 and FY 2026 Labor, Health and Human Services, Education, and Related Agencies Appropriation bills.
Increasing the affordability and accessibility of treatments for Parkinsons disease.
General education on the importance of the Department of Defense medical research programs for military service personnel and Veterans living with Parkinson's disease.
Lobbying to ban the use of known environmental risk factors of Parkinsons disease, including Trichloroethylene (TCE) and paraquat, in the United States. S.J.Res.19/H.J.Res.27/ H.J.Res.34 - A joint resolution providing for congressional disapproval under chapter 8 of title 5, United States Code, of the rule submitted by the Environmental Protection Agency relating to ""Trichloroethylene (TCE); Regulation Under the Toxic Substances Control Act (TSCA)"" The Harmonizing Environmental Analyses and Launching Therapeutic Hubs to Yield Bolstered Research And Innovation in Neurological Science (HEALTHY BRAINS) Act (to be reintroduced): creates a Centers of Excellence grant program within the National Institutes of Health to conduct and support of research, training, and health information dissemination with respect to environmental risk factors of neurodegenerative diseases, including Parkinsons disease.
Clinical Trials Modernization Act (to be reintroduced): seeks to improve participation in clinical research trials by removing economic barriers faced by patients. The legislation would allow HHS to issue grants or enter in contractual arrangements to support education, outreach, and recruitment for clinical trials and address financial barriers faced by patients, including excluding renumeration for participation in clinical trials from taxable income. Credit for Caring Act (to be reintroduced): seeks to amend the Internal Revenue Code of 1986 to provide a nonrefundable credit for working family caregivers.
Filing targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Defense, Dept of (DOD), Environmental Protection Agency (EPA), Food & Drug Administration (FDA), General Services Administration (GSA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Institutes of Health (NIH), Office of Science & Technology Policy (OSTP), President of the U.S., SENATE, Veterans Affairs, Dept of (VA), White House Office
THE MICHAEL J. FOX FOUNDATION FOR PARKINSON'S RESEARCH via THE MICHAEL J. FOX FOUNDATION FOR PARKINSON'S RESEARCH
2024 · fourth_quarter · Q4
Lobbying to Improve Prescription Drug Affordability and Accessibility: Advocacy for people living with Parkinson's via Medicare Part D redesign and benefits, including expanding the low-income subsidy (LIS) program, capping out-of-pocket costs, implementing a smoothing mechanism, and streamlining utilization management processes. Medicare Part D Six Protected Classes Policy: Requires Part D plans to cover all drugs in six classes: immunosuppressants, antidepressants, antipsychotics, anticonvulsants, antiretrovirals, and antineoplastics. Access to a wide range of treatment options for antidepressants and antipsychotics is essential for Parkinson's patients due to non-motor symptoms such as depression and psychosis. Advocacy includes coalition meetings and letters to CMS in response to Medicare Prescription Payment Plan Part One Guidance to support continued protection for the six protected classes. H.R.2360/S.652/S.1339 - Safe Step Act: A bill requiring group health plans to provide an exception process for any medication step therapy protocol to ensure that Parkinson's patients can access treatments safely and efficiently. Led a digital campaign to allow constituents to write to members of Congress in support of the legislation. H.R.830/S.1375 - Help Ensure Lower Patient Copays Act: This bill requires health insurance plans to apply third-party payments, financial assistance, discounts, and other reductions in out-of-pocket expenses toward a plan's cost-sharing requirements. Many Parkinson's patients rely on such payments to afford medications, and this legislation ensures they count toward out-of-pocket costs. S.1544/H.R.1199 - Facilitating Innovative Nuclear Diagnostics Act of 2023: A bill to establish separate payment requirements for diagnostic radiopharmaceuticals, including DaTscans, under the Medicare prospective payment system for hospital outpatient department services. This will help confirm Parkinson's diagnoses more efficiently. CMS-1809-P (2025 Medicare Outpatient Prospective Payment System Proposed Rule): Supported CMS's proposal to separate payment for certain diagnostic radiopharmaceuticals, including those used to diagnose Parkinson's disease and atypical parkinsonisms, from the procedure payment and reimburse them separately. H.R.8702/S.4532 - Improving Seniors Timely Access to Care Act: A bill to establish requirements regarding the use of prior authorization under Medicare Advantage plans. Lobbying CMS: Advocacy efforts to direct Durable Medical Equipment Medicare Administrative Contractors to provide clarification on the use of claim modifiers for DME therapies administered via an external infusion pump to expedite patient access to new Parkinson's therapies once they are approved by the FDA.
Advocating for a ban on Trichloroethylene (TCE) and paraquat. H.R.9233 - The Harmonizing Environmental Analyses and Launching Therapeutic Hubs to Yield Bolstered Research And Innovation in Neurological Science (HEALTHY BRAINS) Act of 2024 - a bill to create a Centers of Excellence grant program within the National Institute of Health to focus on the intersection between environmental risk factors and neurodegenerative disease. Efforts to ban paraquat.
General education on the importance of the Department of Defense medical research programs for military service personnel and Veterans living with Parkinson's disease. H.R.8774/ S.4921: FY25 Defense Appropriations bills to support increased funding for DOD Congressionally Directed Medical Research Programs Parkinson's Research Program. H.R.542/S.141 - The Elizabeth Dole Home Care Act: Increases access to home care and caregiver programs provided by the Department of Veterans Affairs (VA) and seeks to address VA home health workforce shortages. Inclusion of Parkinson's disease and PD-related diseases as presumptive conditions when military Veterans are exposed to associated toxins. H.R.8580 / S.4677 - FY25 Military Construction, Veterans Affairs and Related Agencies Appropriations bill: Supports increased funding for the VA's Parkinson's Disease Research, Education and Clinical Center as part of Neurology Centers of Excellence. General education regarding the importance of the Department of Defense medical research programs for military service personnel and Veterans living with Parkinson's disease.
General Education on Parkinson's Risk Factors: Focused on raising awareness about triggers and risks of Parkinson's disease, including exposure to TCE, paraquat, air pollution, and other environmental chemicals. H.R.9233/S. - The HEALTHY BRAINS Act: Draft legislation to create a Centers of Excellence grant program within the National Institutes of Health to focus on the intersection between environmental risk factors and neurodegenerative diseases. Supporting FDA Neurology Drug Program Funding: Advocacy for funding through the FY 2025 Agriculture Appropriations bills (H.R. 9027, S. 4690) and the Labor, Health and Human Services FY 2025 Appropriations bill (not yet filed). S.269 - Protect America's Children from Toxic Pesticides Act (PACTPA): Legislation focused on protecting children from harmful pesticides, including those linked to Parkinson's. S.806 - The Healthy H2O Act: A bill that addresses concerns about water quality and its effects on health, relevant to Parkinsons disease prevention. Neurodegenerative Disease Center of Excellence: Ongoing development of a legislative proposal to create a center at the National Institute of Environmental Health Sciences (NIEHS) to focus on neurodegenerative diseases like Parkinsons. Efforts to ban paraquat.
H.R.2365/S.1064 - National Plan to End Parkinson's Act: A bill to create an advisory council comprising members of federal agencies that support research, care, and services for Parkinson's disease, as well as patients, care partners, researchers, clinicians, and other non-federal experts, to ensure efficient and effective coordination among all federal entities responsible for managing, treating, and curing Parkinson's disease. General Parkinson's Disease Information: Covers symptoms, triggers, health coverage, health costs, social determinants of health, data collection, research, environmental risks, and health access for underserved communities, particularly through the CDC's National Neurological Conditions Surveillance System (NNCSS). H.R.2630/S.652/S.1339 - Safe Step Act: Requires group health plans to provide an exception process for any medication step therapy protocol to ensure that individuals living with Parkinson's disease can access treatments safely and efficiently. Establishing Parkinson's Disease ICD-10-CM Codes: Aims to assist in the coordination of care for Parkinson's patients who experience OFF episodes and to allow researchers to gather data to study disease progression. S.1544/H.R.1199 - Facilitating Innovative Nuclear Diagnostics Act of 2023: A bill to establish separate payment requirements for diagnostic radiopharmaceuticals, including DaTscans, which aid in confirming a Parkinson's diagnosis under the Medicare prospective payment system for hospital outpatient services. H.R.3432 - Telemental Health Care Access Act of 2023: Permanently removes Medicare's originating site requirements for mental health services furnished via telehealth. Parkinson's non-motor symptoms include mental health conditions, and many people with Parkinson's are Medicare beneficiaries who may face barriers due to in-person requirements. H.R.830/S.1375 - Help Ensure Lower Patient Copays Act: A bill requiring health insurance plans to apply certain payments, including third-party payments, financial assistance, and product vouchers, toward a plan's cost-sharing requirements. This helps Parkinson's patients afford medications for managing symptoms. The Medicare Part D Six Protected Classes Policy: Requires Part D plans to cover all drugs in six protected classes, including antidepressants and antipsychotics. For individuals with Parkinson's disease, these medications are crucial for managing non-motor symptoms such as depression and psychosis. H.R.4752/S.2379 - CHANGE Act of 2023: A bill to improve early screening, detection, and diagnosis of Alzheimer's and related dementias, including Parkinson's disease dementia, during Medicare wellness visits. H.R.4942/S.655 - Conrad State 30 and Physician Access Reauthorization Act: Reauthorizes the Conrad State 30 program and improves policies to address health care provider shortages, supporting neurological care for Parkinson's patients. H.R.8702/S.4532 - Improving Seniors Timely Access to Care Act: Establishes requirements regarding the use of prior authorization under Medicare Advantage plans. H.R.9233/S.- The HEALTHY Brains Act: Draft legislation to create a Centers of Excellence grant program within the National Institutes of Health to focus on the intersection between environmental risk factors and neurodegenerative diseases. H.R.8331/S. 4280 - Essential Caregivers Act of 2024: To amend titles XVIII and XIX of the Social Security Act to require skilled nursing facilities, nursing facilities, intermediate care facilities for the intellectually disabled, and inpatient rehabilitation facilities to permit essential caregivers access during any period in which regular visitation is restricted. General Outreach for Establishing an ""Office of Caregiver Health"": Supports the creation of an Office of Caregiver Health within the Department of Health and Human Services to address the needs of caregivers, particularly in relation to Parkinson's disease care.
FY 2025 Appropriations bills including funding requests for Parkinson's research within: H.R.8774/ S.4921: The Department of Defense within the FY 2025 Defense Appropriation bill. Funding for the Parkinson's Research Program (PRP) under the Department of Defense's Congressionally Directed Medical Research Programs (CDMRP). H.R.9029/S.4942: The National Institute of Health and Centers for Disease Control and Prevention within the FY 2025 Labor, Health and Human Services, Education, and Related Agencies Appropriation bill. Possible funding to implement the National Plan to End Parkinson's Act (HR 2365/ PL 118-66) within LHHS appropriations. H.R.9027/ S.4690: The Food and Drug Administration within the FY 2025 Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriation bill. H.R.8580/ S.4677: The Department of Veterans Affairs within the FY 2025 Military Construction, Veterans Affairs, and Related Agencies Appropriation bill. Support funding for Neurology Centers of Excellence and medical care and research through Veterans Health Administration, including the Parkinson's Disease Research, Education and Clinical Centers. H.R.9029/S.4942: General advocacy in support of robust non-defense discretionary investments in Labor, Health and Human Services, Education and Related Agencies appropriations bill for FY 2025. Funding for discretionary, non-defense priorities including overall investment in the National Institute of Health, ARPA-H, and Centers for Disease Control and Prevention within the FY 2025 Labor, Health and Human Services, Education, and Related Agencies Appropriation bills. Funding for the Parkinson's Research Program (PRP) under the Department of Defense's Congressionally Directed Medical Research Programs (CDMRP). Increased funding for NIEHS (no bill introduced). H.R.9233: The HEALTHY BRAINS Act - developing support for implementation funding for centers of excellence within NIH.
Lobbying to Increase Prescription Drug Affordability and Accessibility: Advocacy for Medicare Part D redesign and benefits for people living with Parkinson's, including expanding the low-income subsidy (LIS) program, capping out-of-pocket costs, implementing a smoothing mechanism, and streamlining utilization management processes. The Medicare Part D Six Protected Classes Policy: Requires Part D plans to cover all drugs in six classes: immunosuppressants, antidepressants, antipsychotics, anticonvulsants, antiretrovirals, and antineoplastics. For people living with Parkinson's, most of whom are Medicare beneficiaries, it is essential to have access to a wide range of treatment options for antidepressants and antipsychotics, which are crucial for managing non-motor symptoms like depression and psychosis. Signed Coalition Letters: - Medicare Access for Prescription Rx (MAPRx): Comment letter in response to Medicare Prescription Payment Plan Part One Guidance. - Patient and Provider Advocates for Telehealth: Comment letter in response to CMS CY 2024 Medicare Physician Fee Schedule (PFS) supporting expanded access to telehealth. - Alliance for Aging Research: Coalition letter in response to Medicare Prescription Payment Plan Part One Guidance supporting proposed beneficiary protections. H.R.4752/S.2379 - CHANGE Act of 2023: A bill to better utilize existing Medicare wellness visits for early screening, detection, and diagnosis of Alzheimer's and related dementias, including Parkinson's disease dementia. S.1544/H.R.1199 - Facilitating Innovative Nuclear Diagnostics Act of 2023: A bill to establish separate payment requirements for diagnostic radiopharmaceuticals, including DaTscans used to confirm Parkinson's diagnoses, under the Medicare outpatient prospective payment system. CMS-1809-P (2025 Medicare OPPS Proposed Rule): Comment supporting CMS's proposal to separately reimburse certain diagnostic radiopharmaceuticals used in diagnosing Parkinson's disease and atypical parkinsonisms. H.R.8702/S.4532 - Improving Seniors' Timely Access to Care Act: Establishes requirements for the use of prior authorization under Medicare Advantage plans to ensure timely access to care for seniors, including those with Parkinson's. S.3109/H.R.8018 - Alleviating Barriers for Caregivers (ABC) Act: Requires the Centers for Medicare & Medicaid Services (CMS) and Social Security to simplify processes and communications for family caregivers to assist individuals in accessing and utilizing benefits. S.3766/H.R.7274 - Connecting Caregivers to Medicare Act: Amends the Social Security Act to provide outreach and education to Medicare beneficiaries and simplify access to information for family caregivers through 1-800-MEDICARE. Advocacy for Durable Medical Equipment (DME) Access: Lobbying CMS to direct Medicare contractors to clarify claims procedures for DME therapies requiring administration via external infusion pumps, ensuring quick access to new Parkinson's therapies after FDA approval. H.R.8331/S. 4280 - Essential Caregivers Act of 2024: To amend titles XVIII and XIX of the Social Security Act to require skilled nursing facilities, nursing facilities, intermediate care facilities for the intellectually disabled, and inpatient rehabilitation facilities to permit essential caregivers access during any period in which regular visitation is restricted.
Filing targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Defense, Dept of (DOD), Environmental Protection Agency (EPA), Food & Drug Administration (FDA), General Services Administration (GSA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Institutes of Health (NIH), Office of Science & Technology Policy (OSTP), President of the U.S., SENATE, Veterans Affairs, Dept of (VA), White House Office
THE MICHAEL J. FOX FOUNDATION FOR PARKINSON'S RESEARCH via THE MICHAEL J. FOX FOUNDATION FOR PARKINSON'S RESEARCH
2024 · third_quarter · Q3
Lobbying to Increase Prescription Drug Affordability and Accessibility: Advocacy for Medicare Part D redesign and benefits for people living with Parkinson's, including expanding the low-income subsidy (LIS) program, capping out-of-pocket costs, implementing a smoothing mechanism, and streamlining utilization management processes. The Medicare Part D Six Protected Classes Policy: Requires Part D plans to cover all drugs in six classes: immunosuppressants, antidepressants, antipsychotics, anticonvulsants, antiretrovirals, and antineoplastics. For people living with Parkinson's, most of whom are Medicare beneficiaries, it is essential to have access to a wide range of treatment options for antidepressants and antipsychotics, which are crucial for managing non-motor symptoms like depression and psychosis. Signed Coalition Letters: - Medicare Access for Prescription Rx (MAPRx): Comment letter in response to Medicare Prescription Payment Plan Part One Guidance. - Patient and Provider Advocates for Telehealth: Comment letter in response to CMS CY 2024 Medicare Physician Fee Schedule (PFS) supporting expanded access to telehealth. - Alliance for Aging Research: Coalition letter in response to Medicare Prescription Payment Plan Part One Guidance supporting proposed beneficiary protections. H.R.4752/S.2379 - CHANGE Act of 2023: A bill to better utilize existing Medicare wellness visits for early screening, detection, and diagnosis of Alzheimer's and related dementias, including Parkinson's disease dementia. S.1544/H.R.1199 - Facilitating Innovative Nuclear Diagnostics Act of 2023: A bill to establish separate payment requirements for diagnostic radiopharmaceuticals, including DaTscans used to confirm Parkinson's diagnoses, under the Medicare outpatient prospective payment system. CMS-1809-P (2025 Medicare OPPS Proposed Rule): Comment supporting CMS's proposal to separately reimburse certain diagnostic radiopharmaceuticals used in diagnosing Parkinson's disease and atypical parkinsonisms. H.R.8702/S.4532 - Improving Seniors' Timely Access to Care Act: Establishes requirements for the use of prior authorization under Medicare Advantage plans to ensure timely access to care for seniors, including those with Parkinson's. S.3109/H.R.8018 - Alleviating Barriers for Caregivers (ABC) Act: Requires the Centers for Medicare & Medicaid Services (CMS) and Social Security to simplify processes and communications for family caregivers to assist individuals in accessing and utilizing benefits. S.3766/H.R.7274 - Connecting Caregivers to Medicare Act: Amends the Social Security Act to provide outreach and education to Medicare beneficiaries and simplify access to information for family caregivers through 1-800-MEDICARE. Advocacy for Durable Medical Equipment (DME) Access: Lobbying CMS to direct Medicare contractors to clarify claims procedures for DME therapies requiring administration via external infusion pumps, ensuring quick access to new Parkinson's therapies after FDA approval.
General education on the importance of the Department of Defense medical research programs for military service personnel and Veterans living with Parkinson's disease. H.R.8774/ S.4921: FY25 Defense Appropriations bills to support increased funding for DOD Congressionally Directed Medical Research Programs Parkinson's Research Program. H.R.542/S.141 - The Elizabeth Dole Home Care Act: Increases access to home care and caregiver programs provided by the Department of Veterans Affairs (VA) and seeks to address VA home health workforce shortages. Inclusion of Parkinson's disease and PD-related diseases as presumptive conditions when military Veterans are exposed to associated toxins. H.R.8580 / S.4677 - FY25 Military Construction, Veterans Affairs and Related Agencies Appropriations bill: Supports increased funding for the VA's Parkinson's Disease Research, Education and Clinical Center as part of Neurology Centers of Excellence. General education regarding the importance of the Department of Defense medical research programs for military service personnel and Veterans living with Parkinson's disease.
H.R.2365/S.1064 - National Plan to End Parkinson's Act: A bill to create an advisory council comprising members of federal agencies that support research, care, and services for Parkinson's disease, as well as patients, care partners, researchers, clinicians, and other non-federal experts, to ensure efficient and effective coordination among all federal entities responsible for managing, treating, and curing Parkinson's disease. General Parkinson's Disease Information: Covers symptoms, triggers, health coverage, health costs, social determinants of health, data collection, research, environmental risks, and health access for underserved communities, particularly through the CDC's National Neurological Conditions Surveillance System (NNCSS). H.R.2630/S.652/S.1339 - Safe Step Act: Requires group health plans to provide an exception process for any medication step therapy protocol to ensure that individuals living with Parkinson's disease can access treatments safely and efficiently. Establishing Parkinson's Disease ICD-10-CM Codes: Aims to assist in the coordination of care for Parkinson's patients who experience OFF episodes and to allow researchers to gather data to study disease progression. S.1544/H.R.1199 - Facilitating Innovative Nuclear Diagnostics Act of 2023: A bill to establish separate payment requirements for diagnostic radiopharmaceuticals, including DaTscans, which aid in confirming a Parkinson's diagnosis under the Medicare prospective payment system for hospital outpatient services. H.R.3432 - Telemental Health Care Access Act of 2023: Permanently removes Medicare's originating site requirements for mental health services furnished via telehealth. Parkinson's non-motor symptoms include mental health conditions, and many people with Parkinson's are Medicare beneficiaries who may face barriers due to in-person requirements. H.R.830/S.1375 - Help Ensure Lower Patient Copays Act: A bill requiring health insurance plans to apply certain payments, including third-party payments, financial assistance, and product vouchers, toward a plan's cost-sharing requirements. This helps Parkinson's patients afford medications for managing symptoms. The Medicare Part D Six Protected Classes Policy: Requires Part D plans to cover all drugs in six protected classes, including antidepressants and antipsychotics. For individuals with Parkinson's disease, these medications are crucial for managing non-motor symptoms such as depression and psychosis. H.R.4752/S.2379 - CHANGE Act of 2023: A bill to improve early screening, detection, and diagnosis of Alzheimer's and related dementias, including Parkinson's disease dementia, during Medicare wellness visits. H.R.4942/S.655 - Conrad State 30 and Physician Access Reauthorization Act: Reauthorizes the Conrad State 30 program and improves policies to address health care provider shortages, supporting neurological care for Parkinson's patients. H.R.8702/S.4532 - Improving Seniors Timely Access to Care Act: Establishes requirements regarding the use of prior authorization under Medicare Advantage plans. H.R.9233/S.- The HEALTHY Brains Act: Draft legislation to create a Centers of Excellence grant program within the National Institutes of Health to focus on the intersection between environmental risk factors and neurodegenerative diseases. General Outreach for Establishing an ""Office of Caregiver Health"": Supports the creation of an Office of Caregiver Health within the Department of Health and Human Services to address the needs of caregivers, particularly in relation to Parkinson's disease care.
Advocating for a ban on Trichloroethylene (TCE) and paraquat. H.R.9233 - The Harmonizing Environmental Analyses and Launching Therapeutic Hubs to Yield Bolstered Research And Innovation in Neurological Science (HEALTHY BRAINS) Act of 2024 - a bill to create a Centers of Excellence grant program within the National Institute of Health to focus on the intersection between environmental risk factors and neurodegenerative disease.
FY 2025 Appropriations bills including funding requests for Parkinson's research within: H.R.8774/ S.4921: The Department of Defense within the FY 2025 Defense Appropriation bill. Funding for the Parkinson's Research Program (PRP) under the Department of Defense's Congressionally Directed Medical Research Programs (CDMRP). H.R.9029/S.4942: The National Institute of Health and Centers for Disease Control and Prevention within the FY 2025 Labor, Health and Human Services, Education, and Related Agencies Appropriation bill. Possible funding to implement the National Plan to End Parkinson's Act (HR 2365/ PL 118-66) within LHHS appropriations. H.R.9027/ S.4690: The Food and Drug Administration within the FY 2025 Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriation bill. H.R.8580/ S.4677: The Department of Veterans Affairs within the FY 2025 Military Construction, Veterans Affairs, and Related Agencies Appropriation bill. Support funding for Neurology Centers of Excellence and medical care and research through Veterans Health Administration, including the Parkinson's Disease Research, Education and Clinical Centers. H.R.9029/S.4942: General advocacy in support of robust non-defense discretionary investments in Labor, Health and Human Services, Education and Related Agencies appropriations bill for FY 2025. Funding for discretionary, non-defense priorities including overall investment in the National Institute of Health, ARPA-H, and Centers for Disease Control and Prevention within the FY 2025 Labor, Health and Human Services, Education, and Related Agencies Appropriation bills. Funding for the Parkinson's Research Program (PRP) under the Department of Defense's Congressionally Directed Medical Research Programs (CDMRP). Increased funding for NIEHS (no bill introduced).
Lobbying to Improve Prescription Drug Affordability and Accessibility: Advocacy for people living with Parkinson's via Medicare Part D redesign and benefits, including expanding the low-income subsidy (LIS) program, capping out-of-pocket costs, implementing a smoothing mechanism, and streamlining utilization management processes. Medicare Part D Six Protected Classes Policy: Requires Part D plans to cover all drugs in six classes: immunosuppressants, antidepressants, antipsychotics, anticonvulsants, antiretrovirals, and antineoplastics. Access to a wide range of treatment options for antidepressants and antipsychotics is essential for Parkinson's patients due to non-motor symptoms such as depression and psychosis. Advocacy includes coalition meetings and letters to CMS in response to Medicare Prescription Payment Plan Part One Guidance to support continued protection for the six protected classes. H.R.2360/S.652/S.1339 - Safe Step Act: A bill requiring group health plans to provide an exception process for any medication step therapy protocol to ensure that Parkinson's patients can access treatments safely and efficiently. Led a digital campaign to allow constituents to write to members of Congress in support of the legislation. H.R.830/S.1375 - Help Ensure Lower Patient Copays Act: This bill requires health insurance plans to apply third-party payments, financial assistance, discounts, and other reductions in out-of-pocket expenses toward a plan's cost-sharing requirements. Many Parkinson's patients rely on such payments to afford medications, and this legislation ensures they count toward out-of-pocket costs. S.1544/H.R.1199 - Facilitating Innovative Nuclear Diagnostics Act of 2023: A bill to establish separate payment requirements for diagnostic radiopharmaceuticals, including DaTscans, under the Medicare prospective payment system for hospital outpatient department services. This will help confirm Parkinson's diagnoses more efficiently. CMS-1809-P (2025 Medicare Outpatient Prospective Payment System Proposed Rule): Supported CMS's proposal to separate payment for certain diagnostic radiopharmaceuticals, including those used to diagnose Parkinson's disease and atypical parkinsonisms, from the procedure payment and reimburse them separately. H.R.8702/S.4532 - Improving Seniors Timely Access to Care Act: A bill to establish requirements regarding the use of prior authorization under Medicare Advantage plans. Lobbying CMS: Advocacy efforts to direct Durable Medical Equipment Medicare Administrative Contractors to provide clarification on the use of claim modifiers for DME therapies administered via an external infusion pump to expedite patient access to new Parkinson's therapies once they are approved by the FDA.
Filing targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Defense, Dept of (DOD), Environmental Protection Agency (EPA), Food & Drug Administration (FDA), General Services Administration (GSA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Institutes of Health (NIH), Office of Science & Technology Policy (OSTP), President of the U.S., SENATE, Veterans Affairs, Dept of (VA), White House Office
THE MICHAEL J. FOX FOUNDATION FOR PARKINSON'S RESEARCH via THE MICHAEL J. FOX FOUNDATION FOR PARKINSON'S RESEARCH
2024 · second_quarter · Q2
FY 2025 Appropriations bills including funding requests for Parkinson's research at: The Department of Defense within the FY 2025 Defense Appropriation bill. The National Institute of Health and Centers for Disease Control and Prevention within the FY 2025 Labor, Health and Human Services, Education, and Related Agencies Appropriation bill. The Food and Drug Administration within the FY 2025 Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriation bill. The Department of Veterans Affairs within the FY 2025 Military Construction, Veterans Affairs, and Related Agencies Appropriation bill. Increased funding for NIEHS (no bill introduced). The National Institute of Health and Centers for Disease Control and Prevention within the FY 2025 Labor, Health and Human Services, Education, and Related Agencies Appropriation bills. Funding for the Parkison's Research Program (PRP) under the Department of Defense's Congressionally Directed Medical Research Programs (CDMRP). FY 2025 Appropriations bills with investments relevant to Parkinson's research, including: The Department of Defense within the FY 2025 Defense Appropriation bill. Support funding for the Parkinson's Research Program (PRP) under the Department of Defense's Congressionally Directed Medical Research Programs (CDMRP). The Department of Veterans Affairs within the FY 2025 Military Construction, Veterans Affairs, and Related Agencies Appropriation bill. Support funding for Neurology Centers of Excellence and medical care and research through Veterans Health Administration. The National Institute of Health, ARPA-H and Centers for Disease Control and Prevention within the FY 2025 Labor, Health and Human Services, Education, and Related Agencies Appropriation bill. The Food and Drug Administration within the FY 2025 Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriation bill. General advocacy in support of robust non-defense discretionary investments in Labor, Health and Human Services, Education and Related Agencies appropriations bill for FY 2025.
Lobbying to increase prescription drug affordability and accessibility for people living with Parkinson's via Medicare Part D redesign and benefits, including expanding the low-income subsidy (LIS) program, capping out-of-pocket costs, implementing a smoothing mechanism, and streamlining utilization management processes. The Medicare Part D Six Protected Classes Policy: requires Part D plan to cover all drugs in six classes: immunosuppressants, antidepressants, antipsychotics, anticonvulsants, antiretrovirals, and antineoplastics. For people living with Parkinson's, most of whom are Medicare beneficiaries, it is essential to have access to wide range of treatment options for antidepressants and antipsychotics. Parkinson's causes non-motor symptoms, including depression and psychosis, and individuals often experience different side effects, reactions, and efficacy based on which medications they take. Partnership for Part D Access coalition congressional meetings and signed coalition letter to CMS in response to Medicare Prescription Payment Plan Part One Guidance in support of continued protection for the six protected classes policy. Signed Medicare Access for Prescription Rx (MAPRx) coalition comment letter in response to Medicare Prescription Payment Plan Part One Guidance. Signed Patient and Provider Advocates for Telehealth coalition comment letter in response to CMS CY 2024 Medicare Physician Fee Schedule (PFS) in support prioritizing the needs of patients by expanding policies that improved access to safe and timely health care via telehealth. Signed Alliance for Aging Research coalition letter in response to Medicare Prescription Payment Plan Part One Guidance in support of proposed beneficiary protections and to provide feedback on implementation considerations for the Medicare Prescription Payment Plan program. H.R.4752/S.2379 - the Concentrating High-value Alzheimer's Needs to Get to an End (CHANGE) Act of 2023: a bill to better utilize the existing Welcome to Medicare initial exam and Medicare annual wellness visits to screen, detect, and diagnose Alzheimers and related dementias, including Parkinson's disease dementia, in their earliest stages. Signed Leaders Engaged on Alzheimer's Disease (LEAD) Coalition letter to members of Congress in support of this legislation. S. 3109- Alleviating Barriers for Caregivers (ABC) Act- bill to require the Administrator of the Centers for Medicare & Medicaid Services and the Commissioner of Social Security to review and simplify the processes, procedures, forms, and communications for family caregivers to assist individuals in establishing eligibility for, enrolling in, and maintaining and utilizing coverage and benefits under the Medicare, Medicaid, CHIP, and Social Security programs respectively, and for other purposes. Lobbying the Centers for Medicare and Medicaid Services to direct Durable Medical Equipment Medicare Administrative Contractors to provide additional clarification regarding the use of claim modifiers for DME therapies that require administration via an external infusion pump to expedite patient access once new Parkinson's therapies receive approvals from the Food and Drug Administration. S.1544/H.R.1199 - Facilitating Innovative Nuclear Diagnostics Act of 2023: a bill to establish separate payment requirements for diagnostic radiopharmaceuticals, including DaTscans, which can aid in confirming a Parkinson's diagnosis, under the Medicare prospective payment system for hospital outpatient department services. S. 3766/H.R. 7274- Connecting Caregivers to Medicare Act -To amend title XVIII of the Social Security Act to provide for outreach and education to Medicare beneficiaries to simplify access to information for family caregivers through 1-800-MEDICARE, and for other purposes. H.R. 8018/S. 3109- Alleviating Barriers for Caregivers (ABC) Act- bill to require the Administrator of the Centers for Medicare & Medicaid Services and the Commissioner of Social Security to review and simplify the processes, procedures, forms, and communications for family caregivers to assist individuals in establishing eligibility for, enrolling in, and maintaining and utilizing coverage and benefits under the Medicare, Medicaid, CHIP, and Social Security programs respectively, and for other purposes. H.R.8702/S.4532 - Improving Seniors Timely Access to Care Act: a bill to establish requirements with respect to the use of prior authorization under Medicare Advantage plans.
Lobbying to improve prescription drug affordability and accessibility for people living with Parkinson's via Medicare Part D redesign and benefits, including expanding the low-income subsidy (LIS) program, capping out-of-pocket costs, implementing a smoothing mechanism, and streamlining utilization management processes. The Medicare Part D Six Protected Classes Policy: requires Part D plan to cover all drugs in six classes: immunosuppressants, antidepressants, antipsychotics, anticonvulsants, antiretrovirals, and antineoplastics. For people living with Parkinson's, most of whom are Medicare beneficiaries, it is essential to have access to wide range of treatment options for antidepressants and antipsychotics. Parkinson's causes non-motor symptoms, including depression and psychosis, and individuals often experience different side effects, reactions, and efficacy based on which medications they take. Partnership for Part D Access coalition congressional meetings and signed coalition letter to CMS in response to Medicare Prescription Payment Plan Part One Guidance in support of continued protection for the six protected classes policy. Signed Medicare Access for Prescription Rx (MAPRx) coalition comment letter in response to Medicare Prescription Payment Plan Part One Guidance. Signed Alliance for Aging Research coalition letter in response to Medicare Prescription Payment Plan Part One Guidance in support of proposed beneficiary protections and to provide feedback on implementation considerations for the Medicare Prescription Payment Plan program. H.R.2360/S.652/S.1339 - Safe Step Act: a bill to require group health plans to provide an exception process for any medication step therapy protocol to help ensure that people living with Parkinson's disease can safely and efficiently access treatments. Led a digital campaign to allow constituents to write their members of Congress in support of this legislation. Lobbying the Centers for Medicare and Medicaid Services to direct Durable Medical Equipment Medicare Administrative Contractors to provide additional clarification regarding the use of claim modifiers for DME therapies that require administration via an external infusion pump to expedite patient access once new Parkinson's therapies receive approvals from the Food and Drug Administration. Lobbying the Centers for Medicare and Medicaid Services to direct Durable Medical Equipment Medicare Administrative Contractors to provide additional clarification regarding the use of claim modifiers for DME therapies that require administration via an external infusion pump to expedite patient access once new Parkinson's therapies receive approvals from the Food and Drug Administration. H.R.2360/S.652/S.1339 - Safe Step Act: a bill to require group health plans to provide an exception process for any medication step therapy protocol to help ensure that people living with Parkinson's disease can safely and efficiently access treatments. Led an digital campaign to allow constituents to write their members of Congress in support of this legislation. H.R.8702/S.4532 - Improving Seniors Timely Access to Care Act: a bill to establish requirements with respect to the use of prior authorization under Medicare Advantage plans. H.R.830/S.1375 - Help Ensure Lower Patient Copays Act: a bill to require health insurance plans to apply certain payments made by, or on behalf of, a plan enrollee toward a plan's cost-sharing requirements. Specifically, plans must apply third-party payments, financial assistance, discounts, product vouchers, and other reductions in out-of-pocket expenses toward the requirements. Many Parkinson's patients rely on such third-party payments to afford medications to treat and manage their disease symptoms, and this legislation will ensure that all payments whether they come directly out of a pocket or with the help of copay assistance-counts toward out-of-pocket costs of patients. S.1544/H.R.1199 - Facilitating Innovative Nuclear Diagnostics Act of 2023: a bill to establish separate payment requirements for diagnostic radiopharmaceuticals, including DaTscans, which can aid in confirming a Parkinson's diagnosis, under the Medicare prospective payment system for hospital outpatient department services.
H.R.2365/S.1064 - National Plan to End Parkinson's Act: a bill to create an advisory council comprising members of federal agencies that support research, care, and services for Parkinsons, plus patients, care partners, researchers, clinicians, and other non-federal experts to ensure efficient and effective coordination among all federal entities with responsibility for managing, treating, and curing Parkinsons disease. General Parkinson's disease information about symptoms, triggers, health coverage, health costs, social determinants of health related to Parkinson's disease and data collection, research, environmental risks, and health access for underserved communities. Information related to prevalence particularly at CDC's National Neurological Conditions Surveillance System (NNCSS). H.R.2630/S.652/S.1339 - Safe Step Act: a bill to require group health plans to provide an exception process for any medication step therapy protocol to help ensure that people living with Parkinson's disease can safely and efficiently access treatments. Establishing Parkinson's disease ICD-10-CM codes to assist in the continuation and coordination of care for people living with Parkinson's who experience OFF episodes and to allow researchers to gather more data to study the progression of the disease. Reauthorization of CDCs National Neurological Conditions Surveillance System (NNCSS). S.1544/H.R.1199 - Facilitating Innovative Nuclear Diagnostics Act of 2023: a bill to establish separate payment requirements for diagnostic radiopharmaceuticals, including DaTscans, which can aid in confirming a Parkinson's diagnosis, under the Medicare prospective payment system for hospital outpatient department services. H.R.3432 - Telemental Health Care Access Act of 2023: a bill to permanently remove Medicare's originating site requirements for mental health services furnished via telehealth. Parkinson's non-motor symptoms encompass mental health conditions, including anxiety, depression, dementia, and other memory problems, and the majority of people living with Parkinson's in the United States are Medicare beneficiaries, many of whom will face undue burdens meeting the unnecessary in-person requirement for telemental health services after the delay of the requirement enforcement expires December 31, 2024. H.R.830/S.1375 - Help Ensure Lower Patient Copays Act: a bill to require health insurance plans to apply certain payments made by, or on behalf of, a plan enrollee toward a plan's cost-sharing requirements. Specifically, plans must apply third-party payments, financial assistance, discounts, product vouchers, and other reductions in out-of-pocket expenses toward the requirements. Many Parkinson's patients rely on such third-party payments to afford medications to treat and manage their disease symptoms, and this legislation will ensure that all payments whether they come directly out of a pocket or with the help of copay assistance-counts toward out-of-pocket costs of patients. The Medicare Part D Six Protected Classes Policy: requires Part D plan to cover all drugs in six classes: immunosuppressants, antidepressants, antipsychotics, anticonvulsants, antiretrovirals, and antineoplastics. For people living with Parkinson's, most of whom are Medicare beneficiaries, it is essential to have access to wide range of treatment options for antidepressants and antipsychotics. Parkinson's causes non-motor symptoms, including depression and psychosis, and individuals often experience different side effects, reactions, and efficacy based on which medications they take. H.R.4752/S.2379 - the Concentrating High-value Alzheimer's Needs to Get to an End (CHANGE) Act of 2023: a bill to better utilize the existing Welcome to Medicare initial exam and Medicare annual wellness visits to screen, detect, and diagnose Alzheimers and related dementias, including Parkinson's disease dementia, in their earliest stages. Signed Leaders Engaged on Alzheimer's Disease (LEAD) Coalition letter to members of Congress in support of this legislation. H.R.4942/S.655 - the Conrad State 30 and Physician Access Reauthorization Act: a bill to reauthorize the Conrad State 30 program for three years, make several targeted policy improvements, and permit the gradual expansion of the number of waivers granted to each state to address health care provider shortages. Signed American Academy of Neurology letter to member of Congress in support of this legislation. The Medicare Part D Six Protected Classes Policy: requires Part D plan to cover all drugs in six classes: immunosuppressants, antidepressants, antipsychotics, anticonvulsants, antiretrovirals, and antineoplastics. For people living with Parkinson's, most of whom are Medicare beneficiaries, it is essential to have access to wide range of treatment options for antidepressants and antipsychotics. Parkinson's causes non-motor symptoms, including depression and psychosis, and individuals often experience different side effects, reactions, and efficacy based on which medications they take. Partnership for Part D Access coalition congressional meetings and signed coalition letter to CMS in response to Medicare Prescription Payment Plan Part One Guidance in support of continued protection for the six protected classes policy. Signed Medicare Access for Prescription Rx (MAPRx) coalition comment letter in response to Medicare Prescription Payment Plan Part One Guidance. Signed Patient and Provider Advocates for Telehealth coalition comment letter in response to CMS CY 2024 Medicare Physician Fee Schedule (PFS) in support prioritizing the needs of patients by expanding policies that improved access to safe and timely health care via telehealth. Signed Alliance for Aging Research coalition letter in response to Medicare Prescription Payment Plan Part One Guidance in support of proposed beneficiary protections and to provide feedback on implementation considerations for the Medicare Prescription Payment Plan program. H.R.8702/S.4532 - Improving Seniors Timely Access to Care Act: a bill to establish requirements with respect to the use of prior authorization under Medicare Advantage plans. H.R./S.- The HEALTHY Brains Act- draft legislation to create a Centers of Excellence grant program within the National Institute of Health to focus on the intersection between environmental risk factors and neurodegenerative disease. General outreach and support for the establishment of an "Office of Caregiver Health" within the Office of the Secretary at the Department of Health and Human Services.
FY25 Military Construction, Veterans Affairs and Related Agencies Appropriations bill to support increased funding for the VA's Parkinson's Disease Research, Education and Clinical Center. General education regarding the importance of the Department of Defense medical research programs for military service personnel and Veterans living with Parkinson's disease. Inclusion of Parkinson's disease and PD-related diseases as presumptive conditions when military Veterans are exposed to associated toxins. FY24 and FY25 Defense Appropriations bills to support increased funding for DOD Congressionally Directed Medical Research Programs Parkinson's Research Program. H.R.542/S.141 -The Elizabeth Dole Home Care Act- increases access to home care and caregiver programs provided by the Department of Veterans Affairs (VA) and seeks to address VA home health workforce shortages. H.R. 8580 / Senate bill not filed - FY25 Military Construction, Veterans Affairs and Related Agencies Appropriations bill to support increased funding for the VA's Parkinson's Disease Research, Education and Clinical Center as part of Neurology Centers of Excellence. H.R. 8774/ Senate bill not yet filed - FY25 Defense Appropriations bills to support increased funding for DOD Congressionally Directed Medical Research Programs Parkinson's Research Program. General education regarding the importance of the Department of Defense medical research programs for military service personnel and Veterans living with Parkinson's disease. Inclusion of Parkinson's disease and PD-related diseases as presumptive conditions when military Veterans are exposed to associated toxins.
Filing targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Defense, Dept of (DOD), Environmental Protection Agency (EPA), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Institutes of Health (NIH), President of the U.S., SENATE, Veterans Affairs, Dept of (VA)
THE MICHAEL J. FOX FOUNDATION FOR PARKINSON'S RESEARCH via THE MICHAEL J. FOX FOUNDATION FOR PARKINSON'S RESEARCH
2024 · first_quarter · Q1
FY 2024 Appropriations bills including funding requests for Parkinson's research at: H.R.4365/S.2587 - The Department of Defense within the FY 2024 Defense Appropriation bill. H.R.5894/S.2624 - The National Institute of Health and Centers for Disease Control and Prevention within the FY 2024 Labor, Health and Human Services, Education, and Related Agencies Appropriation bill. H.R.4368/S.2131 - The Food and Drug Administration within the FY 2024 Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriation bill. H.R.4366/S.2127 - The Department of Veterans Affairs within the FY 2024 Military Construction, Veterans Affairs, and Related Agencies Appropriation bill. Increased funding for NIEHS (no bill introduced). Funding for the Parkinson's Research Program (PRP) under the Department of Defense's Congressionally Directed Medical Research Programs (CDMRP).
H.R.4366/S.2127 - FY24 Military Construction, Veterans Affairs and Related Agencies Appropriations bill to support increased funding for the VA's Parkinson's Disease Research, Education and Clinical Center. FY24 (H.R.4365/S.2587) and FY25 Defense Appropriations bills to support increased funding for DOD Congressionally Directed Medical Research Programs Parkinson's Research Program. General education regarding the importance of the Department of Defense medical research programs for military service personnel and Veterans living with Parkinson's disease. Inclusion of Parkinson's disease and PD-related diseases as presumptive conditions when military Veterans are exposed to associated toxins.
H.R.2365/S.1064 - National Plan to End Parkinson's Act: a bill to create an advisory council comprising members of federal agencies that support research, care, and services for Parkinsons, plus patients, care partners, researchers, clinicians, and other non-federal experts to ensure efficient and effective coordination among all federal entities with responsibility for managing, treating, and curing Parkinsons disease. General Parkinson's disease information about symptoms, triggers, health coverage, health costs, social determinants of health related to Parkinson's disease and data collection, research, environmental risks, and health access for underserved communities. Information related to prevalence particularly at CDC's National Neurological Conditions Surveillance System (NNCSS). H.R.2630/S.652/S.1339 - Safe Step Act: a bill to require group health plans to provide an exception process for any medication step therapy protocol to help ensure that people living with Parkinson's disease can safely and efficiently access treatments. Establishing Parkinson's disease ICD-10-CM codes to assist in the continuation and coordination of care for people living with Parkinson's who experience OFF episodes and to allow researchers to gather more data to study the progression of the disease. Reauthorization of CDCs National Neurological Conditions Surveillance System (NNCSS). S.1544/H.R.1199 - Facilitating Innovative Nuclear Diagnostics Act of 2023: a bill to establish separate payment requirements for diagnostic radiopharmaceuticals, including DaTscans, which can aid in confirming a Parkinson's diagnosis, under the Medicare prospective payment system for hospital outpatient department services. H.R.3432 - Telemental Health Care Access Act of 2023: a bill to permanently remove Medicare's originating site requirements for mental health services furnished via telehealth. Parkinson's non-motor symptoms encompass mental health conditions, including anxiety, depression, dementia, and other memory problems, and the majority of people living with Parkinson's in the United States are Medicare beneficiaries, many of whom will face undue burdens meeting the unnecessary in-person requirement for telemental health services after the delay of the requirement enforcement expires December 31, 2024. H.R.830/S.1375 - Help Ensure Lower Patient Copays Act: a bill to require health insurance plans to apply certain payments made by, or on behalf of, a plan enrollee toward a plan's cost-sharing requirements. Specifically, plans must apply third-party payments, financial assistance, discounts, product vouchers, and other reductions in out-of-pocket expenses toward the requirements. Many Parkinson's patients rely on such third-party payments to afford medications to treat and manage their disease symptoms, and this legislation will ensure that all payments whether they come directly out of a pocket or with the help of copay assistance-counts toward out-of-pocket costs of patients. The Medicare Part D Six Protected Classes Policy: requires Part D plan to cover all drugs in six classes: immunosuppressants, antidepressants, antipsychotics, anticonvulsants, antiretrovirals, and antineoplastics. For people living with Parkinson's, most of whom are Medicare beneficiaries, it is essential to have access to wide range of treatment options for antidepressants and antipsychotics. Parkinson's causes non-motor symptoms, including depression and psychosis, and individuals often experience different side effects, reactions, and efficacy based on which medications they take. H.R.4752/S.2379 - the Concentrating High-value Alzheimer's Needs to Get to an End (CHANGE) Act of 2023: a bill to better utilize the existing Welcome to Medicare initial exam and Medicare annual wellness visits to screen, detect, and diagnose Alzheimers and related dementias, including Parkinson's disease dementia, in their earliest stages. Signed Leaders Engaged on Alzheimer's Disease (LEAD) Coalition letter to members of Congress in support of this legislation. H.R.4942/S.655 - the Conrad State 30 and Physician Access Reauthorization Act: a bill to reauthorize the Conrad State 30 program for three years, make several targeted policy improvements, and permit the gradual expansion of the number of waivers granted to each state to address health care provider shortages. Signed American Academy of Neurology letter to member of Congress in support of this legislation. The Medicare Part D Six Protected Classes Policy: requires Part D plan to cover all drugs in six classes: immunosuppressants, antidepressants, antipsychotics, anticonvulsants, antiretrovirals, and antineoplastics. For people living with Parkinson's, most of whom are Medicare beneficiaries, it is essential to have access to wide range of treatment options for antidepressants and antipsychotics. Parkinson's causes non-motor symptoms, including depression and psychosis, and individuals often experience different side effects, reactions, and efficacy based on which medications they take. Partnership for Part D Access coalition congressional meetings and signed coalition letter to CMS in response to Medicare Prescription Payment Plan Part One Guidance in support of continued protection for the six protected classes policy. Signed Medicare Access for Prescription Rx (MAPRx) coalition comment letter in response to Medicare Prescription Payment Plan Part One Guidance. Signed Patient and Provider Advocates for Telehealth coalition comment letter in response to CMS CY 2024 Medicare Physician Fee Schedule (PFS) in support prioritizing the needs of patients by expanding policies that improved access to safe and timely health care via telehealth. Signed Alliance for Aging Research coalition letter in response to Medicare Prescription Payment Plan Part One Guidance in support of proposed beneficiary protections and to provide feedback on implementation considerations for the Medicare Prescription Payment Plan program.
Filing targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Defense, Dept of (DOD), Environmental Protection Agency (EPA), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Natl Institutes of Health (NIH), SENATE, Veterans Affairs, Dept of (VA)
THE MICHAEL J. FOX FOUNDATION FOR PARKINSON'S RESEARCH via THE MICHAEL J. FOX FOUNDATION FOR PARKINSON'S RESEARCH
2023 · fourth_quarter · Q4
FY 2024 Appropriations bills including funding requests for Parkinson's research at: The Department of Defense within the FY 2024 Defense Appropriation bill (no bill introduced); The National Institute of Health and Centers for Disease Control and Prevention within the FY 2024 Labor, Health and Human Services, Education, and Related Agencies Appropriation bill (no bill introduced); The Food and Drug Administration within the FY 2024 Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriation bill (no bill introduced); The Department of Veterans Affairs within the FY 2024 Military Construction, Veterans Affairs, and Related Agencies Appropriation bill (no bill introduced). Increased funding for NIEHS (no bill introduced).
FY24 Military Construction, Veterans Affairs and Related Agencies Appropriations bill to support increased funding for the VA's Parkinson's Disease Research, Education and Clinical Center. General education regarding the importance of the Department of Defense medical research programs for military service personnel and Veterans living with Parkinson's disease. Inclusion of Parkinson's disease and PD-related diseases as presumptive conditions when military Veterans are exposed to associated toxins.
THE MICHAEL J. FOX FOUNDATION FOR PARKINSON'S RESEARCH via THE MICHAEL J. FOX FOUNDATION FOR PARKINSON'S RESEARCH
2023 · third_quarter · Q3
FY 2024 Appropriations bills including funding requests for Parkinson's research at: The Department of Defense within the FY 2024 Defense Appropriation bill (H.R.4365/S.2927); The National Institute of Health and Centers for Disease Control and Prevention within the FY 2024 Labor, Health and Human Services, Education, and Related Agencies Appropriation bill (H.R.5894); The Food and Drug Administration within the FY 2024 Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriation bill (H.R.4368/S.2131); The Department of Veterans Affairs within the FY 2024 Military Construction, Veterans Affairs, and Related Agencies Appropriation bill (H.R.4366/S.2127). Increased funding for NIEHS (no bill introduced).
FY24 Military Construction, Veterans Affairs and Related Agencies Appropriations bill (H.R.4366/S.2127) to support increased funding for the VA's Parkinson's Disease Research, Education and Clinical Center. General education regarding the importance of the Department of Defense medical research programs for military service personnel and Veterans living with Parkinson's disease. Inclusion of Parkinson's disease and PD-related diseases as presumptive conditions when military Veterans are exposed to associated toxins.
THE MICHAEL J. FOX FOUNDATION FOR PARKINSON'S RESEARCH via THE MICHAEL J. FOX FOUNDATION FOR PARKINSON'S RESEARCH
2023 · second_quarter · Q2
H.R.2365/S.1064 - National Plan to End Parkinson's Act: a bill to create an advisory council comprising members of federal agencies that support research, care, and services for Parkinsons, plus patients, care partners, researchers, clinicians, and other non-federal experts to ensure efficient and effective coordination among all federal entities with responsibility for managing, treating, and curing Parkinsons disease. General Parkinson's disease information about symptoms, triggers, health coverage, health costs, social determinants of health related to Parkinson's disease and data collection, research, environmental risks, and health access for underserved communities. Information related to prevalence particularly at CDC's National Neurological Conditions Surveillance System (NNCSS). S.652/S.1339 - Safe Step Act: a bill to require group health plans to provide an exception process for any medication step therapy protocol to help ensure that people living with Parkinson's disease can safely and efficiently access treatments. Establishing Parkinson's disease ICD-10-CM codes to assist in the continuation and coordination of care for people living with Parkinson's who experience OFF episodes and to allow researchers to gather more data to study the progression of the disease. Reauthorization of CDCs National Neurological Conditions Surveillance System (NNCSS). S.1544/H.R.1199 - Facilitating Innovative Nuclear Diagnostics Act of 2023: a bill to establish separate payment requirements for diagnostic radiopharmaceuticals, including DaTscans, which can aid in confirming a Parkinson's diagnosis, under the Medicare prospective payment system for hospital outpatient department services. H.R.3432 - Telemental Health Care Access Act of 2023: a bill to permanently remove Medicare's originating site requirements for mental health services furnished via telehealth. Parkinson's non-motor symptoms encompass mental health conditions, including anxiety, depression, dementia, and other memory problems, and the majority of people living with Parkinson's in the United States are Medicare beneficiaries, many of whom will face undue burdens meeting the unnecessary in-person requirement for telemental health services after the delay of the requirement enforcement expires December 31, 2024. H.R.830/S.1375 - Help Ensure Lower Patient Copays Act: a bill to require health insurance plans to apply certain payments made by, or on behalf of, a plan enrollee toward a plan's cost-sharing requirements. Specifically, plans must apply third-party payments, financial assistance, discounts, product vouchers, and other reductions in out-of-pocket expenses toward the requirements. Many Parkinson's patients rely on such third-party payments to afford medications to treat and manage their disease symptoms, and this legislation will ensure that all payments whether they come directly out of a pocket or with the help of copay assistance-counts toward out-of-pocket costs of patients. The Medicare Part D Six Protected Classes Policy: requires Part D plan to cover all drugs in six classes: immunosuppressants, antidepressants, antipsychotics, anticonvulsants, antiretrovirals, and antineoplastics. For people living with Parkinson's, most of whom are Medicare beneficiaries, it is essential to have access to wide range of treatment options for antidepressants and antipsychotics. Parkinson's causes non-motor symptoms, including depression and psychosis, and individuals often experience different side effects, reactions, and efficacy based on which medications they take.
THE MICHAEL J. FOX FOUNDATION FOR PARKINSON'S RESEARCH via THE MICHAEL J. FOX FOUNDATION FOR PARKINSON'S RESEARCH
2023 · first_quarter · Q1
H.R.2365/S.1064 - National Plan to End Parkinson's Act: a bill to create an advisory council comprising members of federal agencies that support research, care, and services for Parkinsons, plus patients, care partners, researchers, clinicians, and other non-federal experts to ensure efficient and effective coordination among all federal entities with responsibility for managing, treating, and curing Parkinsons disease. General Parkinson's disease information about symptoms, triggers, health coverage, health costs, social determinants of health related to Parkinson's disease and data collection, research, environmental risks, and health access for underserved communities. Information related to prevalence particularly at CDC's National Neurological Conditions Surveillance System (NNCSS). S.652 - Safe Step Act: a bill to require group health plans to provide an exception process for any medication step therapy protocol to help ensure that people living with Parkinson's disease can safely and efficiently access treatments. Establishing Parkinson's disease ICD-10-CM codes to assist in the continuation and coordination of care for people living with Parkinson's who experience OFF episodes and to allow researchers to gather more data to study the progression of the disease. Reauthorization of CDCs National Neurological Conditions Surveillance System (NNCSS).
THE MICHAEL J. FOX FOUNDATION FOR PARKINSON'S RESEARCH via THE MICHAEL J. FOX FOUNDATION FOR PARKINSON'S RESEARCH
2022 · fourth_quarter · Q4
General education regarding environmental triggers of neurological disease and Parkinson's along with support for more research. S. 3283, the Protect America's Children from Toxic Pesticides Act (PACTPA)
FY 2022 Appropriation bills including Parkinson's research funding requests for: Department of Defense National Institute of Health Centers for Disease Control and Prevention Food and Drug Administration FY 2023 Appropriations bills including Parkinson's research funding requests for: Department of Defense National Institute of Health Centers for Disease Control and Prevention Food and Drug Administration Department of Veterans Affairs H.R.2617 Consolidated Appropriations Act, 2023 H.R.5376 Inflation Reduction Act of 2022
THE MICHAEL J. FOX FOUNDATION FOR PARKINSON'S RESEARCH via THE MICHAEL J. FOX FOUNDATION FOR PARKINSON'S RESEARCH
2022 · third_quarter · Q3
General education regarding the importance of the Department of Defense medical research programs for military service personnel and Veterans living with Parkinson's disease. Inclusion of Parkinson's disease and PD-related diseases as presumptive conditions when military Veterans are exposed to associated toxins Support for VA's Parkinson's Disease Research, Education and Clinical Center H.R. 3967, the Honoring Our PACT Act and associated legislation H.R. 6774, the Boxing Therapy for Parkinson's Access Act of 2022 H.R. 6659/S. 3541, the Health Care for Burn Pit Veterans Act
Expanding Medicare benefits to include dental, hearing, and vision Extending and making permanent COVID-19 telehealth flexibilities Increasing drug affordability and accessibility via drug pricing, Medicare Part D redesign and benefits, capping out-of-pocket costs and smoothing, and streamlining prior authorization processes Advocating for improvements to Medicare Part C and Part D proposed rule Inflation Reduction Act of 2022 H.R. 4417, the Capping Drug Costs for Seniors Act S. 2327, the Seniors Prescription Drug Relief Act S. 828/H.R. 432, the Mental Health Access Improvement Act of 2021 H.R. 2080, the Seniors Access to Vaccine Ensured Act of 2021 H.R. 3173/S. 3018, the Improving Seniors Timely Access to Care Act H.R. 4011, the Capping Drug Costs for Seniors Act of 2022 H.R. 4479/S. 2609, the Facilitating Innovative Nuclear Diagnostics (FIND) Act of 2021 S. 2061/H.R. 4058, the Telemental Health Care Access Act of 2021 S. 1512/H.R. 2903, the Creating Opportunities Now for Necessary and Effective Care Technologies (CONNECT) for Health Act of 2021 H.R. 1332/S. 368, the Telehealth Modernization Act H.R. 366, the Protecting Access to Post-COVID-19 Telehealth Act of 2021 H.R. 3733: Essential Caregivers Act of 2021 H.R. 6202, the Telehealth Extension Act of 2021 S. 3575, the Stop the Wait Act of 2022 S. 3593, the Telehealth Extension and Evaluation Act S. 3675, the Beneficiary Enrollment Notification and Eligibility Simplification (BENES) 2.0 Act H.R. 7051/S. 3791, the Access to Prescription Digital Therapeutics Act of 2022 H.R. 5375, the Inflation Reduction Act of 2022
THE MICHAEL J. FOX FOUNDATION FOR PARKINSON'S RESEARCH via THE MICHAEL J. FOX FOUNDATION FOR PARKINSON'S RESEARCH
2022 · second_quarter · Q2
General education on triggers of Parkinson's disease, including TCE, paraquat, and other chemicals. Supporting creation of Neuroscience Center of Excellence at FDA. S. 3427, the Neuroscience Center of Excellence Act H.R. 5435, the BRAIN Act H.R. 6000, the Cures 2.0 Act S. 3282, the Protect Americas Children from Toxic Pesticides Act H.R. 3967 Honoring our Promise to Address Comprehensive Toxics (PACT) Act and other associated legislation
General education regarding the importance of the Department of Defense medical research programs for military service personnel and Veterans living with Parkinson's disease. Inclusion of Parkinson's disease and PD-related diseases as presumptive conditions when military Veterans are exposed to associated toxins Support for VA's Parkinson's Disease Research, Education and Clinical Center H.R. 3967, the Honoring Our PACT Act and associated legislation H.R. 6774, the Boxing Therapy for Parkinson's Access Act of 2022 H.R. 6659/S. 3541, the Health Care for Burn Pit Veterans Act
THE MICHAEL J. FOX FOUNDATION FOR PARKINSON'S RESEARCH via THE MICHAEL J. FOX FOUNDATION FOR PARKINSON'S RESEARCH
2022 · first_quarter · Q1
General education regarding environmental triggers of neurological disease and support for more research. S. 3283, the Protect America's Children from Toxic Pesticides Act
FY 2022 Appropriation bills including Parkinson's research funding requests for: Department of Defense National Institute of Health Centers for Disease Control and Prevention Food and Drug Administration FY 2023 Appropriations bills including Parkinson's research funding requests for: Department of Defense National Institute of Health Centers for Disease Control and Prevention Food and Drug Administration Department of Veterans Affairs
THE MICHAEL J. FOX FOUNDATION FOR PARKINSON'S RESEARCH via THE MICHAEL J. FOX FOUNDATION FOR PARKINSON'S RESEARCH
2021 · fourth_quarter · Q4
FY 2022 Appropriation bills including funding requests for: Department of Defense National Institute of Health Centers for Disease Control and Prevention Food and Drug Administration
General education on triggers of Parkinson's disease, including TCE, paraquat, and other chemicals. Supporting creation of Neuroscience Center of Excellence at FDA. S.3427 Neuroscience Center of Excellence Act. H.R.5435 The BRAIN Act H.R.6000 Cures 2.0
General education around pharmaceuticals related to Parkinson's disease HR 5801 The HELP Copays Act Prescription Drug User Fee Act
THE MICHAEL J. FOX FOUNDATION FOR PARKINSON'S RESEARCH via THE MICHAEL J. FOX FOUNDATION FOR PARKINSON'S RESEARCH
2021 · third_quarter · Q3
FY 2022 Appropriation bills including funding requests for: Department of Defense National Institute of Health Centers for Disease Control and Prevention Food and Drug Administration
General education regarding environmental triggers of neurological disease and support for more research.
General education around pharmaceuticals related to Parkinson's disease
THE MICHAEL J. FOX FOUNDATION FOR PARKINSON'S RESEARCH via THE MICHAEL J. FOX FOUNDATION FOR PARKINSON'S RESEARCH
2021 · second_quarter · 2A
Funding for the 2022 Appropriations bill including requests for: Department of Defense National Institutes of Health Centers for Disease Control and Prevention Food and Drug Administration
General education on chemicals that trigger Parkinson's disease, including TCE, paraquat, and others.
Telehealth flexibilities and making current telehealth rules permanent Medicare Part D design and benefits, drug pricing principle S.464/H.R.2163, the Safe Step Act of 2021 S.828/H.R.432, the Mental Health Access Improvement Act H.R.2080, the Seniors Access to Vaccine Ensured Act H.R.3173 Improving Seniors Timely Access to Care S.2061 the Telemental Health Care Access Act
THE MICHAEL J. FOX FOUNDATION FOR PARKINSON'S RESEARCH via THE MICHAEL J. FOX FOUNDATION FOR PARKINSON'S RESEARCH
2021 · second_quarter · Q2
General education on chemicals that trigger Parkinson's disease, including TCE, paraquat, and others.
Funding for the 2022 Appropriations bill including requests for: Department of Defense National Institutes of Health Centers for Disease Control and Prevention Food and Drug Administration
Telehealth flexibilities and making current telehealth rules permanent Medicare Part D design and benefits, drug pricing principle S.464/H.R.2163, the Safe Step Act of 2021 S.828/H.R.432, the Mental Health Access Improvement Act H.R.2080, the Seniors Access to Vaccine Ensured Act H.R.3173 Improving Seniors Timely Access to Care S.2061 the Telemental Health Care Access Act
H.R.2365/S.1064 - National Plan to End Parkinson's Act: a bill to create an advisory council comprising members of federal agencies that support research, care, and services for Parkinsons, plus patients, care partners, researchers, clinicians, and other non-federal experts to ensure efficient and effective coordination among all federal entities with responsibility for managing, treating, and curing Parkinsons disease. General Parkinson's disease information about symptoms, triggers, health coverage, health costs, social determinants of health related to Parkinson's disease and data collection, research, environmental risks, and health access for underserved communities. Information related to prevalence particularly at CDC's National Neurological Conditions Surveillance System (NNCSS). S.652/S.1339 - Safe Step Act: a bill to require group health plans to provide an exception process for any medication step therapy protocol to help ensure that people living with Parkinson's disease can safely and efficiently access treatments. Establishing Parkinson's disease ICD-10-CM codes to assist in the continuation and coordination of care for people living with Parkinson's who experience OFF episodes and to allow researchers to gather more data to study the progression of the disease. Reauthorization of CDCs National Neurological Conditions Surveillance System (NNCSS). S.1544/H.R.1199 - Facilitating Innovative Nuclear Diagnostics Act of 2023: a bill to establish separate payment requirements for diagnostic radiopharmaceuticals, including DaTscans, which can aid in confirming a Parkinson's diagnosis, under the Medicare prospective payment system for hospital outpatient department services. H.R.3432 - Telemental Health Care Access Act of 2023: a bill to permanently remove Medicare's originating site requirements for mental health services furnished via telehealth. Parkinson's non-motor symptoms encompass mental health conditions, including anxiety, depression, dementia, and other memory problems, and the majority of people living with Parkinson's in the United States are Medicare beneficiaries, many of whom will face undue burdens meeting the unnecessary in-person requirement for telemental health services after the delay of the requirement enforcement expires December 31, 2024. H.R.830/S.1375 - Help Ensure Lower Patient Copays Act: a bill to require health insurance plans to apply certain payments made by, or on behalf of, a plan enrollee toward a plan's cost-sharing requirements. Specifically, plans must apply third-party payments, financial assistance, discounts, product vouchers, and other reductions in out-of-pocket expenses toward the requirements. Many Parkinson's patients rely on such third-party payments to afford medications to treat and manage their disease symptoms, and this legislation will ensure that all payments whether they come directly out of a pocket or with the help of copay assistance-counts toward out-of-pocket costs of patients. The Medicare Part D Six Protected Classes Policy: requires Part D plan to cover all drugs in six classes: immunosuppressants, antidepressants, antipsychotics, anticonvulsants, antiretrovirals, and antineoplastics. For people living with Parkinson's, most of whom are Medicare beneficiaries, it is essential to have access to wide range of treatment options for antidepressants and antipsychotics. Parkinson's causes non-motor symptoms, including depression and psychosis, and individuals often experience different side effects, reactions, and efficacy based on which medications they take. H.R.4752/S.2379 - the Concentrating High-value Alzheimer's Needs to Get to an End (CHANGE) Act of 2023: a bill to better utilize the existing Welcome to Medicare initial exam and Medicare annual wellness visits to screen, detect, and diagnose Alzheimers and related dementias, including Parkinson's disease dementia, in their earliest stages. Signed Leaders Engaged on Alzheimer's Disease (LEAD) Coalition letter to members of Congress in support of this legislation. H.R.4942/S.655 - the Conrad State 30 and Physician Access Reauthorization Act: a bill to reauthorize the Conrad State 30 program for three years, make several targeted policy improvements, and permit the gradual expansion of the number of waivers granted to each state to address health care provider shortages. Signed American Academy of Neurology letter to member of Congress in support of this legislation. The Medicare Part D Six Protected Classes Policy: requires Part D plan to cover all drugs in six classes: immunosuppressants, antidepressants, antipsychotics, anticonvulsants, antiretrovirals, and antineoplastics. For people living with Parkinson's, most of whom are Medicare beneficiaries, it is essential to have access to wide range of treatment options for antidepressants and antipsychotics. Parkinson's causes non-motor symptoms, including depression and psychosis, and individuals often experience different side effects, reactions, and efficacy based on which medications they take. Partnership for Part D Access coalition congressional meetings and signed coalition letter to CMS in response to Medicare Prescription Payment Plan Part One Guidance in support of continued protection for the six protected classes policy. Signed Medicare Access for Prescription Rx (MAPRx) coalition comment letter in response to Medicare Prescription Payment Plan Part One Guidance. Signed Patient and Provider Advocates for Telehealth coalition comment letter in response to CMS CY 2024 Medicare Physician Fee Schedule (PFS) in support prioritizing the needs of patients by expanding policies that improved access to safe and timely health care via telehealth. Signed Alliance for Aging Research coalition letter in response to Medicare Prescription Payment Plan Part One Guidance in support of proposed beneficiary protections and to provide feedback on implementation considerations for the Medicare Prescription Payment Plan program.
Filing targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Defense, Dept of (DOD), Environmental Protection Agency (EPA), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Natl Institutes of Health (NIH), SENATE, Veterans Affairs, Dept of (VA)
H.R.2365/S.1064 - National Plan to End Parkinson's Act: a bill to create an advisory council comprising members of federal agencies that support research, care, and services for Parkinsons, plus patients, care partners, researchers, clinicians, and other non-federal experts to ensure efficient and effective coordination among all federal entities with responsibility for managing, treating, and curing Parkinsons disease. General Parkinson's disease information about symptoms, triggers, health coverage, health costs, social determinants of health related to Parkinson's disease and data collection, research, environmental risks, and health access for underserved communities. Information related to prevalence particularly at CDC's National Neurological Conditions Surveillance System (NNCSS). S.652/S.1339 - Safe Step Act: a bill to require group health plans to provide an exception process for any medication step therapy protocol to help ensure that people living with Parkinson's disease can safely and efficiently access treatments. Establishing Parkinson's disease ICD-10-CM codes to assist in the continuation and coordination of care for people living with Parkinson's who experience OFF episodes and to allow researchers to gather more data to study the progression of the disease. Reauthorization of CDCs National Neurological Conditions Surveillance System (NNCSS). S.1544/H.R.1199 - Facilitating Innovative Nuclear Diagnostics Act of 2023: a bill to establish separate payment requirements for diagnostic radiopharmaceuticals, including DaTscans, which can aid in confirming a Parkinson's diagnosis, under the Medicare prospective payment system for hospital outpatient department services. H.R.3432 - Telemental Health Care Access Act of 2023: a bill to permanently remove Medicare's originating site requirements for mental health services furnished via telehealth. Parkinson's non-motor symptoms encompass mental health conditions, including anxiety, depression, dementia, and other memory problems, and the majority of people living with Parkinson's in the United States are Medicare beneficiaries, many of whom will face undue burdens meeting the unnecessary in-person requirement for telemental health services after the delay of the requirement enforcement expires December 31, 2024. H.R.830/S.1375 - Help Ensure Lower Patient Copays Act: a bill to require health insurance plans to apply certain payments made by, or on behalf of, a plan enrollee toward a plan's cost-sharing requirements. Specifically, plans must apply third-party payments, financial assistance, discounts, product vouchers, and other reductions in out-of-pocket expenses toward the requirements. Many Parkinson's patients rely on such third-party payments to afford medications to treat and manage their disease symptoms, and this legislation will ensure that all payments whether they come directly out of a pocket or with the help of copay assistance-counts toward out-of-pocket costs of patients. The Medicare Part D Six Protected Classes Policy: requires Part D plan to cover all drugs in six classes: immunosuppressants, antidepressants, antipsychotics, anticonvulsants, antiretrovirals, and antineoplastics. For people living with Parkinson's, most of whom are Medicare beneficiaries, it is essential to have access to wide range of treatment options for antidepressants and antipsychotics. Parkinson's causes non-motor symptoms, including depression and psychosis, and individuals often experience different side effects, reactions, and efficacy based on which medications they take. H.R.4752/S.2379 - the Concentrating High-value Alzheimer's Needs to Get to an End (CHANGE) Act of 2023: a bill to better utilize the existing Welcome to Medicare initial exam and Medicare annual wellness visits to screen, detect, and diagnose Alzheimers and related dementias, including Parkinson's disease dementia, in their earliest stages. Signed Leaders Engaged on Alzheimer's Disease (LEAD) Coalition letter to members of Congress in support of this legislation. H.R.4942/S.655 - the Conrad State 30 and Physician Access Reauthorization Act: a bill to reauthorize the Conrad State 30 program for three years, make several targeted policy improvements, and permit the gradual expansion of the number of waivers granted to each state to address health care provider shortages. Signed American Academy of Neurology letter to member of Congress in support of this legislation. The Medicare Part D Six Protected Classes Policy: requires Part D plan to cover all drugs in six classes: immunosuppressants, antidepressants, antipsychotics, anticonvulsants, antiretrovirals, and antineoplastics. For people living with Parkinson's, most of whom are Medicare beneficiaries, it is essential to have access to wide range of treatment options for antidepressants and antipsychotics. Parkinson's causes non-motor symptoms, including depression and psychosis, and individuals often experience different side effects, reactions, and efficacy based on which medications they take. Partnership for Part D Access coalition congressional meetings and signed coalition letter to CMS in response to Medicare Prescription Payment Plan Part One Guidance in support of continued protection for the six protected classes policy. Signed Medicare Access for Prescription Rx (MAPRx) coalition comment letter in response to Medicare Prescription Payment Plan Part One Guidance. Signed Patient and Provider Advocates for Telehealth coalition comment letter in response to CMS CY 2024 Medicare Physician Fee Schedule (PFS) in support prioritizing the needs of patients by expanding policies that improved access to safe and timely health care via telehealth. Signed Alliance for Aging Research coalition letter in response to Medicare Prescription Payment Plan Part One Guidance in support of proposed beneficiary protections and to provide feedback on implementation considerations for the Medicare Prescription Payment Plan program.
Filing targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Environmental Protection Agency (EPA), HOUSE OF REPRESENTATIVES, Natl Institutes of Health (NIH), SENATE, Veterans Affairs, Dept of (VA)
FY 2024 Appropriations bills including funding requests for Parkinson's research at: The Department of Defense within the FY 2024 Defense Appropriation bill (H.R.4365); The National Institute of Health and Centers for Disease Control and Prevention within the FY 2024 Labor, Health and Human Services, Education, and Related Agencies Appropriation bill (no bill introduced); The Food and Drug Administration within the FY 2024 Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriation bill (H.R.4368); The Department of Veterans Affairs within the FY 2024 Military Construction, Veterans Affairs, and Related Agencies Appropriation bill (S.2127).
FY24 Military Construction, Veterans Affairs and Related Agencies Appropriations bill to support increased funding for the VA's Parkinson's Disease Research, Education and Clinical Center. General education regarding the importance of the Department of Defense medical research programs for military service personnel and Veterans living with Parkinson's disease. Inclusion of Parkinson's disease and PD-related diseases as presumptive conditions when military Veterans are exposed to associated toxins.
Filing targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Environmental Protection Agency (EPA), HOUSE OF REPRESENTATIVES, Natl Institutes of Health (NIH), SENATE, Veterans Affairs, Dept of (VA)
FY24 Military Construction, Veterans Affairs and Related Agencies Appropriations bill to support increased funding for the VA's Parkinson's Disease Research, Education and Clinical Center. General education regarding the importance of the Department of Defense medical research programs for military service personnel and Veterans living with Parkinson's disease. Inclusion of Parkinson's disease and PD-related diseases as presumptive conditions when military Veterans are exposed to associated toxins.
FY 2024 Appropriations bills including funding requests for Parkinson's research at: The Department of Defense within the FY 2024 Defense Appropriation bill (no bill introduced); The National Institute of Health and Centers for Disease Control and Prevention within the FY 2024 Labor, Health and Human Services, Education, and Related Agencies Appropriation bill (no bill introduced); The Food and Drug Administration within the FY 2024 Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriation bill (no bill introduced); The Department of Veterans Affairs within the FY 2024 Military Construction, Veterans Affairs, and Related Agencies Appropriation bill (no bill introduced).
Filing targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Environmental Protection Agency (EPA), HOUSE OF REPRESENTATIVES, Natl Institutes of Health (NIH), SENATE, Veterans Affairs, Dept of (VA)
Expanding dental health coverage in Medicare by clarifying CMS's interpretation of the statutory dental exclusion. Expanding access to health care for people living with Parkinson's via telehealth by removing Medicare telehealth geographic and originating site restrictions, extending coverage and reimbursement for health care providers who bill Medicare for providing services via telehealth (including seeing new patients and audio-only telehealth for clinically appropriate services/visits), ensuring payment parity for telehealth and in-person services, and removing Medicare in-person requirements for accessing mental health services via telehealth. H.R. 2617, Consolidated Appropriations Act, 2023; S. 2061/H.R. 4058, Telemental Health Care Access Act of 2021; CY 2023 Payment Policies Under the Physician Fee Schedule and Other Changes to Part B Payment Policies Increasing drug affordability and accessibility for people living with Parkinsons via drug pricing, Medicare Part D redesign and benefits, capping out-of-pocket costs and smoothing, and streamlining prior authorization processes. H.R. 5375, Inflation Reduction Act of 2022; H.R. 4417, Capping Drug Costs for Seniors Act; S. 4011, Capping Drug Costs for Seniors Act of 2022 Establishing separate Medicare payment requirements for diagnostic radiopharmaceuticals, including DaTscans, so health care providers are adequately reimbursed for furnishing diagnostic tests to help validate patients Parkinsons diagnoses. S. 2609/H.R. 4479, Facilitating Innovative Nuclear Diagnostics (FIND) Act of 2021 H.R. 3733: Essential Caregivers Act of 2021
General education around pharmaceuticals related to Parkinson's disease. Increasing drug affordability and accessibility for people living with Parkinsons via drug pricing, Medicare Part D redesign and benefits, capping out-of-pocket costs and smoothing, and streamlining prior authorization processes. H.R. 5375, Inflation Reduction Act of 2022; H.R. 4417, Capping Drug Costs for Seniors Act; S. 4011, Capping Drug Costs for Seniors Act of 2022. S. 464/H.R. 2163, the Safe Step Act - to amend the Employee Retirement Income Security Act of 1974 (ERISA) to require a group health plan or health insurance coverage offered in connection with such a plan to provide an exceptions process for any medication step therapy protocol to enable people living with Parkinsons disease to access the medications they need to best manage their disease Establishing separate Medicare payment requirements for diagnostic radiopharmaceuticals, including DaTscans, so health care providers are adequately reimbursed for furnishing diagnostic tests to help validate patients Parkinsons diagnoses. S. 2609/H.R. 4479, Facilitating Innovative Nuclear Diagnostics (FIND) Act of 2021
General education regarding the importance of the Department of Defense medical research programs for military service personnel and Veterans living with Parkinson's disease. Inclusion of Parkinson's disease and PD-related diseases as presumptive conditions when military Veterans are exposed to associated toxins. Support for VA's Parkinson's Disease Research, Education and Clinical Center H.R. 3967, the Honoring Our PACT Act and associated legislation H.R. 6774, the Boxing Therapy for Parkinson's Access Act of 2022 H.R. 6659/S. 3541, the Health Care for Burn Pit Veterans Act
General education on triggers of Parkinson's disease, including TCE, paraquat, and other chemicals. Supporting creation of Neuroscience Center of Excellence at FDA. S. 3427, the Neuroscience Center of Excellence Act H.R. 5435, the BRAIN (Bringing Regulatory Advances Into Neuroscience Act of 2021 H.R. 6000, the Cures 2.0 Act S. 3282, the Protect Americas Children from Toxic Pesticides Act (PACTPA) H.R. 3967 / S. 3373 Honoring our Promise to Address Comprehensive Toxics (PACT) Act and other associated legislation
Filing targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Defense, Dept of (DOD), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Justice, Dept of (DOJ), Natl Institutes of Health (NIH), Office of Science & Technology Policy (OSTP), SENATE, Veterans Affairs, Dept of (VA)
General education on triggers of Parkinson's disease, including TCE, paraquat, and other chemicals. Supporting creation of Neuroscience Center of Excellence at FDA. S. 3427, the Neuroscience Center of Excellence Act H.R. 5435, the BRAIN Act H.R. 6000, the Cures 2.0 Act S. 3282, the Protect Americas Children from Toxic Pesticides Act H.R. 3967 / S. 3373 Honoring our Promise to Address Comprehensive Toxics (PACT) Act and other associated legislation
General education regarding environmental triggers of neurological disease and support for more research. S. 3283, the Protect America's Children from Toxic Pesticides Act
FY 2022 Appropriation bills including Parkinson's research funding requests for: Department of Defense National Institute of Health Centers for Disease Control and Prevention Food and Drug Administration FY 2023 Appropriations bills including Parkinson's research funding requests for: Department of Defense National Institute of Health Centers for Disease Control and Prevention Food and Drug Administration Department of Veterans Affairs
General education around pharmaceuticals related to Parkinson's disease Increasing drug affordability and accessibility via drug pricing, Medicare Part D redesign and benefits, and streamlining prior authorization processes and step therapy protocols Prescription Drug User Fee Act H.R. 4417, the Capping Drug Costs for Seniors Act H.R. 4479/S. 2609, the Facilitating Innovative Nuclear Diagnostics Act of 2021 S. 2327, the Seniors Prescription Drug Relief Act H.R. 3173/S. 3018, the Improving Seniors Timely Access to Care Act of 2021 H.R. 2163, the Safe Step Act H.R. 5801, the Help Ensure Lower Patient (HELP) Copays Act H.R. 5376, the Inflation Reduction Act of 2022
Filing targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Defense, Dept of (DOD), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Justice, Dept of (DOJ), Natl Institutes of Health (NIH), Office of Science & Technology Policy (OSTP), SENATE, Veterans Affairs, Dept of (VA)
General education regarding environmental triggers of neurological disease and support for more research. S. 3283, the Protect America's Children from Toxic Pesticides Act
General education around pharmaceuticals related to Parkinson's disease Increasing drug affordability and accessibility via drug pricing, Medicare Part D redesign and benefits, and streamlining prior authorization processes and step therapy protocols Prescription Drug User Fee Act H.R. 4417, the Capping Drug Costs for Seniors Act H.R. 4479/S. 2609, the Facilitating Innovative Nuclear Diagnostics Act of 2021 S. 2327, the Seniors Prescription Drug Relief Act H.R. 3173/S. 3018, the Improving Seniors Timely Access to Care Act of 2021 H.R. 2163, the Safe Step Act H.R. 5801, the Help Ensure Lower Patient (HELP) Copays Act
Expanding Medicare benefits to include dental, hearing, and vision Extending and making permanent COVID-19 telehealth flexibilities Increasing drug affordability and accessibility via drug pricing, Medicare Part D redesign and benefits, capping out-of-pocket costs and smoothing, and streamlining prior authorization processes Advocating for improvements to Medicare Part C and Part D proposed rule H.R. 4417, the Capping Drug Costs for Seniors Act S. 2327, the Seniors Prescription Drug Relief Act S. 828/H.R. 432, the Mental Health Access Improvement Act of 2021 H.R. 2080, the Seniors Access to Vaccine Ensured Act of 2021 H.R. 3173/S. 3018, the Improving Seniors Timely Access to Care Act H.R. 4011, the Capping Drug Costs for Seniors Act of 2022 H.R. 4479/S. 2609, the Facilitating Innovative Nuclear Diagnostics (FIND) Act of 2021 S. 2061/H.R. 4058, the Telemental Health Care Access Act of 2021 S. 1512/H.R. 2903, the Creating Opportunities Now for Necessary and Effective Care Technologies (CONNECT) for Health Act of 2021 H.R. 1332/S. 368, the Telehealth Modernization Act H.R. 366, the Protecting Access to Post-COVID-19 Telehealth Act of 2021 H.R. 3733: Essential Caregivers Act of 2021 H.R. 6202, the Telehealth Extension Act of 2021 S. 3575, the Stop the Wait Act of 2022 S. 3593, the Telehealth Extension and Evaluation Act S. 3675, the Beneficiary Enrollment Notification and Eligibility Simplification (BENES) 2.0 Act H.R. 7051/S. 3791, the Access to Prescription Digital Therapeutics Act of 2022
FY 2022 Appropriation bills including Parkinson's research funding requests for: Department of Defense National Institute of Health Centers for Disease Control and Prevention Food and Drug Administration FY 2023 Appropriations bills including Parkinson's research funding requests for: Department of Defense National Institute of Health Centers for Disease Control and Prevention Food and Drug Administration Department of Veterans Affairs
Filing targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Defense, Dept of (DOD), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Justice, Dept of (DOJ), Natl Institutes of Health (NIH), Office of Science & Technology Policy (OSTP), SENATE, Veterans Affairs, Dept of (VA)
Expanding Medicare benefits to include dental, hearing, and vision Extending and making permanent COVID-19 telehealth flexibilities Increasing drug affordability and accessibility via drug pricing, Medicare Part D redesign and benefits, capping out-of-pocket costs and smoothing, and streamlining prior authorization processes Advocating for improvements to Medicare Part C and Part D proposed rule H.R. 4417, the Capping Drug Costs for Seniors Act S. 2327, the Seniors Prescription Drug Relief Act S. 828/H.R. 432, the Mental Health Access Improvement Act of 2021 H.R. 2080, the Seniors Access to Vaccine Ensured Act of 2021 H.R. 3173/S. 3018, the Improving Seniors Timely Access to Care Act H.R. 4479/S. 2609, the Facilitating Innovative Nuclear Diagnostics (FIND) Act of 2021 S. 2061/H.R. 4058, the Telemental Health Care Access Act of 2021 S. 1512/H.R. 2903, the Creating Opportunities Now for Necessary and Effective Care Technologies (CONNECT) for Health Act of 2021 S. 3593, the Telehealth Extension and Evaluation Act H.R. 6202, the Telehealth Extension Act of 2021 H.R. 1332/S. 368, the Telehealth Modernization Act H.R. 366, the Protecting Access to Post-COVID-19 Telehealth Act of 2021
General education regarding the importance of the Department of Defense medical research programs for military service personnel and Veterans living with Parkinson's disease. Inclusion of Parkinson's disease and PD-related diseases as presumptive conditions when military Veterans are exposed to associated toxins Support for VA's Parkinson's Disease Research, Education and Clinical Center H.R. 3967, the Honoring Our PACT Act H.R. 6774, the Boxing Therapy for Parkinson's Access Act of 2022 H.R. 6659/S. 3541, the Health Care for Burn Pit Veterans Act
General education on triggers of Parkinson's disease, including TCE, paraquat, and other chemicals. Supporting creation of Neuroscience Center of Excellence at FDA. S. 3427, the Neuroscience Center of Excellence Act H.R. 5435, the BRAIN Act H.R. 6000, the Cures 2.0 Act S. 3282, the Protect Americas Children from Toxic Pesticides Act H.R. 3967 Honoring our Promise to Address Comprehensive Toxics (PACT) Act
General education around pharmaceuticals related to Parkinson's disease Increasing drug affordability and accessibility via drug pricing, Medicare Part D redesign and benefits, and streamlining prior authorization processes and step therapy protocols Prescription Drug User Fee Act H.R. 4417, the Capping Drug Costs for Seniors Act H.R. 4479/S. 2609, the Facilitating Innovative Nuclear Diagnostics Act of 2021 S. 2327, the Seniors Prescription Drug Relief Act H.R. 3173/S. 3018, the Improving Seniors Timely Access to Care Act of 2021 H.R. 2163, the Safe Step Act H.R. 5801, the Help Ensure Lower Patient (HELP) Copays Act
Filing targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Defense, Dept of (DOD), Environmental Protection Agency (EPA), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Justice, Dept of (DOJ), Natl Institutes of Health (NIH), Office of Science & Technology Policy (OSTP), SENATE, Veterans Affairs, Dept of (VA)
General education regarding environmental triggers of neurological disease and support for more research. S.3283 Protect America's Children from Toxic Pesticides Act
General education regarding the importance of the Department of Defense medical research programs for military service personnel and Veterans living with Parkinson's disease. Inclusion of Parkinson's disease and PD-related diseases as presumptive conditions when military Veterans are exposed to associated toxins Support for VA's Parkinson's Disease Research, Education and Clinical Center
Expanding Medicare benefits to include dental, hearing, and vision Telehealth flexibilities and making current telehealth rules permanent Medicare Part D design and benefits, drug pricing principle S.464/H.R.2163, the Safe Step Act of 2021 S.8282/H.R.432, the Mental Health Access Improvement Act H.R.2080, the Seniors Access to Vaccine Ensured Act H.R.3173, Improving Seniors Timely Access to Care S.2061/H.R.4058 the Telemental Health Care Access Act
Filing targets: Centers For Medicare and Medicaid Services (CMS), Defense, Dept of (DOD), Environmental Protection Agency (EPA), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Institutes of Health (NIH), SENATE, Veterans Affairs, Dept of (VA)
Expanding Medicare benefits to include dental, hearing, and vision Telehealth flexibilities and making current telehealth rules permanent Medicare Part D design and benefits, drug pricing principle S.464/H.R.2163, the Safe Step Act of 2021 S.8282/H.R.432, the Mental Health Access Improvement Act H.R.2080, the Seniors Access to Vaccine Ensured Act H.R.3173, Improving Seniors Timely Access to Care S.2061, the Telemental Health Care Access Act
General education on triggers of Parkinson's disease, including TCE, paraquat, and other chemicals.
General education regarding the importance of the Department of Defense medical research programs for military service personnel and Veterans living with Parkinson's disease. Inclusion of Parkinson's disease and PD-related diseases as presumptive conditions when military Veterans are exposed to associated toxins
Filing targets: Centers For Medicare and Medicaid Services (CMS), Environmental Protection Agency (EPA), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Institutes of Health (NIH), SENATE
Filing targets: Centers For Medicare and Medicaid Services (CMS), Environmental Protection Agency (EPA), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Institutes of Health (NIH), SENATE
Filing targets: Centers For Medicare and Medicaid Services (CMS), Environmental Protection Agency (EPA), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Institutes of Health (NIH), SENATE